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Abstract 
Small molecules that are approved as drugs are largely the result of extensive synthetic efforts. 
A robust synthetic method is required to access the natural products and their analogs to study their 
biological activities. This thesis largely focuses on the synthesis of cardiotonic steroids, the 
steroids that are known for the treatment of heart conditions and more recently has shown 
promising prospect in anticancer studies against various human cancer cell lines. Furthermore, the 
anti-cancer activities of the molecules of this class were studied and substantial data on structure-
activity relationship (SAR) were obtained. In addition, this thesis also presents an anion binding 
catalysis, the process by which anions are selectively transported between membranes in human 
body, of a new class of catalyst thiophosphoramide that showed promising ability to bind with 
anions. 
The first chapter describes the utility of three hydrogen-bond donor, thiophosphoramide-based 
catalyst anion binding catalysis. The study illustrates that the thiophosphoramide-based HBDs 
could significantly accelerate Cu(II)-catalyzed reactions of potassium carboxylates with 
diaryliodonium salts. The scope of counterion on both the diaryliodonium salt and the copper salt 
is explored, followed by the application of this method in a wide-variety of carboxylic acid 
including some naturally available carboxylic acid. 
The second chapter introduces cardiotonic steroids and the discusses the relevant prior 
synthesis.  Impressive synthesis of digitoxigenin by Yoshii and Nakada followed by the synthesis 
of strophanthidin by Yoshii and Kočovsky are discussed in detail. The total synthesis of 
cannogenol-3-O-α-L-rhamnoside that will be discussed in following chapter is inspired by the 
xvii 
 
work previously published by Nagorny and coworkers on enantioselective synthesis of oxygenated 
steroids by copper-catalyzed Michael reaction followed by double aldol reaction and the utilization 
of this method in the total synthesis of 19-hydroxysermentogenin and trewianin aglycone are 
discussed in this chaper.  
The third chapter describes the development of a robust and divergent synthetic pathway to 
access natural product of the class called cardiotonic steroids. The chapter highlights the first 
enantioselective total synthesis of two cardiotonic steroids that have been recently of interest 
because of their anti-cancer activities: 1) cannogenol 2) cannogenol-3-O-α-L-rhamnoside. The 
challenges during the development of this method, that could provide analogs with different 
heterocycles and sugar moieties with minimum deviations, are described in detail. 
Finally, the fourth chapter focuses on the generation of natural products and analogs using the 
method developed in chapter 3. Another natural product cannogenol-3-O-glucopyranoside and an 
analog of cannogenol-3-O-α-L-rhamnoside with alkyne incorporation in the sugar moiety for the 
target identification studies were synthesized.  In addition to the molecules synthesized in our 
group, other commercial steroids of diverse functional group at different part of the molecule were 
collected. The collaboration with Dr. Yimon Aye’s group at Cornell University presented us with 
significant structure-activity relationship (SAR) data. In addition, an analog of strophanthidin with 
amine incorporation instead of alcohol at C19 was synthesized by reductive amination of aldehyde. 
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Chapter 1 
Thiophosphoramides as Cooperative Catalysts for Copper-catalyzed Arylation of 
Carboxylates with Diaryliodonium Salts 
(A part of this work has been published in Bhattarai, B.; Tay, J.H.; Nagorny, P. 
Thiophosphoramides as cooperative catalysts for copper-catalyzed arylation of carboxylates with 
diaryliodonium salts. Chem. Commun. 2015, 51, 5398-5401) 
1.1. Introduction 
Over the past two decades, the use of organocatalysts in asymmetric organic reactions has 
emerged as a powerful tool for stereoselective organic transformations. This popularity of 
organocatalysts, in recent years, is due to their robustness, inexpensiveness, ease of availability, 
and non-toxic nature.1–3 When compared to other methods using metal-based catalysts, 
organocatalysis does not require demanding reaction conditions and is usually inert towards 
moisture and oxygen.2 In addition, the absence of transition metals makes this field more attractive 
for pharmaceuticals industry since it avoids the task of controlling and removing trace metal 
impurities in the final product. Despite the rapid developments in the field in the recent years, there 
is still much room for advancement with regard to catalytic activity and substrate scope. Due to 
the historical reasons proline,4,5 cinchona alkaloids6,7 and other secondary amine derivatives8 are 
among the most frequently used organocatalysts; however, new classes of organic catalysts are 
emerging. Thus, the studies of H-bond donor-catalysts and their chiral analogs have also become 
a rapidly growing and important area of organocatalysis and numerous  reports have shown these 
catalysts to be an effective alternative to metal-based catalysts and other organocatalysts.1–3  
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Although organocatalysis is popularized since 2000s,9,10 the reports of organic molecules 
catalyzing organic reactions date back to 1860, when Liebig performed the reaction of cyanogen 
in presence of water and acetaldehyde to obtain oxamide.11 Later in 1896, Knoevenagel discovered 
the condensation reaction of aromatic aldehydes with malonic acid catalyzed by amines as an 
organocatalyst.12 The first asymmetric organocatalytic reaction was attained by Bredig and Fiske 
in 1912 where they reported the ability of cinchona alkaloids to catalyze a reaction of hydrogen 
cyanide with aldehydes to provide cyanohydrins in ~10% ee.13 Since then, protic organic 
compounds have been used to catalyze various organic reactions. For an instance, Wassermann 
reported the first example of catalytic Diels-Alder cycloaddition between cyclopentadiene 1.1 and 
benzoquinone 1.2 in 1942,14 where he used several organic molecules (Phenol, CH2ClCO2H, 
CH3CO2H, CCl3CO2H) as single proton donor to catalyze the cycloaddition reaction (Scheme 1.1). 
Scheme 1.1 First Example of Catalytic Diels- Alder Cycloaddition Catalyzed by Organic Molecule 
 
A pioneering work in this field was the discovery of proline in the catalysis of intramolecular 
aldol reaction in Hajos-Parrish-Eder-Sauer-Wiechert reaction in 1971 (Scheme 1.2).15,16 This 
chemistry has since been widely elaborated in the enantioselective synthesis of steroids and various 
other natural products. 
Scheme 1.2 Proline Catalysis in Hajos-Parris-Eder-Sauer-Wiechert Reaction    
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Organocatalysis based on catalyst’s H-bond donating abilities has been explored in a variety 
of organic reactions. They depend on either the activation or deactivation of a nucleophile or an 
electrophile to facilitate the reactions (Figure 1.1).  There are two different modes of activation 1) 
a neutral substrate can be activated by the enhancement of its electrophilicity, and then undergo a 
subsequent nucleophilic attack, or 2) binding to an anionic counterion of an electrophile results in 
a significant enhancement of its electrophilicity and results in a subsequent reaction with a 
nucleophile.   
Figure 1.1 Different Modes of Activation by H-Bond Catalysis 
 
Among the early examples of organic hydrogen bond donors (HBDs) is 1,8-Biphenylenediol 
1.10 that based on previously reported X-ray crystallographic data, is known to form two H-bonds 
with a single oxygen atom.17  In one of a pioneering work by Hine et al., the authors were able to 
take advantage of this particular characteristic of 1,8-biphenylenediol (1.10) to catalyze the 
reaction of an epoxide 1.7 with diethyl amine 1.8 (Scheme 1.3). This catalyst was found to be 
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superior to several phenols tested with either electron-donating or electron-withdrawing groups 
that were explored in this study and the reaction was observed to proceed 12.5 times faster than 
with a phenol as a catalyst. This effect was attributed to superior substrate activation by 1.10, 
which is able to form two hydrogen bonds simultaneously. 18 
Scheme 1.3 1,8-biphenylenediol as Two H-bond Donor in Catalysis 
 
In 1994, Curran and Kuo investigated the diarylureas as the catalyst for the allylation of cyclic 
α-sulfinyl radicals.19 For the first time, the authors demonstrated that these H-bond donors could 
catalyze complex organic transformations of this type. They further studied Claisen rearrangement 
of allyl vinyl ether catalyzed by thiourea catalyst 1.13 (Scheme 1.4).20 The acceleration of the 
Claisen rearrangement by 2.7 times was observed, as compared to the reaction in the absence of 
catalyst.  
Scheme 1.4. Claisen Rearrangement of Allyl Vinyl Ether Catalyzed by 1.13 
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A variant of thiourea 1.13 was later used by Schreiner in 2002, where they showed capability 
of this class of catalyst towards Diels-Alder reactions.21 Furthermore, in 2003, Schreiner et al. 
screened catalyst efficiencies (Scheme 1.5) by carrying out a series of Diels-Alder reactions of 
cyclopentadiene with α, β-unsaturated carbonyl compounds (Scheme 1.5). Most thiourea catalysts 
demonstrated a catalytic behavior and the introduction of disubstituted non-coordinating electron-
withdrawing groups (i.e. CF3) in the meta positions of the ring enhanced the hydrogen bonding 
ability of the N–H bonds. These thiourea derivatives, with rigid electron-withdrawing aromatic 
substituents, were found to be the most effective H-bonding catalysts for the Diels-Alder reactions. 
Relative rate constant (Krel) (Table 1.5b) and conversion of the reaction catalyzed by 1.17a, 
however, was significantly higher than for the majority of the other thiourea derivaties.22 
Scheme 1.5. Diels-Alder Reaction of Cyclopentadiene with Dienophile Catalyzed by Thiourea 
Derivatives  
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Utilization of H-bonding as an activation force is widespread in asymmetric organocatalysis. 
Chiral ureas and thioureas, squaramides, diols, and phosphoric acids have dominated the field of 
H-bonding catalysis for the past decade and great advances have been attained.2,3,23 During this 
period, urea and thiourea based organocatalysts have been extensively studied due to their ability 
of strong activation of carbonyl and nitro-groups through efficient H-bonding interactions. Chiral, 
bifunctional thiourea-based organocatalysts, that can catalyze the reaction while transferring chiral 
information, are widely used in enantioselective reactions like acyl-Pictet-Spengler,24 Michael-
addition,25,26 Baylis-Hillman,27 aza-Henry,6 and Mannich6,7 reactions. Though most often utilized 
to activate electrophiles by binding to a carbonyl, chiral thioureas have also been demonstrated to 
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promote anion abstraction from neutral organic electrophiles to generate highly reactive cationic 
intermediates.28  
In 1998, one of the first thiourea catalysts was synthesized by the Jacobsen group, which was 
applied in an asymmetric Strecker reaction. From their parallel synthetic libraries, they identified 
that 1.20 was an effective catalyst for the asymmetric Strecker reaction as depicted in Scheme 1.6 
(hydrocyanation of 1.18). Notably, it exhibited promising enantioselectivity both on solid phase 
and in solution and was easily prepared from inexpensive components.29 
Scheme 1.6. Asymmetric Strecker Reaction Catalyzed by 1.20 
 
In addition to the aforementioned HBD-based catalysts, a variety of hybrid organic catalysts 
that contain other catalytic sites in addition to the hydrogen bonds have been developed. Thus, 
Takemoto catalyst (1.23) is the first bifunctional thiourea catalyst with rigid electron-withdrawing 
aromatic substituents (-CF3 group). This catalyst activates both the nucleophile, by general base 
catalysis, and the electrophile, by H-bonding to the nitro group. Thiourea catalyst 1.23 worked 
well to promote the Michael reactions of malonates and various nitroolefins (1.21), with high 
enantioselectivities (Scheme 1.7).25 
Scheme 1.7. Enantioselective Michael Reaction of Malonate and Nitroolefin Catalyzed by 1.23 
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In 2007, Jacobsen et al. reported the successful application of thiourea catalysis to the Pictet-
Spengler-type cyclization of hydrolactams, affording highly enantioenriched indolizidinones and 
quinolizidinones (Scheme 1.8). Furthermore, it was also discovered that thiourea catalyst 1.27 
promoted enantioselective cyclization by inducing dissociation of the chloride counterion and 
formation of a chiral N-acyliminium chloride-thiourea complex (1.28-1.29).24  
Scheme 1.8. Asymmetric Cyclization of Hydroxylactams Catalyzed by 1.27 and the Proposed 
Anion Binding
 
Interestingly, the scope of HBD-based catalysts is not limited to conventionally strong HBDs 
such as ureas or thioureas, and even alcohols may serve as the catalysts in certain transformations. 
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Thus, Rawal’s TADDOL 1.32 is considered to be one of first successful application of chiral diols 
in asymmetric H-bond donating catalysis (ref). In a Diels-Alder reaction of aminosiloxydiene 1.30 
and methacrolein 1.31, aldehyde 1.34 was obtained in 91% ee after desilylation and amine 
elimination (Scheme 1.9).30 TADDOL 1.32 is a simple and easily available and promoted this 
reaction as efficiently as a previously known Lewis acid catalyst would. Since the publication of 
this work, research on various organic transformations with TADDOL, BINOL, BINOL based 
Chiral Phosphoric Acids and others have followed.31–33 
Scheme 1.9. Rawal’s TADOOL 1.32 in Asymmetric Catalysis 
 
1.2. Three Hydrogen Bond Donors 
In addition to the catalysts that may serve as a single or double HBDs, catalysts that may 
potentially form three HBDs with a substrate have been developed and studied. Seidel and co-
workers further explored of the thiourea-based dual catalysis and reported several examples of 
carboxylic acid-based thiourea that could act as a dual catalyst in a series of organic 
transformations like Pictet-Spengler reaction,34 Povarov reaction,35 and Intramolecular Aza-Diels-
Alder Reactions.36 In the following example, internal anion-binding concept was used using chiral 
anion/Bronsted acid catalysis. Catalyst 1.39 functions as a dual catalyst, wherein, it contains both 
anion-recognition site, specifically, thiourea moiety and covalently connected carboxylic acid 
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functional group.34 Upon the exposure to this catalyst, the substrate gets protonated and a 
substrate/catalyst ion pair is formed by anion recognition, which leads to the enhanced 
electrophilicity of the substrate. The authors screened multitude of catalysts with a variety of 
carboxylic acid and they found catalyst 1.39 to be the most efficient at promoting Pictet-Spengler 
reaction of tryptamine 1.35 with aldehyde 1.36.  Following a protection of the amine with Boc 
generated β-carbolines 1.38 in very good yield and % ee.  
Scheme 1.10. Pictet-Spengler Reaction Catalyzed by Dual Catalyst 1.39 
 
A more direct use of multiple hydrogen bond donors for the substrate activation was reported 
by the Shea group. The Friedel-Crafts reaction between β-nitrostyrene 1.40 and N-methyl indole 
1.41 (Scheme 1.11) was executed by Rodriguez et al. in 2009 to compare the catalytic activity of 
thiourea A, sulfamide B, thiophosphoric triamide C, and phosphoric triamide D (Scheme 1.11a). 
Thiophosphoric triamide C displayed a 2.6-fold increase in activity compared to the most active 
and versatile thiourea catalyst A that had been designed by Schreiner. This finding lead to the 
recategorization of the thiophosphoric triamide as an HBD catalyst, and its superior catalytic 
activity was attributed to its ability to form up the three hydrogen bonds at the same time.27  
Scheme 1.11. Friedel-Crafts Reaction of N-methyl Indole with β-nitrosyrene 
11 
 
 
Another case describing improved substrate activation with additional hydrogen bonds was 
reported by the Kass group. Thus, in their 2012 publication, a new class of H-bond catalyst 1.46 
was presented which could efficiently catalyze a Friedel-Craft reaction of N-methyl indole 1.43 
with β-nitrosyrene 1.44 (Scheme 1.12). This catalyst was found to use all three of its H-bond 
donors to bind with a single functional group and consequently, catalyze the reaction 100 times 
faster. It bound anions more tightly than the other, two H-bond donating counterparts.37 
Scheme 1.12. New Class of Three H-bond Donors 1.46 
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1.3. Anion Recognition 
It has been long known that the anion recognition is essential for biological function especially, 
for the transfer of anions between membranes selectively. Chloride channel is no exception 
(Figure 1.2). Chloride anion is essential for numbers of cellular and physiological tasks that 
control the membrane potentials. The three amino acids that are highly aligned act as a selective 
filter for anion channel and enable the selective flow of chloride ions across the cell membranes.38 
Such interaction 1.47 is very common in biological systems and the study of the interaction 
between proteins and anions like nitrate, sulfate, phosphate, chloride and their recognition, 
binding, and transportation is of interest to the scientific community. 38 
Figure 1.2. Anion Recognition in Chloride Channel 
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In that regard, Cranwell et al. demonstrated in 2013 
that new H-bonding motifs based on phosphoric triamide 
and thiophosphoric triamide could be effective anion 
receptors, which would be capable of mediating the 
exchange of chloride and nitrate anions across the lipid 
bilayer membrane. Interestingly, phosphoric triamide was 
also found to have high selectivity for sulfate ions in DMSO-d6/0.5% water solution (Figure 1.3).
39 
In addition to chloride, nitrate, and sulfate anions, they found C to be a good receptor of other 
halogen, phosphate, carboxylate, and acetate anions as well.  
In recent years, ureas and thioureas have gained a great deal of attention for their ability to 
operate as dual HBD catalysts. However, the discussed above cases imply that additional hydrogen 
bonds could enhance the substrate activation. Therefore, HBD catalysts capable of forming more 
than two hydrogen bonds, like thiophosphoramides or their bifunctional modifications represent a 
newer area of study. Our research group was among the pioneers in exploring 
thiosphosphoramides as HBD catalysts as these compounds could form three hydrogen bonds with 
an acceptor, unlike two H-bond donors, but at the same time are significantly more stable to 
hydrolysis then squaramides and thioureas.    
Parallel to Cranwell’s finding, our group identified the thiophosphoramide C as  powerful 
HBDs which significantly enhanced the reactivity of oxocarbenium ion 1.51 via anion binding 
1.52 by forming a more separated ion pair (Scheme 1.13).40 During the study, Bronsted acid was 
used as a co-catalyst in the formation of oxocarbenium ion, reactivity of which was enhanced by 
the separation of counterion, sulfonate, by a binding of thiophosphoramide with the anion. This is 
the first example of thiophosphoramide being used for anion-binding organocatalysis. 
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Furthermore, 1H NMR supported a strong binding affinity of sulfonate anions with 
thiophosphoramide. Computational studies indicated the binding of all three of the N–H bond of 
the catalyst to the oxygen atom of the sulfonate anion (1.52). Thiophosphoramide was also found 
to be superior to traditionally used two H-bond donor catalysts.  
Scheme 1.13. HBD-based Cocatalysts for the Ionic [2 + 4] Cycloaddition and the Proposed 
Activation of Oxocarbenium Ion by Anion Binding 
 
 
Subsequently, in an effort to quantify the electrophilic activation (LUMO-lowering), 
Kozlowski and co-workers were able to use spectrophotometric sensor to assess the reactivity of 
an array of commonly used H-bonding organocatalysts with different structures.41 
Imidazopyrazinone was used as a sensor or chromatophore that underwent electronic excitation 
after binding to H-bond donor and this interaction was detected by UV-vis absorption. Significant 
visible blue shift was observed even in presence of weaker donors like diphenylthiourea upon 
interaction with the sensor. The measured shift in sensor wavelength and binding equilibrium 
15 
 
constant of sensor-catalyst complex in a broad range of widely used organocatalysts were plotted 
(Figure 1.4). In addition, the correlation in wavelength shift and the rate of enhancement in 
presence of the catalyst in a Diels-Alder reaction between cyclopentadiene and methyl vinyl ketone 
was also plotted. Similar correlation data was obtained for a Friedel-Crafts reaction. They 
concluded that the measurement from the sensor provided good assessment of inherent reactivity 
of these organocatalysts.  
Figure 1.4. Correlation between Sensor Wavelength Shift and Sensor-catalyst Binding 
Equilibrium 
 
 
(Figure 1.4 is used directly from https://pubs.acs.org/doi/abs/10.1021/ja5086244 with permission from American 
Chemical Society (ACS) and further permissions related to the material excerpted should be directed to the ACS) 
From these studies, they found thiophosphoramide catalyst C to be one of the best performers 
and the strongest non-cationic binder because of its ability to act as three N–H donors. It was 
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shown to have superior reactivity compared to uncharged two hydrogen bond catalysts like 
squaramide, sulfonamides, and thioureas that have previously shown good results in catalysis.22,42 
Following our publication on the work discussed in this chapter, thiophosphoramide has been 
used in ring-opening polymerization (ROP), utilizing its anion binding abilities and stability to 
acids (Scheme 1.14).43 Hydrogen bond donor 1.57 was able to bind with a Bronsted acid to form 
the BA-HBD complex 1.60 and catalyze living ROP. Thiophosphoramide bonded with 
methanesulfonate anion by using three H-bonds (which enhanced the catalytic activity of 
methanesulfonic acid) and promoted the polymerization. In the example described here, 
polylactide was formed by ROP of L-lactide, enabled by the BA-HBD catalysis, of low dispersities 
and predicted molecular weights.   
Scheme 1.14. Mechanism of ROP Promoted by Thiophosphoramide catalyst 1.57 
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1.4. Thiophosphoramides as Cooperative Catalysts for Copper-catalyzed Arylation 
of Carboxylates with Diaryliodonium Salts 
1.4.1. Diaryliodonium Salts 
Hypervalent iodine derivatives have been of great importance to organic synthesis. In addition 
to the standard oxidation state, iodine can form a variety of other organic compounds including 
the ones with (III) and (V)-valent iodine. Iodine(V) reagents like 2-Iodoxybenzoic acid (IBX) and 
Dess-Martin Periodinane (DMP) are widely used in natural products synthesis as a mild oxidant 
of alcohols.44,45 Iodine(III) compounds like iodosylbenzene and diacetoxyiodobenzene (PIDA) are 
similarly used for oxidation of alcohols and have additional applications like α-functionalization 
of carbonyl groups and oxidation of alkenes.46,47 Hypervalent iodine compounds reacts with 
nucleophile to form I-Nu bond by substituting a ligand. Formal reductive elimination or its 
mechanistic equivalents follows to form the product Nu-L with the release of ArI (Figure 1.5b).48  
Figure 1.5 Shape of Hypervalent Iodine and General Reactivity 
 
Diaryliodonium salts have gained popularity as inexpensive and readily available electrophilic 
arylation agents.49,49,50 While X-ray studies indicate that diaryliodonium salts have significant 
secondary bonding with counterions in the solid state, the dissociation of the counterion in solution 
is often proposed.49,51,52 In some instances the observed reactivity trends could be attributed to ion-
pairing effects, and certain parallels could be drawn between the reactivity of diaryliodonium salts 
and classical electrophiles such as iminium or carbenium ions. These salts have received great 
attention in the recent years due to their exceptional ability to transfer sp2- and sp-based carbon 
electrophiles in a reaction with a variety of nucleophiles. Reactions with nucleophiles could 
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proceed under both metal-catalyzed51–55 and metal-free conditions,56–58 and parameters such as the 
polarity of the solvent and the coordinating ability of the diaryliodonium counterion are often 
important for the outcome of these reactions.49–51,59–61 Diaryliodonium salt has been widely used 
in organic synthesis to transfer aryl groups to the nucleophile in presence or absence of metal-
catalyzed reactions where it is found to be more reactive than traditionally used aryl halides. These 
reactions could happen with thermal activation or upon addition of an external catalyst such as 
Cu(I) or Pd(II). Traditionally, strong nucleophiles could directly react with diaryliodonium salts 
although some of these reactions require heating. Thus, as it has been demonstrated by the 
Olofsson and group, the carboxylates could be arylated with diaryliodonium salts to form aryl 
esters, and these reactions are very general to variety of carboxylates and diaryliodonium salts 
albeit require elevated temperatures.62 The arylation of benzoic acid 1.62 with diphenyliodonium 
triflate occurred at 130 oC to provide phenyl benzoate 1.63 in excellent yield but only trace of the 
product was observed in upto 70 oC (Scheme 1.15a). In a separate example by Gaunt and group, 
the N-acetylated indoles were selectively arylated at C2 or C3 position in presence of Cu (II) 
catalyst.63 In the following example (Scheme 1.15b), N-acetylated indole 1.64 was treated with 
diphenyliodonium triflate 1.65 in presence of Cu(OTf)2 and dtbpy at 60 
oC to provide 9:1 
selectivity of C2:C3 in 83% yield. In the work by Zhou and Chen towards the synthesis of N-
arylindole 1.67, diaryliodonium tetrafluoroborate 1.68 salts readily arylates the indoles in presence 
of copper, however, require very high temperature (140-150 oC) as shown in Scheme 1.15c.64   
Scheme 1.15 Reactions of Diaryliodonium Salts with Nucleophiles 
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Diaryliodonium salts have found abundant applications in the field of organic synthesis and 
been widely used in total synthesis of natural products.65–68 One of such examples is the work by 
Olofsson and group in the total synthesis of (-)-epibatidine.65 They developed a direct asymmetric 
α-arylation of cyclohexanones 1.70 where Simpkin’s base 1.71 resulted in the asymmetric 
enolization to desymmetrize the para-substituted cyclohexanones and the reaction of 
diaryliodonium salts yielded 2-aryl ketones 1.73 in excellent enantioselectivities and moderate 
yields (Scheme 1.16). The method was further elaborated to the total synthesis of (-)-epibatidine.  
Scheme 1.16 Diaryliodonium Salt in Total Synthesis of (-)-epibatidine 
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The robustness of thiophosphoramides as well as their unique ability to accomplish counterion 
activation in comparison to other HBDs27,40,41 prompted us to investigate other types of reactions, 
in which counterion activation has not been accomplished with traditional HBDs.  
In most of the examples of the arylation of nucleophiles with diaryliodonium salts, the 
reactions are general to the wide variety of nucleophile and delivers desired products in excellent 
yield making diaryliodonium salts as an attractive reagent for arylation, but unfortunately these 
reactions require very high temperature. Most of the examples require refluxing in solvents like 
toluene or DMF. We identified the need to further enhance the electrophilicity of diaryliodonium 
salts and this could potentially be achieved by ion pair separation by using H-bond donors as shown 
in Figure 1.6.  
Figure 1.6. Proposed Ion Pair Separation by Three H-bond Donor Catalyst 
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The use of HBD-based catalysts can potentially enhance the reactions involving 
diaryliodonium salts and significantly expand the scope of the reaction conditions (i.e. solvents 
and diaryliodonium counterions) that could be used for the transformations involving these 
species. This chapter summarizes our studies illustrating that thiophosphoramide based HBDs 
could significantly accelerate Cu(II)-catalyzed reactions of potassium carboxylates with 
diaryliodonium salts. 
1.4.2. Initial Optimization 
According to studies by Oloffson and coworkers,56,62 an uncatalyzed reaction of metal 
carboxylates and diaryliodonium salts require elevated temperatures and the yield is 
significantly retarded at 70 ºC. To demonstrate that the addition of HBDs as a catalyst or 
co-catalyst could significantly accelerate this transformation at ambient temperature, we 
initiated the experimentations summarized in Table 1.1. The initial screening to identify 
the enhancement of rate using thiophosophoramides was identified by colleague Jia Hui 
Tay. Thus, arylation of potassium benzoate with diphenyliodonium triflate was 
investigated. This reaction does not happen at room temperature or at 70 ºC after 24 h 
(entries 1 and 2), and only 18% yield is observed when performed in presence of catalytic 
quantities of copper(II) trifluoromethanesulfonate (entry 3).  The following evaluation of 
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HBDs A-C revealed that this reaction can indeed be accelerated if a HBD-based co-catalyst 
is used in combination with Cu(OTf)2. Interestingly, among the evaluated HBDs, 
thiophosphoramide C was found to outperform traditional two hydrogen bond donors such 
as Schreiner’s thiourea A22 or squaramide 1.8042 (Table 1, entries 4-6). In the following 
control experiments, reactions with C were conducted at room temperature and 70 ºC in 
the absence of Cu(OTf)2 (entries 7–8).  These experiments clearly indicated that both the 
catalysts were important for the activation of diaryliodonium salts.  The use of C alone 
resulted in the formation of product 1.82 in 36% yield.  Based on this outcome, we 
postulated that C could activate diaryliodonium salts by complexing the counterions; 
however, this effect was weaker compared to the case where a dual catalytic system was 
used. Next, the solvent effects were explored (entries 9–13).  Surprisingly, no product 
(1.82) was observed in the oxygen-containing polar solvents like DMF, diethyl ether, and 
THF either in the presence or absence of C (entries 9–11).  This could be attributed to 
weaker hydrogen bonding due to the increased polarity and hydrogen bond accepting ability 
of these solvents. However, reaction yield in non-coordinating solvents such as methylene 
chloride were found to be comparable to when toluene was used as a solvent (entries 12–
13).  
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     Table 1.1.  Optimization of the Reaction Conditions  
 
1.4.3. Investigation of the Effect of Diaryliodonium Salt Counterions     
Having established the optimized conditions (Table 1.1, entry 6), we sought out to 
investigate the scope of the iodonium salts that could be activated in presence of the 
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combination of C and Cu(OTf)2 (Table 1.2). First, the effect of the counterion was 
evaluated (entries 1–8). In theory, the diphenyliodonium salts containing non-coordinating 
counterions should have higher reactivities than diphenyliodonium triflate. However, the 
counterion activation of such salts would be more difficult due to their lower affinity to 
HBDs. To our knowledge, HBDs are typically not employed for the counterion activation 
of non-coordinating anions such as hexafluorophosphate and tetrafluoroborate through this 
mode. However, under the established reaction conditions both [Ph2I]
+PF6
– and [Ph2I]
+BF4
– 
provided synthetically useful yields in the presence of C and Cu(OTf)2 (entries 3 and 5). 
As expected, no reaction was observed with these salts in the absence of the HBD-catalyst 
(entries 6 and 4). The reactivity of [Ph2I]
+OTs– was lower in comparison with the salts 
containing less coordinating counterions due to the more coordinating nature of tosylate 
anion. No reaction was observed at room temperature with and without C/Cu(OTf)2.  
However, when heated to 70o C in the presence of C and Cu(OTf)2, [Ph2I]
+OTs– provided 
the corresponding product in 55% yield.  As before, no product was observed at this 
temperature in the absence of the catalyst even after 24 h (entry 8).  
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Table 1.2. Investigating Effect of the Diaryliodonium Salt Counterion
 
  Finally, in order to demonstrate that the catalytic reaction is not sensitive to the nature 
of aryl group, arylation with commercially available bis(4-tert-butylphenyl)iodonium 
triflate (entry 9) and bis(4-bromophenyl)iodonium triflate (entry 10) was investigated. As 
before, both of these arylations proceeded with good yields in the presence of C/Cu(OTf)2, 
but no reaction was observed in absence of the catalysts. These studies indicate that the 
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C/Cu(OTf)2 based catalytic activation is less sensitive to the nature of diaryliodonium 
counterion than previously anticipated.  However, this result is not entirely surprising 
considering that in all of the cases described above, trifluoromethanesulfonate anion was 
also present in the reaction medium as a counterion of Cu(II). 
1.4.4. Investigation of the Effect of Copper Salt Counterions     
Table 1.3. Investigating the Effect of the Copper Salt Counterion 
 
Another hypothesis for this reaction is that thiophosphoramide catalyst C is likely to 
complex the trifluoromethanesulfonate anion and consequently activate the arylcopper 
intermediate bound to this anion.59–61 Therefore, the ability of C to co-catalyze the reaction 
should not only depend on the counterion of diaryliodonium salt, but also on the counterion 
of the Cu(II) catalyst. To validate this proposal, the experiments summarized in Table 1.3 
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were conducted. In these studies, the counterions on both the Cu(II) catalyst and the 
diaryliodonium salt was replaced to be tetrafluoroborate instead of 
trifluoromethanesulfonate. In general, replacement of the more coordinating 
trifluoromethanesulfonate to a less coordinating tetrafluoroborate counterion resulted in the 
reduction of the yield. Although such a variation in the diaryliodonium counterion resulted 
in only a minor reduction in the yield (entry 5), the counterion of Cu(II) seems to play a 
more significant role. Thus, when Cu(II) tetrafluoroborate was used in combination with 
[Ph2I]
+OTf–, a 31% reduction in yield was observed (entry 3) and no reaction happened in 
the absence of C (entry 4). Following this trend, the reaction of [Ph2I]
+BF4
– catalyzed by 
Cu(BF4)2 was significantly less efficient, and only 28% of 1.82 was isolated (entry 7).  
These results indicated that C plays a more important role in activating the organocopper 
intermediate than it plays in activating the diaryliodonium salt itself.   
1.4.5. Substrate Scope 
The scope of the nucleophile was investigated next (Scheme 1.17). Under the optimized 
conditions, phenylation of various carboxylates was accomplished in good to excellent 
yields. Introduction of the substituents onto the aromatic ring (entries 1.84a–1.84e) was 
found to affect the reactivity of the carboxylate anion.  As expected, reactions with less 
nucleophilic carboxylates (1.84c–1.84e) were significantly slower and required elevated 
temperatures (40 ºC) to proceed to completion. Olofsson’s group previously reported that 
under the catalyst free conditions in refluxing toluene the yields for 1.84d and 1.84e were 
found to be 65% and 59% respectively. However, using the catalytic conditions, we were 
able to accomplish the formation of 1.84d and 1.84e at 40 oC in 67% and 80% yield 
respectively.   
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This method was found to be equally effective for the arylation of α, β-unsaturated acids 
(entries 1.84f – 1.84h) and aliphatic acids (entries 1.84i – 1.84m).  Importantly, the 
phenylation did not affect electrophile sensitive functionalities such as styrene (1.84j) and 
diene (1.84k). However, the presence of competing nucleophiles such as hydroxyl groups 
of the cholic acid (entry 1.84l) resulted in a reduced yield. The acetylated cholic acid 
however, could be esterified in an excellent yield (entry 1.84m).  
Scheme 1.17. Substrate Scope 
 
1.4.6. Proposed Mechanism 
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The proposed mechanism of this transformation is shown in Scheme 1.18. The addition of 
copper to the diaryliodonium salt forms an organo-copper intermediate II. The carboxylate, 
deprotonated by the base, would displace the triflate counterion to form organo-copper 
intermediate III, which is followed by reductive elimination to provide ester 1.82, restoring the 
Cu catalyst I. Thiophosporamide could activate the counterion of either diaryliodonium salts 
directly or from organocopper intermediates.  
Scheme 1.18. Proposed Mechanism 
 
The sulfur atom in the thiophosphoramide could also be involved in a complexation with Cu(I) 
and Cu(II) salts. While the fact that the observed acceleration effect could arise from such 
complexations cannot be excluded, our control experiments suggest that the presence of an anion-
binding motif in thiophosphoramide C is critical for obtaining 1.82 in high yields. Thus, when C 
is replaced with N,N,N-trimethyl-N’,N’,N’-triphenylphosphothioic triamide 1.86 lacking the N–
H bonds, 3a was obtained in only 36% yield after 24 h and with triphenylphosphine sulfide 1.85 
as co-catalyst provided 27% yield after 24 h (Scheme 1.19).  
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Scheme 1.19. Control Reaction with Co-catalyst 1.85 and 1.86  
 
1.5. Other Reactions 
In theory, this approach can be extended to the arylation of other acidic functionalities. Thus, 
our attempts focused on the arylation N-hydroxyphthalimide. Using the method that was 
previously developed for the arylation of carboxylates using diaryliodonium salts discussed above, 
etherification of N-hydroxyphthalimide 1.87 with diphenyliodonium salt was attempted (entry 5, 
Scheme 1.20). Significant acceleration of the reaction in presence of thiophosphoramide was 
observed (entry 6 and 7) although the formation of inseparable and unidentifiable side product was 
formed. No traces of product was observed in absence of the ligand even when Cu(OTf)2 was 
present (entry 5 and 8). The further investigation was abandoned after the realization that the use 
of DMF as a solvent promotes the reaction without the Cu(OTf)2 or thiophosphoramide (entry 1 
and 2). The poor solubility of starting material in toluene and better solubility in DMF could be 
credited for the need of ligand when toluene was used as a solvent.  
Scheme 1.20. Etherification of N-hydroxyphthalimide with Diphenyliodonium Salt 
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1.6. Conclusion  
In conclusion, HBDs may act as synergistic co-catalysts of the Cu(II)-catalyzed 
arylation of potassium carboxylates with diaryliodonium salts.  Thiophosphoramides were 
found to be significantly better HBDs than conventionally used thioureas or squaramides 
in their ability to accelerate the reaction.  The data suggests that the HBD activation is 
accomplished by the counterion activation of the organocopper intermediate, however, 
further studies are required to clarify the exact origin of activation. The ability of 
thiophosphoramide to bind with the organocopper intermediate to increase the solubility 
and hence increase the reactivity couldn’t be denied. This new catalytic variant of this 
transformation can be used for the arylation of various carboxylic acids including the 
substrates possessing electrophile-sensitive functionalities. The reaction is limited to the 
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solvent like toluene and methylene chloride that cannot participate in accepting H-bond 
donation of the thiophosphoramide. We envision that these findings can be extended to the 
other transformations involving diaryliodonium salts. 
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1.7. Experimental (as it appears in Bhattarai, B.; Tay, J.H.; Nagorny, P. Thiophosphoramides as 
cooperative catalysts for copper-catalyzed arylation of carboxylates with diaryliodonium salts. 
Chem. Commun. 2015, 51, 5398-5401) 
General Information 
Methods and Reagents: 
All the reagents were purchased from the commercial sources and used without further 
purification. All iodonium salts were purchased from TCI America. Abietic acid (technical, ~75% 
by GC) was purchased from Sigma Aldrich. All reactions were carried out under an atmosphere 
of nitrogen in flame or oven dried glassware with a magnetic stirrer. Heating was achieved by use 
of a silicone bath with heating controlled by electronic contact thermometer. Deionized water was 
used in the preparation of all aqueous solutions and for all aqueous extractions. Solvents used for 
purification and extraction were ACS or HPLC grade.  toluene, dichloromethane, diethyl ether, 
tetrahydrofuran, and dimethylformamide were filtered through a column of activated alumina 
under nitrogen atmosphere (Innovative Technology PS-MD-5). Thin-layer chromatography (TLC) 
was conducted on precoated glass plates with 230-400 mesh silica gel impregnated with 
fluorescent indicator (250 nm) for routine monitor of reaction progress and visualized using the 
combination of UV and ceric ammonium molybdate.  All products were purified by flash column 
chromatography using SiliCycle Silica Flash P60 (230-400 mesh) silica gel.  
Instrumentation: 
NMR spectra were recorded on Varian vnmrs 700 (700MHz), Varian vnmrs 500 (500 MHz), 
or Varian Inova 500 (500 MHz) spectrometers and chemical shifts are reported in parts per million 
(ppm) downfield from tetramethylsilane with solvent resonance as the internal standard (CDCl3 at 
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δ 7.26, DMSO-d6 at δ 2.5). Proton coupling patterns are described as singlet (s), doublet (d), triplet 
(t), quarted (q), and multiplet (m). High resolution mass spectra (HRMS) were obtained from 
Micromass AutoSpec Ultima or VG (Micromass) 70-250-S Magnetic Sector mass spectrometers 
at the University of Michigan mass spectrometry facility.  Infrared spectra (IR) were recorded as 
thin films on NaCl plates on a Perkin Elmer Spectrum BX FT-IR spectrophotometer and were 
reported in wavenumbers (cm-1). 
Synthesis and spectra data of compounds 3 
 
General Procedure: 
Potassium tert-butoxide (22 mg, 0.2 mmol), Copper(II) trifluoromethanesulfonate (15 mg, 0.04 
mmol), and benzoic acid (24 mg, 0.2 mmol) were added to an oven dried and nitrogen flushed 10 
mL vial charged with 3 mL dry dichloromethane at rt and then left to stir for 10 minutes. 
Diaryliodonium salt (95 mg, 0.22 mmol) and C (30 mg, 0.04 mmol) were added in one portion 
and reaction was stirred for 24 h. The reaction was then quenched with H2O. The product was 
extracted with diethyl ether and the organic layer was dried over Na2SO4, filtered and concentrated 
in vacuo. Crude material was purified by flash chromatography to give corresponding ester.  
Spectroscopic data of compounds 1.84a-m 
Phenyl benzoate (1.84a) 
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Purification by flash chromatography (99:1→9:1Hexanes: Et2O) to afford the above compound 
1.84a (33 mg, 84%) as white crystal. 1H NMR (700 MHz, CDCl3) δ 8.22 (d, J 
= 7.14 Hz, 2H), 7.65 (t, J = 7.5 Hz, 1H), 7.52 (t, J = 7.8 Hz, 2H), 7.44 (t, J = 
7.9 Hz, 2H), 7.28 (t, J = 7.5 Hz, 1H), 7.22 (d, J = 7.7 Hz, 2H); 13C NMR (175 MHz, CDCl3) δ 
165.34, 151.09, 133.73, 130.32, 129.72, 129.64, 128.71, 126.04, 121.86; IR (film, cm-1): 2918, 
1727, 1598, 1589, 1485, 1449, 1256, 1195, 1177, 1062, 1024; HRMS (ESI+) m/z calcd for 
C13H10O2 [M+H]+ 199.0754, found 199.0750;  
Phenyl 4-methoxybenzoate (1.84b) 
Purification by flash chromatography (99:1→9:1Hexanes: Et2O) to afford 
the above compound 1.84b (43 mg, 93%) as white crystal. 1H NMR (700 MHz, CDCl3) δ 8.16 (d, 
J = 8.75 Hz, 2H), 7.42 (t, J = 7.1 Hz, 2H), 7.26 (t, J = 7.46 Hz, 1H), 7.21 (d, J = 7.8 Hz, 2H), 6.99 
(d, J = 8.82 Hz, 2H), 3.90 (s, 3H); 13C NMR (175 MHz, CDCl3) δ 165.06, 164.01, 151.20, 132.43, 
129.58, 125.86, 122.02, 121.95, 113.97, 55.67; IR (film, cm-1): 2929, 1724, 1605, 1509, 1485, 
1449, 1318, 1255, 1193, 1178, 1162, 1074, 1024; HRMS (ESI+) m/z calcd for C14H12O3 
[M+H]+229.0859, found 229.0868, calcd [M+Na]+ 251.0679, found 251.0672; 
Phenyl 3-chlorobenzoate (1.84c) 
Purification by flash chromatography (95:5→8:2Hexanes: Et2O) to afford the 
above compound 1.84c (40 mg, 86%) as white solid. 1H NMR (700 MHz, CDCl3) δ 8.20 (s, 1H), 
8.10 (d, J = 7.8 Hz, 1H), 7.62 (d, J = 7.98 Hz, 1H), 7.49 – 7.42 (m, 3H), 7.30 (t, J = 7.5 Hz, 1H), 
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7.22 (d, J = 8.0 Hz, 2H); 13C NMR (175 MHz, CDCl3) δ164.13, 150.84, 134.89, 133.74, 131.46, 
130.32, 130.04, 129.71, 128.42, 126.25, 121.70,; IR (film, cm-1): 3068, 2922, 1732, 1590, 1484, 
1248, 1195, 1075; HRMS (EI) m/z calcd for C13H9ClO2 [M]+232.0291, found 232.0292; 
Phenyl 4-nitrobenzoate  (1.84d) 
Purification by flash chromatography (9:1→7:3Hexanes: Et2O) to afford the 
above compound 1.84d (32 mg, 67%) as yellow solid. 1H NMR (700 MHz, CDCl3) δ 8.38 (m, 
4H), 7.47 (t, J = 8.0 Hz, 2H), 7.32 (t, J = 7.5 Hz, 1H), 7.24 (d, J = 7.7 Hz, 2H); 13C NMR (175 
MHz, CDCl3) δ163.46, 151.03, 150.63, 135.11, 131.44, 129.83, 126.56, 123.87, 121.55; IR (film, 
cm-1): 2923, 1738, 1518, 1265, 1182, 1077; HRMS (EI) m/z calcd for C13H9NO4 [M]+243.0532, 
found 243.0535; 
Phenyl 4-bromobenzoate (1.84e) 
Purification by flash chromatography (95:5→9:1Hexanes: Et2O) to afford the 
above compound 1.84e (44 mg, 80%) as white crystal. 1H NMR (700 MHz, CDCl3) δ 8.07 (d, J = 
8.61 Hz, 2H), 7.66 (d, J = 8.61 Hz, 2H), 7.44 (t, J = 7.56 Hz, 2H), 7.29 (t, J = 7.46 Hz, 1H), 7.21 
(d, J = 7.56 Hz, 2H); 13C NMR (175 MHz, CDCl3) δ164.64, 150.89, 132.10, 131.80, 129.69, 
128.98, 128.62, 126.20, 121.75; IR (film, cm-1): 2922, 2852, 1728, 1583, 1484, 1394, 1265, 1192, 
1174, 1155, 1074; HRMS (EI) m/z calcd for C13H9BrO2 [M]+275.9786, found 275.9789; 
Phenyl (E)-2-methylbut-2-enoate (1.84f) 
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Purification by flash chromatography (99:1→9:1Hexanes: Et2O) to afford the 
above compound 1.84f (27 mg, 73%) as colorless liquid. 1H NMR (500 MHz, CDCl3) δ 7.38 (t, J 
= 7.9 Hz, 2H), 7.22 (t, J = 7.4 Hz, 1H), 7.15 – 7.08 (m, 3H), 1.96 (s, 3H), 1.89 (d, J = 7.1 Hz, 3H); 
13C NMR (175 MHz, CDCl3) δ166.71, 151.28, 139.50, 129.49, 128.32, 125.66, 121.86, 14.78, 
12.32; IR (film, cm-1): 2926, 1722, 1650, 1592, 1494, 1485, 1388, 1258, 1242, 1194, 1161, 1110, 
1056, 1001; HRMS (ESI) m/z calcd for C11H12O2 [M+H]+177.0910, found 177.0906; 
phenyl (E)-2-methylpent-2-enoate (1.84g) 
Purification by flash chromatography (99:1→9:1Hexanes: Et2O) to afford the 
above compound 1.84g (31 mg, 83%) as yellow liquid. 1H NMR (500 MHz, CDCl3) δ 7.38 (t, J = 
7.8 Hz, 2H), 7.22 (t, J = 7.1 Hz, 1H), 7.11 (d, J = 7.7 Hz, 2H), 7.01 (td, J = 7.4, 1.1 Hz, 1H), 2.28 
(p, J = 7.5 Hz, 2H), 1.95 (s, 3H), 1.11 (t, J = 7.6 Hz, 3H); 13C NMR (175 MHz, CDCl3) δ 166.87, 
151.29, 146.22, 129.47, 126.80, 125.65, 121.86, 22.38, 13.11, 12.48; IR (film, cm-1): 2965, 1725, 
1646, 1593, 1487, 1231, 1195, 1162, 1126, 1089, 1066; HRMS (ESI) m/z calcd for C12H14O2 
[M+H]+ 191.1067, found 191.1067; 
Phenyl cinnamate (1.84h) 
Purification by flash chromatography (99:1→9:1Hexanes: Et2O) to afford 
the above compound 1.84h (39 mg, 89%) as white crystal. 1H NMR (700 MHz, CDCl3) δ 7.88 (d, 
J = 16.0 Hz, 1H), 7.62 – 7.57 (m, 2H), 7.46 – 7.39 (m, 5H), 7.28 – 7.24 (m, 1H), 7.18 (d, J = 7.6 
Hz, 2H), 6.65 (d, J = 16.0 Hz, 1H); 13C NMR (175 MHz, CDCl3) δ165.54, 150.92, 146.71, 134.30, 
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130.84, 129.58, 129.13, 128.44, 125.93, 121.77, 117.44; IR (film, cm-1): 2923, 1724, 1635, 1483, 
1305, 1202, 1139; HRMS (APCI+) m/z calcd for C15H12O2 [M+H]+225.0910, found 225.0899; 
Phenyl 3-(3-methoxyphenyl)propanoate (1.84i) 
Purification by flash chromatography (95:5→9:1Hexanes: Et2O) to afford the 
above compound 1.84i (34 mg, 67%) as colorless liquid. 1H NMR (700 MHz, CDCl3) δ 7.37 (t, J 
= 7.56 Hz, 2H), 7.27 – 7.21 (m, 2H), 7.04 (d, J = 7.56 Hz, 2H), 6.87 (d, J=7.56 Hz, 1H), 6.82 (s, 
1H), 6.79 (dd, J = 8.2, 2.4 Hz, 1H), 3.81 (s, 3H), 3.06 (t, J = 7.8 Hz, 2H), 2.89 (t, J = 7.8 Hz, 2H); 
13C NMR (175 MHz, CDCl3) δ171.52, 159.89, 150.76, 141.86, 129.72, 129.54, 125.94, 121.66, 
120.84, 114.26, 111.93, 55.31, 36.06, 31.13; IR (film, cm-1): 2940, 1755, 1593, 1584, 1491, 1454, 
1259, 1192, 1161, 1126, 1041; HRMS (APCI+) m/z calcd for C16H16O3 [M+H]+257.1172, found 
257.1172; 
Phenyl (E)-4-phenylbut-3-enoate (1.84j) 
Purification by flash chromatography (99:1→9:1Hexanes: Et2O) to afford 
the above compound 1.84j (35 mg, 71%) as off-white crystal. 1H NMR (700 MHz, CDCl3) δ 7.43 
– 7.36 (m, 4H), 7.33 (t, J = 7.7 Hz, 2H), 7.27 – 7.22 (m, 2H), 7.11 (d, J = 7.7 Hz, 2H), 6.61 (d, J 
= 15.9 Hz, 1H), 6.41 (dt, J = 15.7, 7.1 Hz, 1H), 3.50 (d, J = 7.07 Hz, 2H); 13C NMR (175 MHz, 
CDCl3) δ170.18, 150.80, 136.84, 134.21, 129.59, 128.74, 127.87, 126.50, 126.06, 121.65, 121.13, 
38.60; IR (film, cm-1): 3034, 1742, 1591, 1492, 1364, 1201, 1133; HRMS (APCI+) m/z calcd for 
C16H14O2 [M+H]+ 239.1067, found 239.1060; 
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4-(tert-butyl)phenyl benzoate (SI-1) 
Purification by flash chromatography (99:1→9:1Hexanes: Et2O) to 
afford the above compound (42 mg, 84%) as white crystal. 1H NMR (700 MHz, CDCl3) δ 8.21 (d, 
J = 7.1 Hz, 2H), 7.64 (t, J = 7.4 Hz, 1H), 7.52 (t, J = 7.7 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 7.15 
(d, J = 8.8 Hz, 2H), 1.35 (s, 9H); 13C NMR (175 MHz, CDCl3) δ165.49, 148.83, 148.71, 133.64, 
130.29, 129.83, 128.67, 126.53, 121.13, 34.66, 31.58; IR (film, cm-1): 2964, 1730, 1508, 1262, 
1203, 1170, 1076, 1060, 1021; HRMS (ESI+) m/z calcd for C17H18O2 [M+H]+255.1380, found 
255.1378; 
4-bromophenyl benzoate (SI-2) 
Purification by flash chromatography (99:1→9:1Hexanes: Et2O) to afford 
the above compound (38 mg, 70%) as white crystal. 1H NMR (700 MHz, CDCl3):
 δ 8.19 (d, J = 
7.1 Hz, 2H), 7.65 (t, J = 7.5 Hz, 1H), 7.57 – 7.50 (m, 4H), 7.12 (d, J = 8.82, 2H); 13C NMR (175 
MHz, CDCl3) δ165.01, 150.10, 133.95, 132.68, 130.35, 129.30, 128.78, 123.69, 119.13; IR (film, 
cm-1): 2923, 1730, 1482, 1259, 1198, 1160, 1057; HRMS (EI) m/z calcd for C13H9BrO2 
[M]+275.9786, found 275.9787; 
Phenyl (1R,4aR,4bR,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-
decahydrophenanthrene-1-carboxylate (1.84k) 
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Potassium tert-butoxide (22 mg, 0.2 mmol), copper(II) 
trifluoromethanesulfonate (15 mg, 0.04 mmol), and abietic acid (60 mg of 75% abietic acid, 0.15 
mmol) were added to an oven dried and nitrogen flushed 10 mL vial charged with 3 mL dry 
dichloromethane at rt and then left to stir for 10 minutes. Diaryliodonium salt (95 mg, 0.22 mmol) 
and C (30 mg, 0.04 mmol) were added in one portion and reaction was stirred for 24 h at 40oC. 
The reaction was then quenched with H2O. The product was extracted with diethyl ether and the 
organic layer was dried over Na2SO4, filtered and concentrated. Purification by flash 
chromatography (95:5→9:1 Hexanes: EtOAc) to afford the above compound 1.84k (40 mg, 71%) 
as yellow viscous liquid. Some impurities from the starting material (75% abietic acid) was also 
observed in the product and was inseparable by accessible purification process. 1H NMR (700 
MHz, CDCl3) δ 7.36 (t, J = 7.8 Hz, 2H), 7.21 (t, J = 7.3 Hz, 1H), 7.01 (d, J = 7.9 Hz, 2H), 5.81 (s, 
1H), 5.43 (s, 1H), 2.31 - 2.27 (m, 1H), 2.26 – 2.21 (m, 1H), 2.11 (d, J = 2.7 Hz, 2H), 2.03 – 1.99 
(m, 2H), 1.94 (d, J = 13.1 Hz, 1H),  1.86 – 1.82 (m, 2H), 1.70 – 1.63 (m, 2H), 1.39 (s, 3H), 1.29 – 
1.19 (m, 4H), 1.03 (t, J = 6.7 Hz, 6H), 0.89 (s, 3H); 13C NMR (175 MHz, CDCl3) δ177.26, 151.30, 
145.62, 135.71, 129.45, 125.68, 122.46, 121.67, 120.57, 51.03, 46.99, 45.20, 38.42, 37.20, 35.04, 
34.74, 27.59, 25.92, 22.62, 21.55, 20.97, 18.29, 17.27, 14.20; IR (film, cm-1):2928, 1743, 1594, 
1492, 1458, 1385, 12766, 1227, 1190, 1162, 1129, 1101, 1025, 1000; HRMS (ESI+) m/z calcd for 
C26H34O2 [M+H]+ 379.2632, found 379.2635; 
Phenyl (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (1.84l) 
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Purification by flash chromatography (1:1→0:1Hexanes: 
EtOAc) to afford the above compound 1.84l (33 mg, 34%) as light-yellow solid. 1H NMR (700 
MHz, CDCl3) δ 7.37 (t, J = 7.9 Hz, 2H), 7.22 (t, J = 7.4 Hz, 1H), 7.07 (d, J = 7.7 Hz, 2H), 4.00 (s, 
1H), 3.85 (s, J = 2.5 Hz, 1H), 3.48 (s, 1H), 3.47 – 3.43 (m, 1H), 2.64 – 2.59 (m, 1H), 2.52 – 2.48 
(m, 1H), 2.26 – 2.18 (m, 1H), 1.98 – 1.88 (m, 5H), 1.85 – 1.81 (m, 1H), 1.78 (d, J = 14.4 Hz, 1H), 
1.75 – 1.66 (m, 4H), 1.63 – 1.59 (m, 1H), 1.58 – 1.46 (m, 6H), 1.40 (d, J = 12.1 Hz, 2H), 1.37 – 
1.32 (m, 1H), 1.14 (dd, J = 12.2, 6.1 Hz, 1H), 1.05 (d, J = 6.1 Hz, 3H), 1.01 – 0.96 (m, 1H), 0.89 
(s, 3H), 0.71 (s, 3H); 13C NMR (175 MHz, CDCl3) δ 172.86, 150.91, 129.53, 125.84, 121.70, 
73.15, 72.08, 68.57, 47.28, 46.67, 42.04, 41.58, 39.80, 39.71, 35.36, 35.34, 34.86, 34.77, 31.53, 
31.01, 30.64, 28.47, 27.65, 26.73, 23.35, 22.66, 17.53, 12.70; IR (film, cm-1): 3392, 2924, 1755, 
595, 1456, 1376, 1259, 1234, 1194, 1076, 1036; HRMS (ESI+) m/z calcd for C30H44O5 [M+NH4]+ 
502.3527, found 502.3526; 
(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-dimethyl-17-((R)-5-oxo-5-phenoxypentan-2-
yl)hexadecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triyl triacetate (1.84m) 
Purification by flash chromatography (9:1→7:3 Hexanes: 
EtOAc) to afford the above compound 1.84m (108 mg, 89%) as colorless solid. 1H NMR (700 
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MHz, CDCl3) δ(t, J = 7.98, 2H), 7.22 (t, J = 7.4 Hz, 1H), 7.06 (d, J = 7.6 Hz, 2H), 5.11 (s, 1H), 
4.91 (s, 1H), 4.59 – 4.57 (m, 1H), 2.60 (ddd, J = 15.0, 9.6, 5.1 Hz, 1H), 2.47 (ddd, J = 15.8, 9.1, 
7.0 Hz, 1H), 2.15 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 1.98 – 1.91 (m, 3H), 1.90 – 1.87 (m, 1H), 1.81 
– 1.74 (m, 2H), 1.70 (d, J = 5.6 Hz, 1H), 1.68 (d, J = 13.1 Hz, 1H), 1.65 – 1.62 (m, 1H), 1.61 – 
1.58 (m, 2H), 1.53 – 1.48 (m, 3H), 1.46 – 1.41 (m, 2H), 1.38 – 1.32 (m, 1H), 1.30 – 1.22 (m, 3H), 
1.16 – 1.11 (m, 1H), 1.07 (td, J = 14.4, 3.3 Hz, 1H), 0.92 (s, 3H), 0.89 (d, J = 6.4 Hz, 3H), 0.75 (s, 
3H); 13C NMR (175 MHz, CDCl3) δ172.52, 170.48, 170.32, 150.65, 129.38, 125.73, 121.48, 77.25, 
77.06, 76.88, 75.35, 74.05, 70.65, 47.36, 45.07, 43.39, 40.90, 37.70, 34.66, 34.61, 34.59, 34.31, 
31.21, 31.19, 30.69, 29.66, 28.86, 27.22, 26.86, 25.56, 22.79, 22.54, 21.61, 21.48, 21.43, 17.54, 
12.23; IR (film, cm-1): 2922, 1727, 1446, 1379, 1239, 1199, 1136, 1022; HRMS (EI) m/z calcd for 
C36H50O8 [M+NH4]+ 628.3844, found 628.3848;  
(R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-triacetoxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid (SI-3) 
To an ice cooled solution of cholic acid (1 gm; 2.45 mmol) in 
pyridine (3 mL) and acetic anhydride (2 mL), DMAP (180 mg, 1.47 mmol) was added. The 
reaction mixture was stirred at rt for 3 h. The solution was concentrated in vacuo, dissolved in 50 
mL diethyl ether, washed with 0.1 M HCl, NaHCO3, and brine. The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo to give the crude product. Purification via flash 
chromatography (8:2→1:1Hexanes: EtOAc) to afford the above compound (831 mg, 63%) as 
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colorless solid. 1H NMR (700 MHz, CDCl3) δ5.09 (s, 1H), 4.91 (s, 1H), 4.59 – 4.56 (m, 1H), 2.42 
– 2.36 (m, 1H), 2.27 – 2.22 (m, 1H), 2.14 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.04 – 1.99 (m, 1H), 
1.97 – 1.93 (m, 1H), 1.90 – 1.84 (m, 2H), 1.82 – 1.72 (m, 3H), 1.68 – 1.64 (m, 2H), 1.63 – 1.59 
(m, 2H), 1.54 – 1.48 (m, 2H), 1.45 – 1.41 (m, 2H), 1.34 – 1.25 (m, 4H), 1.14 – 1.08 (m, 1H), 1.08 
– 1.03 (m, 1H), 0.92 (s, 3H), 0.87 (dt, J = 14.4, 7.0 Hz, 2H), 0.83 (d, J = 6.6 Hz, 3H), 0.73 (s, 3H); 
13C NMR (175 MHz, CDCl3) δ 179.36, 170.58, 170.54, 170.42, 75.37, 74.08, 70.70, 47.31, 45.04, 
43.37, 40.89, 37.71, 34.58, 34.52, 34.30, 31.56, 31.21, 30.75, 30.51, 28.86, 27.14, 26.86, 25.55, 
22.63, 22.53, 21.60, 21.47, 17.46, 14.10, 12.21; IR (film, cm-1): 2936, 2013, 1730, 1441, 1374, 
1230, 1023; HRMS (EI) m/z calcd for C30H46O8 [M+NH4]+ 552.3531, found 552.3530; Calcd 
[M+Na]+ 557.3085, found 557.3081; 
2-phenoxyisoindoline-1,3-dione (1.88) 
Potassium tert-butoxide (25 mg, 0.2 mmol), copper(II) 
trifluoromethanesulfonate (15 mg, 0.04 mmol), and phthalimide (33 mg, 0.15 mmol) were added 
to an oven dried and nitrogen flushed 10 mL vial charged with 1 mL dry toluene at rt and then left 
to stir for 10 minutes. The bloody red color of the reaction mixture was observed. Diaryliodonium 
salt (95 mg, 0.22 mmol) and C (30 mg, 0.04 mmol) were added in one portion and reaction was 
stirred for 24 h at 60 oC. The reaction was then quenched with H2O. The product was extracted 
with diethyl ether and the organic layer was dried over Na2SO4, filtered and concentrated. 
Purification by flash chromatography (95:5→7:3 Hexanes: EtOAc) to afford the above compound 
1.88 (29 mg, 78%) as white solid. Some impurities were observed in small quantity and was 
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inseparable by accessible purification process. 1H NMR (400 MHz, CDCl3) δ 7.91 (dd, J = 5.5, 
3.1 Hz, 2H), 7.80 (dd, J = 5.5, 3.1 Hz, 2H), 7.37 – 7.29 (m, 2H), 7.19 – 7.07 (m, 3H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
References: 
(1)  Taylor, M. S.; Jacobsen, E. N. Asymmetric Catalysis by Chiral Hydrogen-Bond Donors. 
Angew. Chem. Int. Ed. 2006, 45 (10), 1520–1543. 
(2)  Akiyama, T. Stronger Brønsted Acids. Chem. Rev. 2007, 107 (12), 5744–5758. 
(3)  Doyle, A. G.; Jacobsen, E. N. Small-Molecule H-Bond Donors in Asymmetric Catalysis. 
Chem. Rev. 2007, 107 (12), 5713–5743. 
(4)  Chandler, C.; Galzerano, P.; Michrowska, A.; List, B. The Proline-Catalyzed Double 
Mannich Reaction of Acetaldehyde with N-Boc Imines. Angew. Chem. Int. Ed. 2009, 48 (11), 
1978–1980. 
(5)  List, B.; Pojarliev, P.; Biller, W. T.; Martin, H. J. The Proline-Catalyzed Direct 
Asymmetric Three-Component Mannich Reaction:  Scope, Optimization, and Application to the 
Highly Enantioselective Synthesis of 1,2-Amino Alcohols. J. Am. Chem. Soc. 2002, 124 (5), 
827–833. 
(6)  Liu, X.; Deng, L.; Song, H.; Jia, H.; Wang, R. Asymmetric Aza-Mannich Addition: 
Synthesis of Modified Chiral 2-(Ethylthio)-Thiazolone Derivatives with Anticancer Potency. 
Org. Lett. 2011, 13 (6), 1494–1497. 
(7)  Lou, S.; Dai, P.; Schaus, S. E. Asymmetric Mannich Reaction of Dicarbonyl Compounds 
with α-Amido Sulfones Catalyzed by Cinchona Alkaloids and Synthesis of Chiral 
Dihydropyrimidones. J. Org. Chem. 2007, 72 (26), 9998–10008. 
(8)  Mukherjee, S.; Yang, J. W.; Hoffmann, S.; List, B. Asymmetric Enamine Catalysis. 
Chem. Rev. 2007, 107 (12), 5471–5569. 
(9)  Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. New Strategies for Organic 
Catalysis:  The First Highly Enantioselective Organocatalytic Diels−Alder Reaction. J. Am. 
Chem. Soc. 2000, 122 (17), 4243–4244. 
(10)  Jen, W. S.; Wiener, J. J. M.; MacMillan, D. W. C. New Strategies for Organic Catalysis:  
The First Enantioselective Organocatalytic 1,3-Dipolar Cycloaddition. J. Am. Chem. Soc. 2000, 
122 (40), 9874–9875. 
(11)  Liebig, J. Ann Chem Pharm 1860, 13, 246–247. 
(12)  Knoevenagel, E. Ber Dtsch Chem Ges 1896, 29, 172. 
(13)  Bredig, G.; Fiske, P. S. Biochem Z 1912, 46, 7–23. 
(14)  Wassermann, A. 127. Homogeneous Catalysis of Diene Syntheses. A New Type of 
Third-Order Reaction. J. Chem. Soc. Resumed 1942, 618. 
(15)  Hajos, Z. G.; Parrish, D. R. DE 2102623, 1971. 
(16)  Hajos, Z. G.; Parrish, D. R. Asymmetric Synthesis of Bicyclic Intermediates of Natural 
Product Chemistry. J. Org. Chem. 1974, 39 (12), 1615–1621. 
(17)  Hine, J.; Ahn, K.; Gallucci, J. C.; Linden, S. M. 1,8-Biphenylenediol Forms Two Strong 
Hydrogen Bonds to the Same Oxygen Atom. J. Am. Chem. Soc. 1984, 106 (25), 7980–7981. 
(18)  Hine, J.; Linden, S. M.; Kanagasabapathy, V. M. 1,8-Biphenylenediol Is a Double-
Hydrogen-Bonding Catalyst for Reaction of an Epoxide with a Nucleophile. J. Am. Chem. Soc. 
1985, 107 (4), 1082–1083. 
(19)  Curran, D. P.; Kuo, L. H. Altering the Stereochemistry of Allylation Reactions of Cyclic 
.Alpha.-Sulfinyl Radicals with Diarylureas. J. Org. Chem. 1994, 59 (12), 3259–3261. 
(20)  Curran, D. P.; Kuo, L. H. Acceleration of a Dipolar Claisen Rearrangement by Hydrogen 
Bonding to a Soluble Diaryl^urea. Tetrahedron Lett. 1995, 36 (37), 6647–6650. 
(21)  Schreiner, P. R.; Wittkopp, A. H-Bonding Additives Act Like Lewis Acid Catalysts. Org. 
Lett. 2002, 4 (2), 217–220. 
46 
 
(22)  Wittkopp, A.; Schreiner, P. R. Metal-Free, Noncovalent Catalysis of Diels–Alder 
Reactions by Neutral Hydrogen Bond Donors in Organic Solvents and in Water. Chem. – Eur. J. 
2003, 9 (2), 407–414. 
(23)  Yang, W.; Du, D.-M. Highly Enantioselective Michael Addition of Nitroalkanes to 
Chalcones Using Chiral Squaramides as Hydrogen Bonding Organocatalysts. Org. Lett. 2010, 12 
(23), 5450–5453. 
(24)  Raheem, I. T.; Thiara, P. S.; Peterson, E. A.; Jacobsen, E. N. Enantioselective 
Pictet−Spengler-Type Cyclizations of Hydroxylactams:  H-Bond Donor Catalysis by Anion 
Binding. J. Am. Chem. Soc. 2007, 129 (44), 13404–13405. 
(25)  Okino, T.; Hoashi, Y.; Takemoto, Y. Enantioselective Michael Reaction of Malonates to 
Nitroolefins Catalyzed by Bifunctional Organocatalysts. J. Am. Chem. Soc. 2003, 125 (42), 
12672–12673. 
(26)  Flock, A. M.; Krebs, A.; Bolm, C. Ephedrine- and Pseudoephedrine-Derived Thioureas in 
Asymmetric Michael Additions of Keto Esters and Diketones to Nitroalkenes. Synlett 2010, 2010 
(8), 1219–1222. 
(27)  Rodriguez, A. A.; Yoo, H.; Ziller, J. W.; Shea, K. J. New Architectures in Hydrogen 
Bond Catalysis. Tetrahedron Lett. 2009, 50 (49), 6830–6833. 
(28)  Wasa, M.; Liu, R. Y.; Roche, S. P.; Jacobsen, E. N. Asymmetric Mannich Synthesis of α-
Amino Esters by Anion-Binding Catalysis. J. Am. Chem. Soc. 2014, 136 (37), 12872–12875. 
(29)  Sigman, M. S.; Jacobsen, E. N. Schiff Base Catalysts for the Asymmetric Strecker 
Reaction Identified and Optimized from Parallel Synthetic Libraries. J. Am. Chem. Soc. 1998, 
120 (19), 4901–4902. 
(30)  Thadani, A. N.; Stankovic, A. R.; Rawal, V. H. Enantioselective Diels–Alder Reactions 
Catalyzed by Hydrogen Bonding. Proc. Natl. Acad. Sci. 2004, 101 (16), 5846–5850. 
(31)  Uraguchi, D.; Sorimachi, K.; Terada, M. Organocatalytic Asymmetric Aza-
Friedel−Crafts Alkylation of Furan. J. Am. Chem. Soc. 2004, 126 (38), 11804–11805. 
(32)  Du, H.; Zhao, D.; Ding, K. Enantioselective Catalysis of the Hetero-Diels–Alder 
Reaction between Brassard’s Diene and Aldehydes by Hydrogen-Bonding Activation: A One-
Step Synthesis of (S)-(+)-Dihydrokawain. Chem. – Eur. J. 2004, 10 (23), 5964–5970. 
(33)  Hasegawa, A.; Naganawa, Y.; Fushimi, M.; Ishihara, K.; Yamamoto, H. Design of 
Brønsted Acid-Assisted Chiral Brønsted Acid Catalyst Bearing a Bis(Triflyl)Methyl Group for a 
Mannich-Type Reaction. Org. Lett. 2006, 8 (15), 3175–3178. 
(34)  Mittal, N.; Sun, D. X.; Seidel, D. Conjugate-Base-Stabilized Brønsted Acids: Catalytic 
Enantioselective Pictet–Spengler Reactions with Unmodified Tryptamine. Org. Lett. 2014, 16 
(3), 1012–1015. 
(35)  Min, C.; Mittal, N.; Sun, D. X.; Seidel, D. Conjugate-Base-Stabilized Brønsted Acids as 
Asymmetric Catalysts: Enantioselective Povarov Reactions with Secondary Aromatic Amines. 
Angew. Chem. Int. Ed. 2013, 52 (52), 14084–14088. 
(36)  Min, C.; Lin, C.-T.; Seidel, D. Catalytic Enantioselective Intramolecular Aza-Diels–
Alder Reactions. Angew. Chem. Int. Ed. 2015, 54 (22), 6608–6612. 
(37)  Beletskiy, E. V.; Schmidt, J.; Wang, X.-B.; Kass, S. R. Three Hydrogen Bond Donor 
Catalysts: Oxyanion Hole Mimics and Transition State Analogues. J. Am. Chem. Soc. 2012, 134 
(45), 18534–18537. 
(38)  Dutzler, R.; Campbell, E. B.; Cadene, M.; Chait, B. T.; MacKinnon, R. X-Ray Structure 
of a ClC Chloride Channel at 3.0 Å Reveals the Molecular Basis of Anion Selectivity. Nature 
2002, 415 (6869), 287–294. 
47 
 
(39)  Cranwell, P. B.; Hiscock, J. R.; Haynes, C. J. E.; Light, M. E.; Wells, N. J.; Gale, P. A. 
Anion Recognition and Transport Properties of Sulfamide-, Phosphoric Triamide- and 
Thiophosphoric Triamide-Based Receptors. Chem. Commun. 2013, 49 (9), 874–876. 
(40)  Borovika, A.; Tang, P.-I.; Klapman, S.; Nagorny, P. Thiophosphoramide-Based 
Cooperative Catalysts for Brønsted Acid Promoted Ionic Diels–Alder Reactions. Angew. Chem. 
Int. Ed. 2013, 52 (50), 13424–13428. 
(41)  Walvoord, R. R.; Huynh, P. N. H.; Kozlowski, M. C. Quantification of Electrophilic 
Activation by Hydrogen-Bonding Organocatalysts. J. Am. Chem. Soc. 2014, 136 (45), 16055–
16065. 
(42)  Malerich, J. P.; Hagihara, K.; Rawal, V. H. Chiral Squaramide Derivatives Are Excellent 
Hydrogen Bond Donor Catalysts. J. Am. Chem. Soc. 2008, 130 (44), 14416–14417. 
(43)  Li, X.; Zhang, Q.; Li, Z.; Xu, S.; Zhao, C.; Chen, C.; Zhi, X.; Wang, H.; Zhu, N.; Guo, K. 
Tripodal Hydrogen Bond Donor Binding with Sulfonic Acid Enables Ring-Opening 
Polymerization. Polym. Chem. 2016, 7 (7), 1368–1374. 
(44)  Nicolaou, K. C.; Montagnon, T.; Baran, P. S.; Zhong, Y.-L. Iodine(V) Reagents in 
Organic Synthesis. Part 4. o-Iodoxybenzoic Acid as a Chemospecific Tool for Single Electron 
Transfer-Based Oxidation Processes. J. Am. Chem. Soc. 2002, 124 (10), 2245–2258. 
(45)  Wirth, T. IBX—New Reactions with an Old Reagent. Angew. Chem. Int. Ed. 2001, 40 
(15), 2812–2814. 
(46)  Wirth, T. Hypervalent Iodine Chemistry in Synthesis: Scope and New Directions. Angew. 
Chem. Int. Ed. 2005, 44 (24), 3656–3665. 
(47)  Richardson, R. D.; Wirth, T. Hypervalent Iodine Goes Catalytic. Angew. Chem. Int. Ed. 
2006, 45 (27), 4402–4404. 
(48)  Silva, Jr., L. F.; Olofsson, B. Hypervalent Iodine Reagents in the Total Synthesis of 
Natural Products. Nat. Prod. Rep. 2011, 28 (10), 1722. 
(49)  Zhdankin, V. V.; Stang, P. J. Chemistry of Polyvalent Iodine. Chem. Rev. 2008, 108 (12), 
5299–5358. 
(50)  Merritt, E. A.; Olofsson, B. Diaryliodonium Salts: A Journey from Obscurity to Fame. 
Angew. Chem. Int. Ed. 2009, 48 (48), 9052–9070. 
(51)  Deprez, N. R.; Sanford, M. S. Synthetic and Mechanistic Studies of Pd-Catalyzed C−H 
Arylation with Diaryliodonium Salts: Evidence for a Bimetallic High Oxidation State Pd 
Intermediate. J. Am. Chem. Soc. 2009, 131 (31), 11234–11241. 
(52)  Chen, D.-W.; Takai, K.; Ochiai, M. The First Example for Reactivity Umpolung of 
Diaryliodonium Salts: Chromium(II)-Mediated Arylation of Aldehydes. Tetrahedron Lett. 1997, 
38 (47), 8211–8214. 
(53)  Phipps, R. J.; Gaunt, M. J. A Meta-Selective Copper-Catalyzed C–H Bond Arylation. 
Science 2009, 323 (5921), 1593–1597. 
(54)  Toh, Q. Y.; McNally, A.; Vera, S.; Erdmann, N.; Gaunt, M. J. Organocatalytic C–H Bond 
Arylation of Aldehydes to Bis-Heteroaryl Ketones. J. Am. Chem. Soc. 2013, 135 (10), 3772–
3775. 
(55)  Allen, A. E.; MacMillan, D. W. C. The Productive Merger of Iodonium Salts and 
Organocatalysis: A Non-Photolytic Approach to the Enantioselective α-Trifluoromethylation of 
Aldehydes. J. Am. Chem. Soc. 2010, 132 (14), 4986–4987. 
(56)  Jalalian, N.; Petersen, T. B.; Olofsson, B. Metal-Free Arylation of Oxygen Nucleophiles 
with Diaryliodonium Salts. Chem. – Eur. J. 2012, 18 (44), 14140–14149. 
48 
 
(57)  Umierski, N.; Manolikakes, G. Metal-Free Synthesis of Diaryl Sulfones from 
Arylsulfinic Acid Salts and Diaryliodonium Salts. Org. Lett. 2013, 15 (1), 188–191. 
(58)  Ghosh, R.; Olofsson, B. Metal-Free Synthesis of N-Aryloxyimides and Aryloxyamines. 
Org. Lett. 2014, 16 (6), 1830–1832. 
(59)  Lockhart, T. P. Mechanistic Investigation of the Copper-Catalyzed Reactions of 
Diphenyliodonium Salts. J. Am. Chem. Soc. 1983, 105 (7), 1940–1946. 
(60)  Canty, A. J.; Ariafard, A.; Sanford, M. S.; Yates, B. F. Mechanism of Pd-Catalyzed Ar–
Ar Bond Formation Involving Ligand-Directed C–H Arylation and Diaryliodonium Oxidants: 
Computational Studies of Orthopalladation at Binuclear Pd(II) Centers, Oxidation To Form 
Binuclear Palladium(III) Species, and Ar···Ar Reductive Coupling. Organometallics 2013, 32 
(2), 544–555. 
(61)  Ichiishi, N.; Canty, A. J.; Yates, B. F.; Sanford, M. S. Cu-Catalyzed Fluorination of 
Diaryliodonium Salts with KF. Org. Lett. 2013, 15 (19), 5134–5137. 
(62)  Petersen, T. B.; Khan, R.; Olofsson, B. Metal-Free Synthesis of Aryl Esters from 
Carboxylic Acids and Diaryliodonium Salts. Org. Lett. 2011, 13 (13), 3462–3465. 
(63)  Phipps, R. J.; Grimster, N. P.; Gaunt, M. J. Cu(II)-Catalyzed Direct and Site-Selective 
Arylation of Indoles Under Mild Conditions. J. Am. Chem. Soc. 2008, 130 (26), 8172–8174. 
(64)  Zhou, T.; Chen, Z.-C. Hypervalent Iodine in Synthesis. 77. an Efficient Method for the 
Synthesis of N-Arylindoles by the Copper-Catalyzed N-Arylation of Indole with Diaryliodonium 
Salts. Synth. Commun. 2002, 32 (6), 903–907. 
(65)  Aggarwal, V. K.; Olofsson, B. Enantioselective α-Arylation of Cyclohexanones with 
Diaryl Iodonium Salts: Application to the Synthesis of (−)-Epibatidine. Angew. Chem. Int. Ed. 
2005, 44 (34), 5516–5519. 
(66)  Gao, P.; Larson, D. L.; Portoghese, P. S. Synthesis of 7-Arylmorphinans. Probing the 
“Address” Requirements for Selectivity at Opioid δ Receptors. J. Med. Chem. 1998, 41 (16), 
3091–3098. 
(67)  Gao, P.; Portoghese, P. S. Monophenylation of Morphinan-6-Ones with 
Diphenyliodonium Iodide. J. Org. Chem. 1995, 60 (7), 2276–2278. 
(68)  Kozmin, S. A.; Rawal, V. H. A General Strategy to Aspidosperma Alkaloids:  Efficient, 
Stereocontrolled Synthesis of Tabersonine. J. Am. Chem. Soc. 1998, 120 (51), 13523–13524. 
 
49 
 
 
 
 
 
Chapter 2 
Cardiac Steroids: Introduction and Previous Synthesis 
(A part of this work has been published in Bhattarai, B.; Nagorny, P. Enantioselective Total 
Synthesis of Cannogenol-3-O-α-L-rhamnoside via Sequential Cu(II)-Catalyzed Michael 
Addition/Intramolecular Aldol Cyclization Reactions. Org. Lett. 2018, 20, 154-157) 
2.1. Introduction 
Cardiac steroids like ouabain and digitoxin (Figure 2.1) were traditionally used in ancient 
China and a big part of Africa to treat congestive heart failure.1 They are also known to be effective 
antiarrhythmic agents. These steroids inhibit the Na+/K+-ATPase pump, which elevates the 
intracellular calcium intake  and improves the cardiac contractility to counteract congestive heart 
failure.2 Cardiac glycoside-based compounds are currently in different phases of clinical trials for 
various ailments such as cancer and hypertension. Some of these steroids include rostafuroxin,3 
bufalin,4 and UNBS 1450 (Figure 2.2).5  
Figure 2.1. Examples of Common Cardiotonic Steroids.  
 
In addition, strophanthidin and ouabain (Figure 2.1) have recently been identified as potent 
inhibitors of DNA double-strand break repair in a study investigating homologous recombination 
(HR) and non-homologous end joining (NHEJ) by Herzon and co-workers.6 This new development 
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has prompted several in vivo and in vitro studies. As a result, these cardiac glycoside-based 
compounds are now on clinical trials for several other human diseases.  
The therapeutic index, the comparison of amount of reagents to show therapeutic effect to the 
amount that leads to toxicity, of these cardiac steroids are narrow and sometimes there is an overlap 
of a dose required to treat the failing heart with one that can show to toxic symptoms.7 This has 
been one of the limiting factor in the development of these compounds as drugs. One way to tackle 
this unfortunate limitation would be to test activity of chemical entities with similar scaffolds. 
Hence, there is an urgent need to utilize the tools of organic synthesis to develop methods to access 
the derivatives of these steroids in quest of less toxic clinical candidates with retained or improved 
activity. 
Figure 2.2. Representative Cardiac Steroids and Analogs in Different Phases of Clinical Trials. 
 
Unfortunately, most of the compounds of this class are found in indigenous plants and animals 
in very low concentration, and are not easily accessible for extraction.8,9 In recent years, the interest 
in developing the synthetic strategies to cardiotonic steroids has been rising, with more focus on 
the members with higher degree of oxygenation.10–12 These approaches either require multiple 
steps to access the chiral building blocks11,12 prior to the construction of steroid framework or rely 
on semisynthetic approaches10,13 which require downstream redox manipulations at key positions 
and often are limited to the access of diverse stereochemistry at ring junctions. Therefore, a 
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modular approach, which utilizes simple achiral building blocks and quickly constructs the 
oxygenated core in a divergent manner, would highly improve the accessibility of various natural 
and unnatural cardiotonic steroids and significantly increases the scope of the subsequent 
biological activity evaluation studies.       
2.2. Class of Cardiotonic Steroids Based on Size of Lactone Ring 
Cardiotonic steroids can be broadly divided into two subclasses based on the heterocycle 
moiety at C17 (Figure 2.3). Cardenolides are mostly extracted from plant extracts and contain 5-
membered unsaturated gamma-butyrolactone, also called butenolide at C-17. Bufadienolides, on 
the other hand, are extracted from animal sources, commonly from toads of genus Bufo and contain 
6- membered, double unsaturated, delta valerolactone or 2-pyrone. This difference in substituent 
at the C17 site results in distinct biological activities. Natural products and their analogs with 
different heterocycles in place of butenolide and 2-pyrone have been studied and have shown 
stimulating results in variety of biological activities.  
Figure 2.3. General Structural Characteristics and Numbering of Cardiac Steroids 
 
Glucose, rhamnose, digitoxose, and mannose are common natural sugars that are attached with 
the steroid aglycone, although a wide variety of other monosaccharaides, disaccharides, and 
trisaccharide sugar moiety are prevalent. Despite no known distinct role of these sugar moieties 
towards biological activity, the attachment of these groups in the cardiac steroids has shown a 
significant difference in their pharmacokinetic and pharmacodynamic profile. In several cases, 
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changing the identity of the sugar moiety changes the potency of the compound. For instance, 
mannoside has no significant effect on the potency, however, introduction of  a rhamnoside is 
shown to increase the potency of these steroids by several folds.14 
2.3. Previous Synthesis of Cardiotonic Steroids 
The biological activities of cardiotonic steroids are well studied and thus, several attempts have 
been made towards the synthesis of these molecules. Due to its biological activity and relatively 
simple structure, digitoxigenin has been one of the most common target, the synthesis of which 
was achieved by Sondheimer,15 Yoshii,13 and Wiesner16 through semi-synthetic efforts. Later, 
Stork17 (first enantioselective) and Nakada18 completed the total synthesis of digitoxigenin. One 
of the most challenging molecules to synthesize in this class is ouabain; it contains numerous 
stereocenters and is highly oxygenated. The first total synthesis of this molecule was completed 
by Deslongchamps using polyanionic cyclization strategy.12,19 In 2013, the Baran group used a 
strategic redox- and stereochemical-relay approach to complete a more practical synthesis of 
ouabagenin, the aglycone of ouabain, albeit through a semi-synthetic route from the readily 
available cortisone acetate.10,20 Other notable total syntheses in this class of natural product include 
the synthesis of rhodexin based on an inverse-electron-demand-Diels-Alder reaction by Jung and 
Yoo,21 and an acetal formation/intramolecular radical coupling strategy to 19-
hydroxysermentogenin by Inoue11 and more recently by Nagorny.22  
2.3.1. Semi-synthesis of Digitoxigenin by Yoshii and Coworkers13 
The early synthesis of digitoxigenin marks as an important precedence on the synthesis of 
cardiotonic steroids.  Pregnan-3β-ol-20-one acetate 2.1 is used as a commercial starting material 
in several synthesis of cardiotonic steroids13,23,24 including Yoshii’s semi-synthesis of 
digitoxigenin.13 Compound 2.1 was provided by the allylic bromination of starting material with 
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NBS or bromine to obtain dibrominated compound which is then dehydrobrominated to obtain 
extended enone 2.2. Selective reduction of Δ16-17 olefin in presence of triethylsilane or 
triphenylstannae provided 2.3 which underwent subsequent α-methylsulfenylation of 2.3 to obtain 
2.4. Refluxing 2.4 with activated zinc dust and methyl bromo-acetate in benzene gave Reformatsky 
product 2.5 that was methylated with trimethyloxonium tetrafluoroborate and exposed to aqueous 
NaOH to provide epoxy ester 2.6 which lactonized upon passing through alumina chromatography 
to give compound 2.7. The method to obtain digitoxigenin from 2.7 via formation of bromohydrin 
at C14-C15 was previously reported25 and hence this completed the formal synthesis of 
digitoxigenin.  
Scheme 2.1. Semi-synthesis of Digitoxigenin by Yoshii 
 
2.3.2. Enantioselective Total Synthesis of (+)-digitoxigenin by Nakada and Coworkers18 
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The enantioselective total synthesis of (+)-digitoxigenin completed by Nakada and coworkers 
is summarized below. Compound 2.8 was obtained from reduction mediated by baker’s yeast of 
the 1,3-cyclopentanedione derivative of 2.8 and used as the starting material. Compound 2.12 was 
obtained by Pd-catalyzed Suzuki-Miyaura cross coupling reaction followed by diastereoselective 
hydrogenation directed by the hydroxyl group. Compound 2.12 was obtained from 
tricyclo[4.4.0.0]decene 2.11, the enantioselective synthesis of which was previously reported 
using CuOTf -BOX ligand.26 Coupling of 2.10 and 2.12 provided diketone 2.13. Intramolecular 
aldol reaction followed by deoxygenation at C7 provided advanced furan intermediate 2.14 that 
was then oxygenated to obtain digitoxigenin as a single enantiomer.  
Scheme 2.2. Enantioselective Total Synthesis of (+)-digitoxigenin by Nakada 
 
As discussed earlier, currently available synthetic methods are designed mostly to synthesize 
cardiotonic steroids containing the C19 and C11 oxygenation, with multiple semi and total 
synthesis of ouabain,19,20 19-hydroxysermentogenin,11,22 and trewianin aglycone appeared in the 
recent decade.22 However, efforts towards the synthesis of the steroids of this class that contains 
oxygenation at the C19 but lacks oxygenation at the C11 are rare. In fact, strophanthidin 2.34 is 
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the only such molecule that has been synthesized despite these compounds showing equal or better 
potential towards a variety of biological activities.  
2.3.3. Semi-synthesis of Strophanthidin by Yoshii and Coworkers 
The synthesis of strophanthidin was first completed by Yoshii in 197823 and is described 
below. The semi-synthesis commenced with the readily available steroid pregnenolone acetate 
2.16 and it was based on the following stages: 1) installation of C19-hydroxide and formation of 
double bond at Δ14-15, 2) installation of butenolide without affecting the functionality in the 
steroidal core, 3) formation of β- hydroxides at C5 and C14, and finally 4) selective oxidation to 
form C19 aldehyde.  
Pregnenolone acetate 2.16 was exposed to the previously developed method27 to obtain 5-
bromo-6,19-oxidopregenolone acetate 2.17 which was then brominated to obtain dibromo 
compound 2.18 in 63% yield (Scheme 2.3). This was followed by dehydrobromination in presence 
of LiBr in DMF to obtained extended enone 2.19, which was refluxed in presence of zinc dust and 
acidic isopropanol to obtain olefin at Δ5-6 to get trienone 2.20. Hydrogenation of conjugated 
dienone 2.20 in presence of triphenylstannane reduced the olefin Δ16-17 selectively to get compound 
2.21 in 82% yield. This completed the first phase of their synthesis and the next challenge was the 
construction of butenolide ring from the intermediate 2.21. 
Base-catalyzed reaction of 2.21 with diethyl oxalate followed by exposure of the intermediate 
oxalyl derivate to methyl thiotosylate and potassium acetate in ethanol provided thiol 2.22 in 44% 
yield. Protection of C3 and C19 alcohol with acetate protecting group and followed by reflux of 
the diacetate in benzene in presence of zinc dust and methyl bromoacetate provided the 
Reformatsky product 2.23. Reaction of 2.23 with the previously developed sequence during the 
synthesis of ditoxigenin13 was followed: a) reaction with trimethyloxonium tetrafluoroborate in 
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nitromethane, b) stirring with 0.5 N sodium hydroxide in methylene chloride, and c) absorption on 
alumina, which finally yielded in anhydropachygenol diacetate 2.25.  
Scheme 2.3. Synthesis of Key Intermediate 2.25 Towards the Synthesis of Strophanthidin 
 
With 2.25 in hand, they focused on the installation of two tertial hydroxy group with β-
orientation and the selective oxidation of the C19 alcohol to get an aldehyde (Scheme 2.4). 
Exposure of diacetate 2.25 to weakly basic condition hydrolyzed the C3 acetate group selectively 
in the presence of the primary acetate and gave 2.26. This, upon oxidation of the C3 alcohol, in 
the presence of chromic acid, followed by immediate reaction with oxalic acid, provided enone 
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2.27 in 60% yield. To install C14 hydroxy group, previously reported procedure that involved 
subjecting 2.27 to hypobromous acid with N-bromoacetamide, followed by hydrogenolysis of the 
bromohydrin intermediate with Raney Ni to give the C14 hydroxylated steroid 2.28, was 
employed. Hydrolysis of C19 acetate in presence of potassium bicarbonate followed by the 
treatment of 2.29 with basic hydrogen peroxide yielded epoxide 2.30 in 87% yield. Epoxide ring-
opening was performed after the C19 protection with acetate through a reductive cleavage reaction 
using chromium acetate in ethanol to obtain 1:1 mixture of desired product 2.31 and elimination 
of the C5 alcohol to retrieve 2.28. Reduction of the C3 ketone with Urushibara Nickel A28 followed 
by saponification of 2.32 with potassium bicarbonate provided strophanthidol 2.33. The final 
oxidation step was challenging as commonly used oxidants like PCC and SO3•Py in DMSO 
oxidized the C3 hydroxyl group instead of C19, however, chromic trioxide in presence of 
hexamethylphsphoric triamide provided strophanthidin 2.34 selectively with no ketonic product 
observed.  
Scheme 2.4. Completion of the Synthesis of Strophanthidin 
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Following this synthesis of Strophanthidin and strophanthidol by Yoshii,23 Kočovsky et al. 
reported another synthesis of these compounds in 1989.24  
2.3.4. Semi-synthesis of Strophanthidin by Kočovsky and Coworkers24 
Commercially available 5,16-pregnadien-3β-yl-20-one acetate 2.35 was used as a starting 
material. The synthesis involves similar strategy as Yoshii’s synthesis to form bromohydrin 
compound 2.36, followed by installation of cyclic bromoether 2.37. This was followed by the 
reduction to form extended enone 2.37 and selective hydrosilylation in presence of palladium 
metal to obtain 2.39. The formation of butanolide involves the following sequence: 1) oxygenation 
of C21 by lead tetraacetate by formation of kinetic enol-ether formed from methyl-ketone and 
MeOH/BF3 2) saponification of 2.40 with KHCO3 3) esterification by diethylphosphonoacetic acid 
to obtain ester 2.42 and finally, 4) cyclization of 2.42 in presence of t-BuOK to obtain lactone 2.43. 
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The synthesis utilizes a creative way towards the installation of C14 and C5 alcohol through the 
formation of double bromohydrin 2.47. The installation of these hydroxy groups is performed by 
the formation of unstable double bromohydrin 2.47 followed by the radical reduction with tri-n-
butyltin hydride, hydrolysis of the formate group with KHCO3 to obtain strophanthidol-3-acetate 
2.49. Jones oxidation of the C19 alcohol produced 2.50, the saponification of which was previously 
published29 to obtain strophanthidin 2.51. This completed the formal synthesis of strophanthidin 
in 16 steps.       
Scheme 2.5. Synthesis of Strophanthidin by Kočovsky and Coworkers 
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2.3.5. Enantioselective Synthesis of Oxygenated Steroids by Nagorny and Coworkers 
In 2015, Nathan Cichowicz, Will Kaplan, and Zhankui Sun from the Nagorny group developed 
an enantioselective synthesis of oxygenated steroids by utilizing copper-catalyzed Michael 
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reaction followed by a double aldol reaction to generate steroidal scaffolds of various ring sizes 
and functionalities in only a few steps.30 The substrate scope (Scheme 2.6) was investigated with 
varying A/D ring sizes and substituents at C13. Five-membered β-ketoesters were found to be 
more reactive than the six-membered counterparts and proceeded with higher diastereoselectivity. 
Changes in the sizes of ring and alteration of substituents at C13 was well tolerated and 
corresponding Michael adducts were obtained in good yields and good selectivities. 
Scheme 2.6. Substrate Scope for Enantioselective Michael Reaction 
 
The Michael adducts thus generated were subjected to a double aldol cyclization, which was 
promoted by DBU to generate epimeric steroids with unnatural configuration i.e. α-CD-ring 
junction. This reactivity was general for all the Michael adducts generated in Scheme 2.6 and 
proceeded with excellent yields and selectivities (Scheme 2.7). 
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Scheme 2.7. Diastereoselective Steroid Formation with Unnatural Configuration 
 
In order to make this reaction more applicable towards the synthesis of natural cardenolides, 
the method to generate natural β-CD ring junction in a very efficient manner was established from 
the unnatural steroids (obtained from Scheme 2.7) or directly from the corresponding Michael 
adducts (Scheme 2.6). Cyclization of Michael adduct 2.7 promoted by pyrrolidine acetate to form 
enamine activates the first aldol condensation to get monocyclized enone 2.59 followed by the 
base promoted aldol addition to obtain steroidal core 2.60 (Scheme 2.8.1). Alternately, the steroids 
with unnatural C13/C14 stereocenter can be epimerized in presence of Cs2CO3 to get 2.63 as major 
product (Scheme 2.8.2).  
Scheme 2.8. Selected Examples for the Diastereoselective Formation of Steroids with Natural 
Configuration 
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2.3.6. Total Synthesis of 19-hydroxysarmentogenin and Trewianin Aglycone by Nagorny Group 
After successful development of the method to rapidly construct the steroid core based on the 
enantioselective Michael-double aldol approach, Will Kaplan and Dr. Hem Raj Khatri reported a 
concise strategy to synthesize oxygenated cardiotonic steroids.27 While there are several semi-
synthetic and total synthetic approaches to the oxygenated cardiotonic steroids,10–12,19,20,35 the 
divergent synthesis of two epimeric cardenolides, 19-hydroxysarmentogenin and trewianin 
aglycone, reported in 2016 is the most concise one. 
The approach for these total syntheses involved designing the Michael reaction fragments with 
preinstalled oxygenations. After a diastereoselective Michael-double aldol cyclization sequence, 
the A/B ring junction would be constructed through a C19-OH controlled regiodivergent 
hydrogenation. The butenolide at C17 would be installed at a late stage of the synthesis using Stille 
coupling reaction. 
The forward synthesis was begun with the synthesis of chiral enone 2.65. The diketone 2.64 
was reacted with acrolein to achieve a Michael addition, which was followed by an organocatalytic 
α-oxidation36,37 using prolinol-derived catalyst I to get the chiral aldehyde. After the Wittig 
reaction with 1-(triphenylphosphoranylidende)-2-propanone II, chiral enone 2.65 was furnished 
in high yields and high enantiomeric excess (95% ee). Enone 2.65 was reacted under Cu(OTf)2-
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catalysed Michael reaction with ketoester III , with preset latent oxidation at C3 in the form of 
vinyl chloride, to give Michael-adduct 2.66 in high diastereoselectivity. This Michael adduct was 
subjected to an acid-mediated cyclization with an excess p-TSA to produce the cyclized product 
2.67 in good yield, albeit with an unnatural configuration at C/D ring junction. Thus, in the next 
step, the C/D ring junction in tetracyclic steroid 2.67 was epimerized under basic conditions via 
retro-Aldol-re-Aldol sequence to generate compound 2.68 with the natural configuration at C/D 
ring junction. Steroid 2.68 was then subjected to global reduction with DIBAL-H followed by 
hydrolysis and an unprecedented transposition of vinyl chloride to generate ketone at C3 in an 
efficient, one-pot transformation. At the end of this sequence of reactions, this intermediate 2.69 
contains oxygenations at C3, C11, C14, C17, and C19 as well as an unsaturation at C5 which is 
required for translation to various natural products. 
Scheme 2.9. Synthesis of Key Intermediate with Pre-set Oxygenation
 
65 
 
The key intermediate 2.69 was then transformed into two cardiotonic steroids 19-
hydroxysarmentogenin and trewianin aglycone, which are epimeric at C5. The enone in 2.69 was 
hydrogenated under slightly alkaline condition,38 directed by C19-OH, to cleanly produce cis A/B 
ring junction en-route to 19-hydroxysarmentogenin. Following a TIPS protection of C19 and DMP 
oxidation of C11 and C17 alcohols afforded triketone 2.70. 
Scheme 2.10. Divergent Synthesis Towards Functionalized Core from Key Intermediate 
 
Next series of transformations included: 1) a chemo- and stereoselective reduction of C3 
ketone with K-selectride, 2) a subsequent protection of resulting C3 alcohol with TBS-ether and 
the masking of C17 ketone as an enol-TBS ether, 3) a Birch reduction of C11 ketone to get an 
equatorial alcohol, 4) an unmasking of C17 ketone using TBAF, and 5) the Bartons’s condition to 
convert C17 ketone to a vinyl iodide 2.73.39 This resulted in a fully functionalized 19-
hydroxysarmentogenin core. 
Scheme 2.11. Synthesis of Fully Oxygenated Vinyl Iodides Epimeric at C5  
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Finally, butenolide was installed at C17, thus completing the synthesis of 19-
hydroxysarmentogenin via a 4-step sequence involving 1) Stille coupling of vinyl iodide 2.73 with 
stannane of the butenolide, 2) TMS protection of C11 and C14 alcohols, 3) hydrogenation of C16-
C17 double bond, and 4) global deprotection of silyl-protecting groups with aqueous HF. 
Scheme 2.12. Total Synthesis of (+)-19-hydroxysermentogenin, and (+)-Trewianin Aglycone 
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In an analogous sequence, the total synthesis of trewianin aglycone was completed from 
intermediate 2.69. The TIPS protection of C19 alcohol imparted enough steric bias to construct a 
trans-A/B ring junction during hydrogenation and thus forming triketone 2.71 following a DMP 
oxidation. With A/B trans junction assembled, subsequent diastereoselective reduction of C3 
ketone was achieved using Li(tBuO)3AlH to obtain β-oriented C3 alcohol. The rest of the synthesis 
followed same sequence of reactions to that of 19-hydroxysarmentogenin. 
The continued interest of our group towards these interesting cardiotonic steroids provoked us 
to develop a concise and divergent synthetic pathway towards numerous natural products and their 
analogs of this class of steroids and subsequent biological activity studies. The total synthesis of 
two natural products cannogenol and cannogenol-3-O-α-L-rhamnoside, with C19 oxygenation but 
lacking C11 oxygenation, would be discussed in Chapter 3 and the follow-up study on the 
anticancer studies of cannogenol based natural products and analogs as well as several cardiotonic 
steroids will be discussed in Chapter 4. 
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Chapter 3 
Enantioselective Total Synthesis of Cannogenol-3-O-α-L-rhamnoside via Sequential Cu(II)-
Catalyzed Michael Addition/Intramolecular Aldol Cyclization Reactions 
(A part of this work has been published in Bhattarai, B.; Nagorny, P. Enantioselective Total 
Synthesis of Cannogenol-3-O-α-L-rhamnoside via Sequential Cu(II)-Catalyzed Michael 
Addition/Intramolecular Aldol Cyclization Reactions. Org. Lett. 2018, 20, 154-157) 
3.1. Introduction of Cannogenol-3-O-α-L-rhamnoside and its Anticancer Activities 
Cannogenol and cannogenol-3-O-α-L-rhamnoside is commonly isolated from plant source of 
genus Convallaria, mostly from Convallaria majalis (popularly known as Lily of the Valley).1 
This plant holds cultural and biblical popularity in native to northern Hemisphere in Asia and 
Europe where it grows and although sweetly scented, is highly poisonous.2 
There has not been as much report as other members of this class of cardiac steroid on the 
Na+/K+-ATPase activity of these two natural products. Instead, there have been a few studies on 
their anticancer activities against a variety of cancer lines as reported in 2007 and 2008 (Table 3.1 
and 3.2) which will be discussed in detail in the following chapter. These reports show nanomolar 
half maximal inhibitory concentration (IC50) of cannogenol-3-O-α-L-rhamnoside against several 
cancer cell lines that were studied (Table 3.2).3,4 Although it exhibited an impressive activity 
against these cells, there have been no follow up reports on the elaboration of the medicinal 
chemistry studies and diversification of cannogenol to generate its different analogs. We believe 
this to be largely due to their low concentration in natural sources and the difficulty associated in 
the extraction of these toxic molecules from these sources. Organic synthesis may significantly 
improve the accessibility of cannogenol and provide otherwise challenging-to-access derivatives. 
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Table 3.1. Reported Anticancer activities of Cannogenol (µM)5 
 
 
Table 3.2. Reported Anticancer activities of cannogenol-3-O-α-L-rhamnoside3,4 (nM)
 
3.2. Initial Objective and Proposed Synthetic Route 
The overarching objective of this project was to build up on the previously established 
methodology from our group and elaborate it to achieve the total synthesis of cannogenol, 
coroglaucinogenin, and several other related steroids and their derivatives like rostafuroxin, an 
analog of this family that is in phase III clinical trial against hypertension. Enantioselectivity in 
the steroid could be introduced early in the total synthesis by utilizing the previously developed 
enantioselective Michael reaction of keto-ester 3.1 and enone 3.2 followed by rapid steroid 
assembly using double aldol condensation (Figure 3.1). This intermediate 3.4 can be transformed 
into the steroidal core with proper oxygenation by a reduction followed by acid promoted 
transposition. The functional group interconversion of this molecule 3.5 followed by a Pd-
catalyzed cross-coupling reaction would allow us to easily install various heterocycles and 
generate multitude of analogs. 
Figure 3.1. Initial Synthetic Route Towards Cannogenol and Other Relevant Cardiotonic Steroids 
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As mentioned above, intermediate 3.3 can be easily synthesized through a reaction previously 
developed in our group.6 However, the generation of the diene 3.4 was necessary for the 
subsequent key reaction, the transposition. We planned to install oxygen at C3 and remove 
unwanted oxidation at C7 in a single step by SN2-type mechanism using H2O, a transformation 
with limited literature precedence (Scheme 3.4a). This key intermediate 3.5 could then be further 
elaborated to several natural products and biologically relevant derivatives as shown in Figure 
3.1.  
Several attempts to achieve oxidation of 3.3 to an extended enone 3.6 were made. Many 
reaction conditions were tried, but all of them in vain (Scheme 3.1). Organic oxidants like chloranil 
and DDQ were used in several solvents (toluene, tBuOH, 1,4 dioxane, benzene, xylene) either in 
presence or absence of various acids (acetic acid, p-toluenesulfonic acid, trifluoroacetic acid). 
However, it resulted in either no reaction, a very slow reaction, or formation of eliminated side 
product 3.7 (observed by MS) when subjected to acidic reflux conditions (Scheme 3.1). 
Scheme 3.1. Oxidation Attempts to Synthesize Extended Enone 3.6 
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During a collaborative effort with Dr. Nathan Cichowicz towards the development of a concise 
enantioselective synthesis of oxygenated steroids via sequential copper (II)-catalyzed Michael 
Addition/intramolecular aldol cyclization reaction, an alternative strategy was developed to 
achieve similar scaffold that we were interested in (Table 3.3). The cardenolide core was 
synthesized through cyclization of monocyclized enone with LiHMDS or NaHMDS. This resulted 
in a clean diastereoselective formation of the corresponding cardenolide core 3.9 with natural 
configuration (Table 3.3). Moreover, this sequential approach allowed us to cleanly extend 
unsaturation in A ring (found to be troublesome to execute in fully cyclized tetracycle previously) 
prior to the closure of B/C ring and C/D ring. 
Table 3.3. Optimization of Aldol Addition to Generate Natural Stereocenters at C13 and C14 
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Scheme 3.2. Formation of Steroid 3.3 with Natural Configuration  
 
Following the promising result from this investigation, elaboration of the described work 
toward the synthesis of cannogenol was attempted. Our synthesis commenced with Cu (II)-
catalyzed intermolecular Michael reaction of 2-substituted beta-ketoesters 3.1 and beta-substituted 
enones 3.2 resulting in vicinal quaternary and tertiary stereocenters (Scheme 3.3). The 
enantioselective variant of this reaction can be achieved using Cu-BOX ligand.6 The Michael 
adduct 3.11 was then treated with pyrrolidine acetate to form an enamine that undergoes first aldol 
condensation reaction to afford efficient formation of monocyclized enone 3.10.This intermediate 
presented us the opportunity to extend the unsaturation to A ring as there is no potentially prone 
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to elimination tertiary alcohol which impeded our previous attempts. Consequently, this enone 
3.10 was further oxidized under acidic condition using DDQ as an oxidant, which cleanly resulted 
in the extended enone 3.12. Base-promoted cyclization developed during our previous efforts 
(Scheme 3.2) to generate natural C13/C14 stereocenter was performed next to achieve the desired 
intermediate 3.6.  LiHMDS instead of NaHMDS provided us with diastereoselective formation of 
the steroidal core with natural stereocenters through an aldol addition reaction. Diketone 3.6 was 
then reduced under Luche condition to afford the triol 3.4. This Intermediate, however, has an 
unwanted oxidation at C7 and lacks a crucial oxidation at C3.  
Scheme 3.3. Initial Route Towards the Synthesis of Cannogenol 
 
Next, we needed to synthesize the key intermediate 3.5 (Figure 3.1) through a crucial 
transposition reaction. The transposition of similar alcohol system had only been reported in an 
acyclic system7 (Scheme 3.4a) and the translation of the reported method in our cyclic and 
conformationally locked substrate was not trivial. An exhaustive screen of the solvent systems 
(H2O: dioxane or benzene) either in presence or absence of acids (acetic acid) was run in attempts 
of getting transposition going. Our initial hypothesis was that the triol 3.4 would transpose in 
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presence of H2O through an SN2-like mechanism and might be promoted by acid. However, due 
to the high temperature required for this transformation to occur, elimination of C14 hydroxyl was 
frequently observed to form the side product, possibly triene 3.18 as observed by MS (Scheme 
3.4b). Use of a mild oxidant like manganese oxide to trap any possible carbocation formed at C3 
was not successful in formation of desired product either. 
Scheme 3.4. Literature Precedence and Optimization of Transposition Reaction 
 
3.3 New Retrosynthetic Analysis 
After various unsuccessful attempts to synthesize a key intermediate in our original strategy, 
we re-designed the synthetic pathway to access molecules of this class. In our new strategy, we 
wanted to design fragments in such a way that necessary oxygenations to be installed early if 
possible and build a more general common intermediate that could be easily functionalized and at 
the very least, was a robust method that would allow us to explore various analogs with different 
sugar and heterocycle moiety appended to the core.  
As it was nicely defined by K. C. Nicolaou in his synthesis of Taxol “the route should be short 
and flexible to allow for the eventuality of producing the natural product and a variety of its analogs 
in a practical way and to deliver the target molecule in its enantiomerically pure and correct form.”8 
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The new retrosynthetic analysis was designed considering all the reaction and challenges described 
above. The literature analysis indicated that the functionalization of the A-ring, C3-glycoside and 
C17-heterocycle play the most important roles in defining the biological activity of cardiotonic 
steroids as they are found to interact with the enzyme during formation of the cardiotonic steroid-
enzyme complex.9 Hence, our approach to cannogenol and related steroids required flexibility in 
adjusting the functionalities of the A-ring and heterocyclic moiety at C17 position. We wanted to 
design a general synthetic pathway that would give us an access to a large number of members in 
this class of natural product with minimum, if any, deviation from original pathway to develop 
analogs with different heterocycles and sugar moieties. The key retrosynthetic disconnection was 
breaking the C3–C1’ bond to facilitate the final stage glycosylation reaction for the sugar 
installation. Another disconnection that we hypothesized would make late stage functionalization 
easier is the C17–C20 bond.  
To put it all together, we envisioned that we could achieve the synthesis of cannogenol-3-O-
α-L-rhamnoside 3.19 by selective C3 glycosylation of another bioactive natural product, 
cannogenol 3.20 (Figure 3.2). We hypothesized that a robust method for the heterocycle 
installation would be a well-studied Pd-catalyzed cross-coupling reaction on steroidal core with 
proper stereocenters already set. Key intermediate 3.21 would be formed by transposition of 
intermediate 3.22 with pre-installed functionality that can be removed during the transposition 
process and circumvents the formation of triene as discussed above (Scheme 3.4). This 
intermediate 3.22 in turn can be achieved by the method discussed above: Michael reaction 
followed by an aldol addition/aldol cascade reaction.6 The proposed starting materials, 
chloroketoester 3.23 and enone 3.2 lack any stereochemistry, hence, the development of an 
enantioselective variant of Michael reaction would be required to complete the asymmetric total 
79 
 
synthesis of cannogenol-3-O-α-L-rhamnoside. The synthesis of chloroketoester and enone have 
been previously reported and are known to work in Cu(II)-catalyzed Michael reactions in different 
setting.6 
Figure 3.2. Retrosynthetic Analysis of Cannogenol-3-O-α-L-rhamnoside 
 
3.4. Enantioselective Total Synthesis of Cannogenol  
We began our studies by generating sufficient quantities of known precursors 3.23 and 3.2 
(Scheme 3.5). β-ketoester 3.23 was prepared in three steps from commercially available 3-ethoxy-
2-cyclohexenone (up to 120 g scale) and enone 3.2 was synthesized in two steps from 2-methyl-
1,3-cyclopentanedione (up to 60 g scale). Initially, Cu(OTf)2, which is a previously reported 
efficient catalyst for these Michael reactions,6,10 was tested for the viability of the reaction. To our 
delight, we obtained the desired product 3.24 in 78% yield.   In order to generate enantiomerically 
pure cannogenol, these substrates were subjected to an asymmetric variant of Michael reaction6 
using a 2,2′-(cyclopropane-1,1-diyl)bis(4-phenyl-4,5-dihydrooxazole) ligand pre-complexed with 
Cu(SbF6)2 as the catalyst (10 mol %) under neat conditions.
11 As expected, this transformation 
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proceeded efficiently, and Michael adduct 3.25 was consistently generated on 7.2 g scale in 92% 
yield, >20:1 dr, and 92% ee (Scheme 3.5).  
Scheme 3.5. Development of Enantioselective Michael Reaction 
The Michael adduct 3.25 was then subjected to a double aldol cyclization with p-TSA, which 
resulted in the steroid 3.26 with an unnatural α-C13/C14 configuration (57%, >20:1 dr, 14 g scale, 
Scheme 3.6). Based on our previous knowledge on a related system containing C11 oxygenation,10 
we were confident that such an unnatural stereochemistry in these steroids could be epimerized 
under basic conditions to form the thermodynamically-preferred, natural β-configuration at the 
C13 and C14 centers. Indeed, subjecting 3.26 to NaHMDS resulted in formation of the desired 
diastereomer 3.22 in good yield, presumably through the intermediacy of retro-aldol product 3.28 
(64%, >20:1 dr; 7.3 g scale). This epimerization is very counterion specific as other counterion 
(such as K+, Li+) on HMDS did not provide comparable yield. 
Scheme 3.6. Generation of Steroidal Framework with Natural Configuration at C/D Ring Junction 
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Intermediate 3.22 was then treated with DIBAL-H (3 g scale), which led to 3.29, which was 
stable at room temperature for up to 2 h (Scheme 3.7). The intermediate 3.29 can be isolated, and 
the NMR characterization of this intermediate has been performed. However, attempts to store this 
intermediate in vacuum, bench top, or as a solution of methanol in counter-top or freezer led to 
decomposition to form black precipitate of unknown identity. In most instances, the triol 3.29 was 
not isolated, but rather the excess DIBAL-H was quenched with water, and the crude mixture was 
heated to reflux in formic acid (enough to bring pH to about 3) and 8:2 water/THF to accomplish 
transposition/vinyl chloride hydrolysis to produce a mixture of C17 epimers in 71% yield, 8:1 dr. 
This mixture was purified by SiO2 column chromatography to afford α-C17 diastereomer 3.21 in 
63% yield. This transformation allowed us to remove the unwanted oxygenation at C7 and 
introduce important oxygenation at C3 in a single step to set the proper steroidal framework 
mimicking the natural product. Thus, the key intermediate 3.21 was synthesized in 6 linear steps 
(9 overall steps) from commercially available building blocks in 17% overall yield and 92% ee.  
Scheme 3.7. Reduction and Transposition Reaction to Afford Key Intermediate 3.21 
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With the key intermediate 3.21 in hand, we turned our attention to installation of the 
stereocenter at C5 and the butenolide ring at C17. Steroid 3.21 was subjected to hydrogenation 
with Pd/C in presence of 1% potassium hydroxide in methanol (Scheme 3.8). This C19 alcohol-
directed hydrogenation resulted in the exclusive formation of the β-C5 center. The subsequent 
global oxidation of the crude material using Dess-Martin periodinane (DMP) followed by the 
selective reduction of the C19 aldehyde and C3 ketone in the presence of the C17 ketone by a 
bulky K-selectride yielded 3.33 in 62% yield over three steps after a single purification at the end 
of the third step. The iodination of 3.33 under Barton’s protocol12 produced vinyl iodide 3.34 in 
77% yield. To confirm the stereochemistry of thus formed steroidal core, compound 77 was 
benzoylated to provide monobenzoate 3.35b (90% yield) along with the crystalline bis-benzoate 
3.35a in 8% yield, the absolute and the relative configuration of which was confirmed by X-ray 
crystallographic analysis (Scheme 3.8).  
Scheme 3.8. Synthesis of Key Vinyl Iodide 3.34 
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Initial attempts to differentiate and selectively protect C19 alcohol as deemed necessary to 
selectively install sugar moieties at C3 at later stage with a variety of different silyl triflates or 
chlorides met with failure because of the steric bulk pocket around the primary alcohol presented 
by C1 and C11 methylene backbone. Despite this, we were pleased to find that acyl chlorides can 
differentiate the two alcohol and we were able to selectively protect the primary alcohol in 
excellent yield. As shown in Scheme 3.8 and Scheme 3.9, protection of primary alcohol with 
benzoyl chloride in presence of pyridine afforded 3.35b in 90% yield and the overreaction resulted 
in bis benzoyl protected compound 3.35a in 8% yield. Protection of secondary alcohol with 
TBSOTf at C3 proceeded smoothly to provide vinyl iodide 3.36 which could then be subjected to 
Stille coupling reaction. The Stille coupling of 3.36 and stannylated butenolide 3.43 proceeded 
efficiently and resulted in steroid 3.37 in 96% yield. This product was elaborated to benozyled 
cannogenol 3.39 via a three-step sequence in 74% yield.13–15 This sequence involved TMS 
protection of the C14 tertiary alcohol, hydrogenation of the Δ16-olefin, and global deprotection of 
the silyl protecting groups. The TMS protection of the C14 tertiary alcohol was required to achieve 
a steric bias for the subsequent hydrogenation to give exclusive β-C17 center. Late stage 
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glycosylation for installing sugar proceeded with moderate yield. Under various basic conditions 
for ester hydrolysis (i.e., Na2CO3, K2CO3, NaOMe, LiOH, or NH3), deprotection of the benzoyl 
esters on the rhamnose moiety could be achieved. However, the deprotection of the C19 benzoyl 
was slow and proceeded with the formation of multiple side products due to concomitant opening 
and isomerization of butenolide.  
Scheme 3.9. Initial Route Towards the Total Synthesis of Cannogenol-3-O-α-L-rhamnoside 
 
As the conditions for the deprotection of the C19 benzoate were not compatible with the 
butenolide functionality, alternative approach was employed. In this approach, cannogenol was 
first synthesized, then other protecting groups were explored for C19 alcohol. Hence, vinyl iodide 
3.34 was subjected to TBS protection (Scheme 3.10) resulting in intermediate 3.44 in 74% yield. 
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This protection was necessary, as the direct Stille coupling of 3.34 and 3.43 was sluggish and 
resulted in lower yields. In contrast, the Stille coupling of 3.44 and commercially available 
stannylated butenolide 3.43 proceeded efficiently and resulted in the steroid 3.45 in 82% yield. 
This was followed by TMS protection, hydrogenation, and global deprotection of silyl groups as 
was described for benzoylated cannogenol to obtain the aglycone in 69% yield over 3 steps 
(Scheme 3.10). It should be noted that an attempt to accomplish TMS protection of C14 hydroxyl 
prior to the Stille coupling reaction, however, resulted in poor yields of the cross-coupled product. 
Thus, the sequence as depicted in Scheme 3.10 constitutes the first enantioselective total synthesis 
of cannogenol. 
Scheme 3.10. Total Synthesis of Cannogenol  
 
3.5. Enantioselective Total Synthesis of cannogenol-3-O-α-L-rhamnoside 
3.5.1. Attempts towards differentiation of C3 and C19 alcohol with Silane Protecting Group 
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In order to avoid the challenging deprotection of primary esters in presence of base sensitive 
lactone moiety, we attempted to differentiate the C3 and the C19 alcohol using different silane 
protecting groups in various intermediates at different stages. We first attempted the selective 
silane protection of primary alcohol at C19 in presence of secondary alcohol at C17 in intermediate 
3.31, but to our disappointment, after exhaustive optimization of temperature and various reagents, 
no desired product was observed at all (Scheme 3.11). TIPSCl and TIPSOTf were too bulky and 
did not undergo the protection reaction. Similarly, no reaction was observed when TBSCl was 
used as a reagent. Unfortunately, heating the reaction with TBSOTf gave the undesired protection 
of C17 alcohol in 60% yield with no desired product observed.  
Scheme 3.11. Attempt to Differentiate C19 and C17 Alcohol of Triol 3.31 
 
Similar attempt to differentiate the C19 and C3 alcohol of vinyl iodide 3.34 with TIPSOTf or 
TIPSCl was not successful (Scheme 3.12). Use of TBSCl or TBSOTf as the reagent provided no 
selectivity even after exhaustive screening and bis-TBS protected compound was isolated in each 
attempted reaction.  
Scheme 3.12. Attempt to Differentiate C19 and C3 Alcohol of Vinyl Iodide 3.34 
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3.5.2. Regioselective Glycosylation 
After the successful synthesis of cannogenol, we investigated the possibility of adopting this 
route to the synthesis of cannogenol-3-O-α-L-rhamnoside (3.19). Our initial studies commenced 
with attempts to accomplish C3-selective glycosylation of triol 3.33 as a model substrate (Scheme 
3.13). Attempts to glycosylate 3.33 with trichloroacetimidate 3.40, which is available in three steps 
from L-rhamnose,16–18, however, resulted in the equimolar mixture of products 3.49 and 3.50 
formed in ∼70% conversion. This result indicated that the C19 hydroxyl is more reactive than the 
secondary C3 alcohol towards glycosylation. Attempts towards regioselective glycosylation to 
favor C3 hydroxyl using chiral phosphoric acids provided similar selectivity. 
Scheme 3.13. Regioselective Glycosylation Attempt in a Model Substrate 
 
3.5.3. C19 protection group exploration 
Upon treating bromobenzoyl-protected C19 primary alcohol under basic conditions resulted in 
the similar side reactions that was observed in benzoyl-protected primary alcohol (Scheme 3.14). 
When acetate group was used as a protecting group for the C19 primary alcohol, in addition to 
similar isomerization and ring opening, to our excitement, we also detected concurrent 
deprotection of the acetate protecting group at C19 (Scheme 3.14) unlike C19 benzoyl group 
which was previously noticed to be difficult to cleave under basic conditions. 
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Scheme 3.14. Optimization of Protecting Group at C19 
 
To address the protecting group challenges encountered earlier, a more labile methoxyacetate 
was investigated. This ester is reported to be almost 20 times easier to hydrolyze than the acetate 
protecting group.19 The selective protection of primary alcohol C19 was developed in an 
intermediate vinyl iodide as a model and highly selective C19 protection was observed (Scheme 
3.15a). The reaction condition optimized in the model substrate was then replicated in the C19 
protection of cannogenol (3.20), and not surprisingly the methoxyacetate protected cannogenol 
3.56 was prepared in 99% yield (Scheme 3.16). This compound was subjected to TfOH catalyzed 
glycosylation with 3.40, which resulted in α-rhamnoside 3.57 in 81% yield (>20:1 dr). The use of 
TMSOTf as promoter for glycosylation, however, resulted in diminished yield. 
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Two control experiments, as described below, were performed before the investigation of 
methoxyacetate as a protecting group in cannogenol:  
i) Determining the total time required for the deprotection of methoxyacetate from the 
C19 alcohol in model system. In order to do that, the methoxyacetate protected vinyl 
iodide was exposed to ammonia solution in methanol and complete deprotection of 
methoxyacetate was observed after overnight stirring in sealed vial (Scheme 3.15a).   
Scheme 3.15. Control Experiments to Ensure the Viability of Final Deprotection Step 
 
ii) Determine the total time required for the reaction condition to react with butenolide. 
The reactivity of ammonia in methanol towards the butenolide ring was tested in 
commercial cardiotonic steroid like digitoxigenin and ouabain and no side product from 
the reaction was observed when they were exposed to this reaction condition for up to 
2 days. (Scheme 3.15b) 
From these two control reactions, it was safely assumed that the final deprotection step would 
undergo completion overnight without impacting the lactone ring. And to our delight, when 
compound 3.57 was subjected to ammonia (50% solution in methanol), the desired cannogenol-3-
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O-α-L-rhamnoside (3.19) was obtained in 69% yield. The 1H/13C NMR data and optical rotation 
data ([α]D20 = −10.8, c = 0.147 in MeOH, reported1,20 [α]D20 = − 15.5, c = 0.55 in MeOH) of the 
synthetic 3.19 were in good agreement with the corresponding data obtained for the natural sample 
of 3.19. 1,3,4,20 
Scheme 3.16. Total Synthesis of Cannogenol-3-O-α-L-rhamnoside 
 
Figure 3.3. 1H NMR and 13C NMR of Synthetic Cannogenol-3-O-α-L-rhamnoside 
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3.6. Conclusion 
In conclusion, a new asymmetric route to cardenolide steroids carrying the C19 oxygenation 
has been developed and applied to the synthesis of the natural products cannogenol 3.20 and 
cannogenol-3-O-α-L-rhamnoside 3.19, the biological activity of which will be discussed in the 
following chapter. This approach features 3 g scale enantioselective synthesis of the functionalized 
cardenolide core 3.21 in 6 linear steps, 17% yield, and 92% ee involving an enantioselective 
Michael/tandem Aldol addition sequence established by our group earlier. This key intermediate 
could be elaborated to cardenolide cannogenol 3.20 in 9 steps, 20% yield. Cannogenol 3.20 
contains multiple hydroxyl functionalities, and a strategy for the selective introduction of sugar 
moieties at the C3 position of 3.20 was developed and successfully applied to the formation of 
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cannogenol-3-O-α-L-rhamnoside 3.19. The herein described strategies will expedite medicinal 
chemistry studies on C19- hydroxylated cardenolides related to cannogenol, and the exploration 
of 3.19, 3.20, and related analogs is the subject of ongoing investigation by our group. 
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3.7. Experimental (as it appears in Bhattarai, B.; Nagorny, P. Enantioselective Total Synthesis 
of Cannogenol-3-O-α-L-rhamnoside via Sequential Cu(II)-Catalyzed Michael 
Addition/Intramolecular Aldol Cyclization Reactions. Org. Lett. 2018, 20, 154-157 and a part 
derived from Cichowicz, N. R.; Kaplan, W.; Khomutnyk, Y.; Bhattarai, B.; Sun, S.; Nagorny, P. 
Concise Enantioselective Synthesis via Sequential Copper (II)-Catalyzed Michael 
Addition/Intramolecular Aldol Cyclization Reactions. J. Am. Chem. Soc. 2015, 137, 14341-14348) 
I. General Information    
i) Reaction equipment, solvents, reagents, and conditions 
All the reagents were purchased of highest quality from the commercial sources and used 
without further purification unless otherwise noted. All reactions were carried out under an 
atmosphere of nitrogen in flame or oven dried glassware with a magnetic stirrer. Heating 
was achieved by use of a silicone bath with heating controlled by electronic contact 
thermometer. Deionized water was used in the preparation of all aqueous solutions and for 
all aqueous extractions. Solvents used for purification and extraction were ACS or HPLC 
grade.  Toluene, dichloromethane, diethyl ether, tetrahydrofuran, and dimethylformamide 
were filtered through a column of activated alumina under nitrogen atmosphere (Innovative 
Technology PS-MD-5). Dry ice/acetone bath was used to create -78 oC reaction 
temperature and Ice/water bath was used to create 0 oC. Cryocool was used for extended 
low temperature experiments and all other low temperature.  
ii) Reaction monitoring and purification 
Thin layer chromatography (TLC) was conducted on precoated glass plates with 230-400 
mesh silica gel impregnated with fluorescent indicator (250 nm) for routine monitor of 
reaction progress and visualized using the combination of UV and ceric ammonium 
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molybdate.  All products were purified by flash column chromatography using SiliCycle 
Silica Flash P60 (230-400 mesh) silica gel. Alternatively, Combiflash Rf+ Lumen 
Automated Flash Chromatography System with UV and ELSD detector using SiliCycle 
Silica Flash P60 (230-400 mesh) silica gel was used for purification.  
iii) Analysis and characterizations 
High-performance liquid chromatography (HPLC) analysis was performed using Waters 
e2695 Separations Module with a Waters 2998 photodiode array detector on a DAICEL 
CHIRALPAK AD column to determine the enantiomeric excess. NMR spectra were 
recorded on Varian vnmrs 700 (700MHz), Varian vnmrs 500 (500 MHz), or Varian Inova 
500 (500 MHz) spectrometers and chemical shifts are reported in parts per million (ppm) 
downfield from tetramethylsilane with solvent resonance as the internal standard (CDCl3 
at δ 7.26, CD3OD at 3.32, or DMSO-d6 at δ 2.5, C5D5N at δ 7.22). Proton coupling patterns 
are described as singlet (s), doublet (d), triplet (t), quartet (q), and multiplet (m). High 
resolution mass spectra (HRMS) were obtained from Agilent 6230 TOF HPLC-MS 
Magnetic Sector mass spectrometers at the University of Michigan mass spectrometry 
facility.  Infrared spectra (IR) were recorded as thin films on a Perkin Elmer Spectrum BX 
FT-IR spectrophotometer and were reported in wavenumbers (cm-1). Optical rotation was 
measured at room temperature in methylene chloride or methanol on a Jasco P-2000 
polarimeter.  
II. Experimental Procedures and Spectroscopic Data 
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a) Cu(BOX), neat, -10 oC; b) p-TSA, THF, 60 °C; c) NaHMDS, PhMe, 40 °C; d) DIBAL-H, 
THF, 60 °C, 18 h; e) HCOOH, H2O:THF (8:2); f) H2, Pd/C in KOH/MeOH, then DMP, DCM, 
then, K-selectride; g) H2NNH2, EtOH, then, I2, Et3N; h) TBSOTf, 2,6-lutidine; i) 3.43, 
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Pd(PPh3)4, CuCl, LiCl; j) TMSOTf, imidazole, then, H2, Pd/C, then, HCl, MeOH; k) 
(MeOCH2CO)2O, DIPEA, DCM; l) 3.40, TfOH, DCM, 0 °C to rt; m) NH3 in MeOH. 
 
Ethyl (3aS,5aS,8aS)-8a-hydroxy-5a-methyl-6,9-dioxo-2,3,3b,4,5,5a,6,7,8,8a,8b,9-
dodecahydrodicyclopenta[a,f]naphthalene-3a(1H)-carboxylate (3.9) 
 
Michael adduct (390 mg, 1.07 mmol, 1.0 equiv.) was dissolved in EtOAc (10 mL, 0.1 M). 
Pyrrolidine (90 µL, 1.07 mmol, 1.0 equiv.) and AcOH (66 µL, 1.07 mmol, 1.0 equiv.) were added 
and the reaction mixture was stirred overnight. The reaction mixture was concentrated in vacuo 
and purified directly by column chromatography (grad. 0%→20% acetone in hexanes) to afford 
3.8 along with the recovered starting material (78 mg, 0.225 mmol, 21% yield).  
HRMS (ESI-MS) calculated for C22H30O5 [M+H]
+: m/z   347.1853, found: 347.1857 
Compound 3.8 (72 mg, 0.21 mmol, 1.0 equiv.) was dissolved in toluene (2 mL, 0.1 M) and cooled 
to -78 ºC. A solution of NaHMDS (46 mg, 0.25 mmol, 1.2 equiv.) in toluene was added dropwise. 
The reaction mixture was then stirred for 15 minutes at -78 ºC. The reaction mixture was then 
immediately heated to 110 ºC and stirred for 30 minutes. The reaction mixture was then filtered 
through a plug of silica gel and washed with EtOAc to afford 3.9 (43 mg, 0.34 mmol, 60% yield, 
20:1 dr, 92% ee) as a white solid along with the recovered starting material (6.0 mg, 0.048 mmol, 
~14%). Enantiopurity was determined to be 92% ee by chiral HPLC (DAICEL CHIRALPAK OJ-
H, 25 cm x 4.6 mm, hexanes/2-proponal = 95/5, flow rate = 1 mL/min, λ = 245.0 nm, RT(major) 
= 19.9 min, RT(minor) = 33.2 min). 
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1H NMR (500 MHz, CDCl3) δ 66.01 (s, 1H), 4.81 (s, 1H), 4.26 (dq, J = 7.2, 10.9 Hz, 1H), 4.19 
(dq, J = 7.2, 10.9 Hz, 1H), 2.77-2.73 (m, 2H), 2.71-2.67 (m, 1H), 2.58-2.49 (m, 2H), 2.37 (ddd, J 
= 3.4, 7.3, 19.1 Hz, 1H), 2.04-2.01 (m, 2H), 1.96-1.86 (m, 2H), 1.77-1.71 (m, 2H), 1.53 (qd, J = 
3.8, 13.5 Hz, 1H), 1.45-1.37 (m, 2H), 1.33-1.25 (m, 5H), 1.07 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 219.9, 202.6, 171.2, 170.4, 124.3, 80.2, 61.8, 58.5, 53.2, 48.7, 
46.7, 36.4, 32.9, 30.9, 30.8, 27.7, 23.5, 21.4, 14.3, 13.0 
[α]D25 = +31.8 (c = 0.4, CHCl3) 
HRMS (ESI-MS) calculated for C20H26O5 [M+H]
+: m/z  347.1853, found: 347.1851 
IR = (thin film, cm-1) 3458 (br), 2936, 1731, 1645, 1391, 1209, 1046, 732 
Ethyl (10S,13S,14S)-14-hydroxy-13-methyl-7,17-dioxo-1,2,3,4,7,8,9,11,12,13,14,15,16,17-
tetradecahydro-10H-cyclopenta[a]phenanthrene-10-carboxylate (3.3) 
 
Michael adduct (518 mg, 1.32 mmol, 1.0 equiv.) was dissolved in EtOAc (13 mL, 0.1 M). 
Pyrrolidine (110 µL, 1.32 mmol, 1.0 equiv.) and AcOH (82 µL, 1.32 mmol, 1.0 equiv.) were added 
and the reaction mixture was stirred overnight. The reaction mixture was diluted with EtOAc and 
washed with aq. NaHCO3 and brine. The organic layer was then dried over MgSO4, filtered, and 
concentrated in vacuo. The reaction mixture was then purified by column chromatography (grad. 
20%→40% EtOAc in hexanes) to afford 3.10 (328 mg, 0.60 mmol, 19:1 dr, 56% yield, 88% ee). 
Enantiopurity was determined to be 88% ee by chiral HPLC (DAICEL CHIRALPAK AD-H, 25 
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cm x 4.6 mm, hexanes/2-proponal = 85/15, flow rate = 1 mL/min, λ = 223.0 nm, RT(minor) = 8.5 
min, RT(major) = 11.0 min). 
1H NMR (500 MHz, CDCl3) δ 5.92 (s, 1H), 4.17-4.13 (m, 2H), 2.76-2.59 (m, 5H), 2.42-2.38 (m, 
2H), 2.26-2.21 (m, 1H), 2.08-2.03 (m, 1H), 1.84-1.82 (m, 1H), 1.78-1.71 (m, 3H), 1.63 (q, J = 7.0 
Hz, 2H), 1.51-1.44 (m, 3H), 1.37 (qt, J = 3.5, 12.6 Hz, 1H), 1.27-1.19 (m, 1H), 1.22 (t, J = 7.0 Hz, 
3H), 1.05 (td, J = 4.2, 13.3 Hz, 1H), 0.78 (t, J = 7.7 Hz, 3H), 0.67 (qd, J = 4.6, 11.2 Hz, 1H) 
13C NMR (126 MHz, CDCl3) δ 216.9, 216.6, 198.5, 170.7, 163.0, 126.4, 61.3, 61.3, 52.3, 44.5, 
38.8, 36.2, 36.1, 34.9, 31.7, 28.9, 26.5, 25.0, 23.1, 14.3, 8.8 
[α]D20 = -29.3 (c = 0.095, CH2Cl2) 
HRMS (ESI-MS) calculated for C22H30O5 [M+H]
+: m/z  375.2166, found: 375.2169 
Compound 3.10 (33 mg, 0.088 mmol, 1.0 equiv.) was dissolved in toluene (0.88 mL, 0.1 M) and 
cooled to -78 ºC. A solution of LiHMDS (15 mg, 0.88 mmol, 1.0 equiv.) in THF was added slowly. 
The reaction mixture was then stirred for 15 minutes at -78 ºC. The reaction mixture was then 
immediatedly heated to 60 ºC and stirred for 45 minutes. THF was removed by concentrating in 
vacuo and the reaction mixture was purified directly by column chromatography (grad. 5%→15% 
acetone in hexanes) to afford 3.3 (17 mg, 0.045 mmol, 52% yield, 88% ee) as a white solid. 
Enantiopurity was determined to be 88% ee by chiral HPLC (DAICEL CHIRALPAK AD-H, 25 
cm x 4.6 mm, hexanes/2-proponal = 90/10, flow rate = 1 mL/min, λ = 225.0 nm, RT(minor) = 8.1 
min, RT(major) = 10.2 min). 
1H NMR (700 MHz, CDCl3) δ 5.97 (s, 1H), 4.52 (s, 1H), 4.29 (dq, J = 7.0, 10.5 Hz, 1H), 4.22 
(dq, J = 7.0, 10.5 Hz, 1H), 2.80 (d, J = 13.3 Hz, 1H), 2.75-2.73 (m, 1H), 2.52-2.43 (m, 2H), 2.35-
2.30 (m, 1H), 2.12-2.04 (m, 3H), 1.94-1.88 (m, 2H), 1.85-1.77 (m, 3H), 1.73 (dt, J = 2.8, 14.0Hz, 
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1H), 1.58 (dt, J = 3.5, 14.0 Hz, 1H), 1.43 (qt, J = 3.9, 14.1 Hz, 1H), 1.35 (sext, J = 7.4 Hz, 1H), 
1.29 (t, J = 7.7 Hz, 3H), 1.21-1.13 (m, 2H), 1.11-1.07 (m, 1H), 1.06 (t, J = 7.7 Hz, 3H) 
13C NMR (175 MHz, CDCl3) δ 220.3, 201.9, 170.3, 164.1, 126.8, 81.6, 61.6, 54.3, 52.2, 48.6, 
45.3, 36.6, 34.8, 33.3, 28.0, 26.7, 26.5, 23.2, 22.0, 20.3, 14.4, 8.9; 
HRMS (ESI-MS) calculated for C22H30O5 [M+H]
+: m/z 375.2166, found: 375.2165 
IR (thin film, cm-1) 3517 (br), 2938, 1730, 1654, 1185 
Ethyl (8R,9S,10S,13S,14S)-14-hydroxy-13-methyl-7,17-dioxo-1,2,7,8,9,11,12,13,14,15,16,17-
dodecahydro-10H-cyclopenta[a]phenanthrene-10-carboxylate (3.6) 
 
Monocyclized enone 3.10 (3.2 mmol, 1.17 g, 1 equiv.) was dissolved in 100 mL benzene and p-
TsOH (6.4 mmol, 1.1 g, 2 equiv.) was added to the reaction vial. DDQ (3.9 mmol, 0.89 g, 1.2 
equiv.) was dissolved in 30 mL benzene and transferred to the reaction mixture and heated to 80 
oC. After 2 h, The reaction mixture was dissolved in 50 mL DCM, washed with water, 2% NaOH, 
and brine then dried with MgSO4 and concentrated in vacuo to obtain slightly yellow residue of 
3.12 that appeared pure by crude NMR and was subjected to next step without further purification.   
To a 10 mL vial with crude extended enone 3.12 (0.279 mmol, 100 mg, 1 equiv.) was added 2 mL 
THF and cooled to -78 oC. In a different vial, LiHMDS (0.335 mmol, 56 mg, 1.2 equiv.) was 
weighed and diluted in 1 mL THF and added dropwise to the solution of enone at -78 oC. The 
reaction mixture was stirred at -78 oC for 20 minutes then transferred to preheated oil bath at 60 
oC. Color change from yellow to dark brown was observed. The reaction was monitored by TLC 
and stopped after 2 h or upon completion. The reaction mixture was passed through silica plug and 
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concentrated in vacuo. The residue was purified by flash chromatography on silica gel (3:2 
Hexanes: EtOAc) to give 3.6 (84 g, 84%) as white solid.  
1H NMR (700 MHz, Benzene-d6) δ 5.88 (s, 1H), 5.80 (dd, J = 9.8, 2.8 Hz, 1H), 5.74 (dd, J = 5.9, 
2.6 Hz, 1H), 5.17 (s, 1H), 3.87 (dq, J = 10.9, 7.0 Hz, 1H), 3.65 (dq, J = 11.1, 7.2 Hz, 1H), 2.87 (d, 
J = 13.2 Hz, 1H), 2.48 (dt, J = 19.3, 9.9 Hz, 1H), 2.36 (dd, J = 13.0, 5.1 Hz, 1H), 2.27 (dddd, J = 
16.8, 11.5, 5.2, 2.4 Hz, 1H), 2.12 (ddd, J = 18.8, 9.3, 1.4 Hz, 1H), 1.97 – 1.89 (m, 1H), 1.79 (dt, J 
= 19.7, 5.6 Hz, 1H), 1.65 – 1.55 (m, 2H), 1.52 – 1.45 (m, 1H), 1.32 (s, 3H), 1.25 (qd, J = 13.3, 3.6 
Hz, 1H), 1.19 (dt, J = 14.0, 3.4 Hz, 1H), 0.94 (ddd, J = 13.1, 11.5, 5.4 Hz, 2H), 0.78 (t, J = 7.1 Hz, 
3H). 
HRMS (ESI-MS) calculated for C21H26O5 [M+H]
+: m/z 359.1858, found: 359.1855 
Ethyl (8S,9S,10S,13R,14S,17R)-7,14,17-trihydroxy-13-methyl-1,2,7,8,9,11,12,13,14,15,16,17-
dodecahydro-10H-cyclopenta[a]phenanthrene-10-carboxylate (3.4) 
 
To the vial was added 3.6 (0.025 mmol, 9 mg, 1 equiv.) and dissolved in 1 mL MeOH. CeCl3.7H2O 
(0.028 mmol, 10 mg, 1.1 equiv.) was added to the reaction mixture and cooled to -78 oC. NaBH4 
(0.0375 mmol, 1.5 mg, 1.5 equiv.) was then added slowly and stirred for 4 h. The reaction mixture 
was quenched with water and the aqueous layer was extracted with EtOAc (3×5 mL), then with 5 
mL brine. The combined organic layer was dried over Na2SO4, filtered and concentrated in vacuo. 
The residue was purified by flash chromatography on silica gel (9:1 DCM: MeOH) to give 3.4 (5.8 
mg, 65%) as white solid.  
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1H NMR (700 MHz, CDCl3) δ 6.05 (dd, J = 9.7, 2.5 Hz, 1H), 5.74 (t, J = 7.9 Hz, 1H), 5.60 (d, J 
= 2.7 Hz, 1H), 4.46 (d, J = 8.7 Hz, 1H), 4.34 – 4.23 (m, 1H), 4.15 (ddt, J = 10.5, 7.2, 3.6 Hz, 
1H), 3.73 (d, J = 6.3 Hz, 1H), 2.69 (d, J = 9.4 Hz, 1H), 2.51 (dd, J = 12.9, 5.6 Hz, 1H), 2.38 – 
2.31 (m, 1H), 2.28 – 2.18 (m, 1H), 2.16 – 2.07 (m, 2H), 2.02 (td, J = 7.1, 6.2, 3.5 Hz, 2H), 1.96 – 
1.86 (m, 1H), 1.80 – 1.68 (m, 1H), 1.42 (td, J = 12.5, 4.2 Hz, 1H), 1.37 – 1.31 (m, 3H), 1.29 (td, 
J = 7.2, 0.0 Hz, 3H) 1.09 (s, 3H), 0.88 (t, J = 6.8 Hz, 1H). 
Synthesis of catalyst  
Bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)methane (SI-2) 
  
To the flask with malonitrile (0.151 mol, 10 g, 1 equiv.) in EtOH (0.31 mol, 18 mL, 2.05 equiv.) 
and dioxane (230 mL) at 0 ˚C was bubbled HCl gas (produced by H2SO4 and NaCl) upon which 
white precipitation was observed. The reaction was warmed to rt and HCl gas was bubbled slowly 
for 2 days. The solution was filtered and the solid was washed with dry Et2O. The resulting white 
solid was dried and used in subsequent step. The spectral data obtained matches those reported 
previously.21 
The flask with diethylmalonimidate SI-1 (0.0865 mol, 20 g, 1 equiv.) and R(-)-2-phenylglycinol 
(0.182 mol, 25 g, 2.1 equiv.) in DCM (290 mL) was refluxed overnight. The solution was quenched 
with 120 mL water and the aqueous layer was extracted with DCM (3 × 450 mL). The combined 
organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. The residue was purified by flash chromatography on silica gel (9:1 DCM: MeOH) to give 
SI-2 (21 g, 83%) as brown viscous oil. The spectral data obtained matches those reported 
previously.22 
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Cyclopropanation and complexation (SI-4)23 
 
To a flask with bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)methane SI-2 (3.3 mmol, 1 g, 1 equiv.) 
in dry THF was added dibromoethane (6.6 mmol, 560 µL, 2 equiv.) and LiHMDS (8.9 mmol, 1.5 
g, 2.7 equiv.) at rt and stirred under N2 for 6 h. Additional LiHMDS (3.3 mmol, 550 mg, 1 equiv.) 
and dibromoethane (3.3 mmol, 280 µL, 1 equiv.) was added to the reaction mixture and stirred for 
16 h. The reaction mixture was quenched with saturated aqueous NH4Cl and the aqueous layer 
was extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with saturated 
aqueous NaHCO3, brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
residue was purified by flash chromatography on triethylamine pretreated silica gel (2:0.5:7.5 
EtOAc: Et3N: Hexanes to 9.5: 5 EtOAc: Et3N) to give SI-3 (806 mg, 74%) as brown viscous oil. 
The spectral data obtained matches those reported previously.6  
To the flask with (4R,4'R)-2,2'-(cyclopropane-1,1-diyl)bis(4-phenyl-4,5-dihydrooxazole) SI-3 
(5.87 mmol, 1.95 g, 1 equiv.), azeotroped with toluene, was added CuCl2 (5.7 mmol, 0.765 g, 0.97 
equiv.), dissolved in DCM (29 mL) and stirred for 3 h. AgSbF6 (11.4 mmol, 3.9 g, 1.94 equiv.) 
dissolved in 8 mL DCM was added to the reaction mixture and stirred for 2.5 h. Upon the addition 
of dry THP to this brown reaction mixture, white precipitate was observed while the solution 
turned green. This mixture was filtered through plug of activated celite into a dry flask and rinsed 
with THP several times. The resulting green solution was concentrated and azeotroped with 
toluene. The catalyst was further dried by dissolving it in dry DCM and dried with activated 4 Å 
molecular sieves overnight. The solution was transferred to a dry flask and dried by blowing 
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nitrogen and then left it in vacuum before transferring the dark green solid SI-4 (3 g, 56%) to the 
glovebox.  
Synthesis of Building blocks: 
Ethyl 4-chloro-2-oxocyclohex-3-ene-1-carboxylate (3.23) 
 
To the solution of LiHMDS (1.712 mol, 286 g, 2 equiv.) in THF (3 L) cooled to -78 ˚C was added 
3-ethoxy-2-cyclohexenone (0.856 mol, 120 g, 1 equiv.) and stirred for 1 h. Diethyl carbonate 
(1.712 mol, 202 g, 2 equiv.) was added slowly to the reaction mixture and stirred for 10 minutes. 
The resulting yellow solution was slowly warmed to rt and stirred overnight. The reaction was 
quenched with saturated aqueous NH4Cl and the aqueous layer was extracted with DCM (4 × 800 
mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered 
and concentrated in vacuo. The crude yellow solid was triturated with hexanes to obtain white 
solid SI-5 upon filtration.  
The crude residue thus obtained was dissolved in THF (780 mL) and water (70 mL). After slow 
addition of 1N HCl (560 mL), the reaction mixture was stirred for 6 h at rt. The reaction was 
quenched with saturated aqueous NaHCO3 and the aqueous layer was extracted with DCM (3 × 
500 mL) and the organic layer was discarded. To the aqueous layer, conc. HCl was added to obtain 
pH of 2 and extracted with DCM (3×700 mL). The combined organic layers were washed with 
brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo to obtain yellow solid SI-
6 that was used directly in the subsequent reaction without further purification.   
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To the solution of crude SI-6 in CHCl3 (900 mL) at 0 ˚C was added PCl3 (1.712 mol, 153 mL, 2 
equiv.) slowly and stirred for 2 hr. The reaction mixture was warmed to rt and stirred overnight. 
Resulting yellow solution was concentrated directly to remove excess PCl3 and redissolved in 
CHCl3. This solution was filtered through cotton and concentrated. The oily residue was then 
purified by flash chromatography on silica gel (9:1 Hexanes: Ethyl acetate) to give chloroketoester 
3.23 (109 g, 63%) as colorless oil. The spectral data obtained matches those reported previously.6 
(E)-2-methyl-2-(5-oxohex-3-en-1-yl)cyclopentane-1,3-dione (3.2) 
 
To the flask with 2-methyl-1,3-cyclopentanedione (0.535 mol, 60 g, 1 equiv.) in water (1.2 L) at 
rt was added acrolein (0.749 mol, 50 mL, 1.4 equiv.) and stirred at rt overnight under N2. The 
reaction mixture was extracted with EtOAc (3×500mL).   The combined organic layers were 
washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo to obtain 
colorless liquid SI-7 that was used directly in the subsequent reaction without further purification.  
To the solution of crude residue in THF (1.2 L) was added 1-(triphenylphosphoranylidene)-2-
propanone y (0.749 mol, 238 g, 1.4 equiv.) and allowed to stir overnight at rt. This solution was 
concentrated in vacuo and purified directly by flash chromatography on silica gel (7:3 Hexanes: 
Ethyl acetate) to give enone 3.2 (81 g, 73%) as viscous colorless oil. The spectral data obtained 
matches those reported previously.6  
4-(tributylstannyl)furan-2(5H)-one (3.43) 
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To the solution of tetronic acid (0.05 mol, 5 g, 1.0 equiv.) in DCM (110 mL) and DMF (5 mL) at 
0 ˚C was added oxalyl bromide (0.06 mol, 5.6 mL, 1.2 equiv.) over 1 hr to obtain orange colored 
solution. The reaction was warmed to rt and stirred for 2 h. The resulting greenish orange solution 
was quenched with water (100 mL) and organic layer was separated. The aqueous layer was 
extracted with diethyl ether (3 × 100 mL). The combined organic layers were washed with water, 
saturated aqueous NaHCO3, brine, dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. The dark brown solid was recrystallized with ether to obtain brown needles shaped solid 
SI-8 (6.5 g, 80% yield). The spectral data obtained matches those reported previously.24 
To a flask in glovebox was added 4-bromofuran-2(5H)-one SI-8 (8.3 mmol, 1.35 g, 1 equiv.), 
hexabutylditin (8.3 mmol, 4.8 g, 1 equiv.), and Pd(PPh3)2Cl2 (0.83, 580 mg, 10 mol%). This 
mixture was dissolved in dioxane (80 mL) and the resulting yellow colored solution was stirred at 
95 ˚C for 16 h. The solution was concentrated in vacuo and purified directly by florisil (8:2 
Hexanes: Ethyl acetate) to give 3.43 (1.9 g, 73%) as viscous colorless oil. The spectral data 
obtained matches those reported previously.25 
Michael Reaction: Ethyl (S)-4-chloro-1-((S)-1-(1-methyl-2,5-dioxocyclopentyl)-5-oxohexan-
3-yl)-2-oxocyclohex-3-ene-1-carboxylate (3.25) 
Racemic synthesis:  
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To the flask with enone (3.23) and chloroketoester (3.2) was added Cu(OTf)2 in the glovebox at 
room temperature. After stirring the reaction mixture neat for 1 h, the mixture was filtered through 
silica with diethyl ether. The ether layer was concentrated in vacuo, then purified by using flash 
chromatography on silica gel (6:4 Hexanes: Ethyl Acetate) to give light-yellow viscous oil.  
Enantioselective Synthesis:  
 
To the flask with enone 3.2 (0.0346 mol, 7.2 g, 1 equiv.) and chloroketoester 3.23 (0.0692 mol, 14 
g, 2 equiv.) was added [Cu(R,R)-PhBox](SbF6)2 SI-4 (0.00346 mol, 3 g, 0.1 equiv.) in the glovebox 
at room temperature. The reaction mixture was diluted with DCM (5 mL) and stirred at -10 ˚C for 
2 days. After confirming the completion of reaction by crude NMR of aliquote, the mixture was 
filtered through silica with diethyl ether. The ether layer was concentrated in vacuo, then purified 
by flash chromatography on silica gel (6:4 Hexanes: Ethyl Acetate) to give Michael adduct 3.25 
(13 g, 92% yield) as a light-yellow viscous oil. Enantiopurity was determined to be 92% ee by 
chiral HPLC (DAICEL CHIRALPAK AD, 25 cm × 4.6 mm, hexanes/2-propanol = 95/5, flow rate 
= 1 mL/min, λ = 237 nm, RT (major) = 27.87 m, RT (minor) = 32.33).  
Rf (Hexanes: EtOAc 6:4): 0.3 
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1H NMR (500 MHz, CDCl3) δ 6.17 (d, J = 2.1 Hz, 1H), 4.09 (dddd, J = 14.2, 10.8, 8.7, 5.3 Hz, 
2H), 2.99 – 2.65 (m, 4H), 2.73 – 2.66 (m, 2H),  2.65 – 2.55 (m, 2H), 2.40 – 2.24 (m, 2H), 2.11 (s, 
3H), 1.92 (ddd, J = 14.5, 10.0, 5.4 Hz, 1H), 1.73 – 1.61 (m, 1H), 1.52 (td, J = 13.2, 12.8, 4.4 Hz, 
1H), 1.21 (t, J = 7.2 Hz, 3H), 1.16 – 1.07 (m, 2H), 1.05 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 216.23, 216.01, 206.81, 192.78, 170.24, 157.23, 128.51, 62.05, 
59.62, 56.84, 44.52, 35.61, 35.17, 35.12, 33.61, 31.75, 30.21, 27.56, 27.36, 19.20, 14.05. 
[α]D20 = -29.3 (c = 0.095, CH2Cl2) 
HRMS (ESI-MS) calculated for C21H27ClO6 [M+NH4]
+: m/z   428.1834, found: 428.1845 
IR = 2936, 2355, 1710, 1680, 1618, 1419, 1364, 1295, 1236 
Ethyl (8R,9S,10S,13R,14R)-3-chloro-14-hydroxy-13-methyl-7,17-dioxo-
1,2,7,8,9,11,12,13,14,15,16,17-dodecahydro-10H-cyclopenta[a]phenanthrene-10-carboxylate 
(3.26) 
 
To the solution of Michael adduct 3.25 (0.034 mol, 14 g, 1 equiv.) in THF (420 mL) was added 
PTSA (0.340 mol, 65 g, 10 equiv.) and heated at 60 ˚C for 60 h. The reaction was quenched with 
saturated aqueous NaHCO3 and the aqueous layer was extracted with DCM (3 × 300 mL). The 
combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel (7:3 
Hexanes: Ethyl acetate) to give unnatural steroid 3.26 (7.6 g, 57%) as yellow solid and unreacted 
starting material (4.4 g, 83% brsm).   
Rf (Hexanes: Ethyl acetate 7:3): 0.6 
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1H NMR (700 MHZ, CDCl3) δ 6.30 (d, J = 1.8 Hz, 1H), 5.87 (s, 1H), 4.24 (dd, J = 10.9, 7.1 Hz, 
1H), 4.07 (dd, J = 10.9, 7.1 Hz, 1H), 3.49 (s, 1H), 2.81 (d, J = 7.6 Hz, 1H), 2.68 (ddd, J = 18.7, 
12.8, 7.0 Hz, 2H), 2.55 (d, J = 12.4 Hz, 1H), 2.54 – 2.51 (m, 1H), 2.47 (dd, J = 19.4, 5.6 Hz, 1H), 
2.16 – 2.03 (m, 3H), 2.01 (d, J = 13.8 Hz, 1H), 1.79 (dd, J = 13.5, 3.2 Hz, 1H), 1.58 – 1.50 (m, 
1H), 1.34 (td, J = 13.7, 3.6 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H), 1.02 (s, 3H), 0.82 (dd, J = 13.1, 3.2 
Hz, 1H). 
13C NMR (176 MHZ, CDCl3) δ 218.51, 200.90, 169.66, 152.44, 144.32, 126.54, 125.70, 77.87, 
61.90, 54.40, 50.61, 48.71, 43.28, 34.90, 32.02, 31.68, 30.86, 28.28, 24.40, 19.87, 14.49. 
[α]D20 = -391.6 (c 0.08 in CH2Cl2) 
HRMS (ESI) calculated for C21H25ClO5 [M+H]
+: 393.1463 m/z, found: 393.1466 
IR = 3508, 2925, 2028, 1727, 1655, 1649, 1620, 1446, 1372, 1351,1254, 1217 
Ethyl (8R,9S,10S,13S,14S)-3-chloro-14-hydroxy-13-methyl-7,17-dioxo-
1,2,7,8,9,11,12,13,14,15,16,17-dodecahydro-10H-cyclopenta[a]phenanthrene-10-carboxylate 
(3.22) 
 
To a solution of 3.26 (0.0185 mol, 7.3 g, 1 equiv.) in toluene (370 mL) at -78 ˚C was added the 
solution of NaHMDS (0.0223 mol, 4 g, 1.2 equiv.) in toluene (30 mL) slowly and let it stir for 25 
minutes. The flask was then moved to a pre-heated oil bath at 40 ˚C and stirred for 1.5 hrs. The 
resulting brown solution was filtered quickly through silica plug and the eluent was concentrated 
in vacuo. The residue was then purified by flash chromatography on silica gel (7:3 Hexanes: Ethyl 
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acetate) to give natural steroid 3.22 (4.74 g, 65%) as off-white solid and unreacted starting material 
(1.7 g, 85% brsm). 
Alternately, the reaction was quenched with saturated aqueous NaHCO3 solution (100 mL) then 
extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with brine, dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography on silica gel (7:3 Hexanes: Ethyl acetate) to obtain comparable yield.  
Rf (Hexanes: Ethyl acetate 7:3): 0.5 
1H NMR (700 MHZ, CDCl3) δ 6.38 (d, J = 2.3 Hz, 1H), 5.92 (s, 1H), 4.75 (s, 1H), 4.30 (dd, J = 
10.9, 7.0 Hz, 1H), 4.19 (dd, J = 10.9, 7.1 Hz, 1H), 2.83 – 2.75 (m, 1H), 2.73 (d, J = 13.2 Hz, 2H), 
2.58 – 2.48 (m, 2H), 2.38 (ddd, J = 19.2, 7.7, 3.2 Hz, 1H), 2.10 – 1.95 (m, 3H), 1.87 (d, J = 15.5 
Hz, 1H), 1.60 (dt, J = 11.6, 5.3 Hz, 1H), 1.45 – 1.31 (m, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.06 (s, 3H). 
13C NMR (175 MHZ, CDCl3) δ 219.79, 202.07, 169.46, 153.95, 144.89, 126.09, 125.96, 80.54, 
62.25, 53.10, 49.72, 48.57, 45.24, 32.98, 31.88, 31.27, 30.91, 27.97, 22.21, 14.55, 13.12. 
[α]D20 = -244.9 (c 0.128 CH2Cl2) 
HRMS (ESI) calculated for C21H25ClO5 [M+H]
+: m/z 393.1463, found: 393.1463 
IR = 3502, 2928, 2862, 2359, 1733, 1644, 1616, 1444, 1373, 1350, 1247, 1206 
(8R,9S,10S,13R,14S,17R)-14,17-dihydroxy-10-(hydroxymethyl)-13-methyl-
1,2,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one (3.21) 
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To the solution of 3.22 (0.0076 mol, 3 g, 1 equiv.) in THF (300 mL) at -78 ˚C was added DIBAL-
H (0.0917 mol, 16 mL, 12 equiv.) and stirred for 30 minutes. The resulting yellow solution was 
heated to 60 ˚C and stirred overnight. Quantitative conversion to the reduced intermediate was 
observed by TLC (9:1 DCM: MeOH). The reaction mixture was cooled to 0 ˚C and quenched with 
saturated aqueous solution of sodium potassium tartrate tetrahydroborate very slowly. The 
resulting cloudy mixture was then extracted with DCM (3 × 150 mL) and the organic layer was 
removed in vacuo. The intermediate 3.29 can be isolated if desired by flash chromatography on 
silica (8:2 Ethyl acetate: Hexanes) and is stable at room temperature for up to 2 hrs.  
The crude mixture obtained after reduction was dissolved in 8:2 H2O: THF (100 mL) and 50% 
formic acid (10 mL) and heated to 70 ˚C for 2 hrs. White precipitate was observed upon the 
addition of formic acid but slowly disappeared. The resulting colorless solution was then cooled 
to -10 ˚C and quenched with saturated aqueous NaHCO3 solution very slowly. The aqueous layer 
was extracted with 2:1 mixture of chloroform: ethanol (4 × 150mL). The combined organic phases 
were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified 
by flash chromatography on silica gel (9:1 DCM: MeOH) to give key intermediate 3.21 (1.5 g, 
63%) as a white solid.  
Rf (DCM:MeOH 9:1) : 0.2 
1H NMR (500 MHZ, CD3OD) δ 6.48 (dd, J = 9.9, 2.1 Hz, 1H), 6.27 (dd, J = 10.0, 2.8 Hz, 1H), 
5.78 (s, 1H), 4.16 (t, J = 8.7 Hz, 1H), 3.84 (d, J = 11.6 Hz, 1H), 3.69 (d, J = 11.7 Hz, 1H), 2.77 
(ddd, J = 18.1, 14.3, 5.9 Hz, 1H), 2.58 – 2.48 (m, 2H), 2.43 – 2.31 (m, 1H) 2.09 (dt, J = 9.3, 4.5 
Hz, 1H), 1.93 (ddd, J = 14.4, 12.5, 5.3 Hz, 1H), 1.77 – 1.67 (m, 3H), 1.62 – 1.43 (m, 3H), 1.39 
(ddd, J = 14.8, 10.1, 5.0 Hz, 1H), 1.22 – 1.13 (m, 1H), 1.08 (s, 3H). 
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13C NMR (175 MHZ, CD3OD) δ 202.78, 162.58, 141.04, 130.16, 125.82, 83.73, 81.25, 63.84, 
48.94, 48.42, 45.15, 42.72, 35.11, 31.24, 30.38, 30.12, 28.77, 21.83, 17.47 
[α]D20 = +9.956 (c 0.095 in MeOH) 
HRMS (ESI) calculated for C19H26O4 [M+H]
+: m/z 319.1909, found:  319.1903 
IR = 3350, 2932, 2030, 1640, 1611, 1578, 1469, 1446, 1418, 1364, 1278, 1223, 1202 
(3S,5R,8R,9S,10R,13S,14S)-3,14-dihydroxy-10-(hydroxymethyl)-13-methylhexadecahydro-
17H-cyclopenta[a]phenanthren-17-one (3.33) 
 
To a flask with 3.21 (1.099 mmol, 350 mg, 1 equiv.) and 10% Pd on activated carbon (0.550 mmol, 
58 mg, 0.5 equiv.) was added a solution of 1% KOH in MeOH (29 mL) and purged with N2. The 
flask was then purged with H2 and stirred under H2 atmosphere for 1 h at rt. The completion of the 
reaction was confirmed by TLC. The reaction mixture was then quenched with pH 7 phosphate 
buffer, then filtered through celite. The eluent was concentrated in vacuo and the crude mixture 
was used in the next step without further purification. The intermediate 3.31 can easily be purified 
if desired by flash chromatography on silica gel (9:1 DCM: MeOH).  
To the solution of crude 3.31 in dry DCM (73 mL) was added DMP (5.5 mmol, 2.331 g, 5 equiv.) 
and stirred vigorously at rt for 3 h under N2 atmosphere. The completion of the reaction was 
determined by crude NMR. Upon completion, the reaction mixture was quenched with 1:1 mixture 
of saturated aqueous solutions of Na2S2O3: NaHCO3 (30 mL) and stirred for 1 h. The mixture was 
extracted with DCM (3 × 50mL). The combined organic layers were washed with brine, dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The aldehyde 3.32 obtained was directly 
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used in the next step without further purification. The intermediate can easily be purified if desired 
by flash chromatography on silica gel (7:3 Ethyl Acetate: Hexanes). 
To the solution of crude 3.32 in dry THF (57 mL) was added K-selectride (3.3 mmol, 0.805 mL, 
3 equiv.) dropwise at -78 ˚C. The reaction mixture was slowly warmed to -10 ˚C and stirred for 3 
h. The resulting mixture was quenched by addition of saturated aqueous NH4Cl solution and the 
aqueous phase was extracted with DCM (3 × 50 mL). The combined organic phases were washed 
with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (9:1 DCM: MeOH) to give triol 3.33 (220 mg, 62% 
over 3 steps) as a white solid.  
Rf (DCM: MeOH 9:1): 0.2 
1H NMR (700 MHZ, CD3OD)  δ 4.05 (t, J = 3.0 Hz, 1H), 3.82 (d, J = 11.2 Hz, 1H), 3.46 (d, J = 
11.2 Hz, 1H), 2.45 – 2.37 (m, 1H), 2.34 – 2.25 (m, 2H), 2.21 (d, J = 13.8 Hz, 1H), 1.98 (td, J = 
13.9, 2.9 Hz, 1H), 1.93 – 1.82 (m, 4H), 1.81 – 1.73 (m, 2H), 1.69 – 1.62 (m, 1H), 1.56 (dt, J = 
13.3, 3.4 Hz, 2H), 1.44 – 1.33 (m, 4H), 1.30 – 1.17 (m, 3H), 1.00 (s, 3H). 
13C NMR (175 MHZ, CD3OD) δ 224.82, 83.56, 67.43, 66.13, 55.36, 41.95, 40.55, 36.51, 34.12, 
33.96, 33.50, 29.97, 28.18, 27.55, 27.15, 24.23, 21.08, 20.27, 13.62. 
 [α]D20 = +33.55 (c 0.094 in MeOH) 
HRMS (ESI) calculated for C19H30O4 [M+Na]
+: m/z 345.2036, found: 345.2039 
IR = 3321, 2849, 2200, 1719, 1648, 1452 
(3S,5R,8R,9S,10R,13S,14S)-10-(hydroxymethyl)-17-iodo-13-methyl-
1,2,3,4,5,6,7,8,9,10,11,12,13,15-tetradecahydro-14H-cyclopenta[a]phenanthrene-3,14-diol 
(3.34) 
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To the solution of 3.33 (0.620 mmol, 200 mg, 1 equiv.) in ethanol (60 mL) were added 
NH2NH2.H2O (12.4 mmol, 600 µL, 20 equiv.) and triethylamine (12.4 mmol, 1.7 mL, 20 equiv.) 
and heated at 65 ˚C for 6 h. The resulting colorless solution was concentrated in vacuo and 
dissolved in THF (35 mL). Triethylamine (12.4 mmol, 1.7 mL, 20 equiv.) was added to the reaction 
mixture followed by dropwise addition of solution of iodine (0.744 mmol, 188 mg, 1.2 equiv.) in 
THF (2 mL) which resulted in white precipitation. The resulting brown solution was stirred for 30 
minutes and quenched with 1:1 mixture of saturated aqueous solution of Na2S2O3:NaHCO3. It was 
then extracted with ethyl acetate (3 × 50mL). The combined organic layers were washed with 
brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified 
by flash chromatography on silica gel (9:1 Ethyl acetate: Hexanes) to give vinyl iodide 3.34 (205 
mg, 77%) as a white solid. 
Rf (EtOAc: hexanes 8:2): 0.2 
1H NMR (500 MHZ, CD3OD) δ 6.06 (t, J = 2.3 Hz, 1H), 4.03 (s, 1H), 3.83 (d, J = 11.2 Hz, 1H), 
3.41 (d, J = 11.2 Hz, 1H), 2.59 (dd, J = 16.3, 1.9 Hz, 1H), 2.27 – 2.09 (m, 2H), 1.97 (td, J = 14.0, 
3.0 Hz, 1H), 1.93 – 1.79 (m, 3H), 1.74 (ddd, J = 21.7, 11.3, 3.3 Hz, 2H), 1.67 (dd, J = 11.6, 2.7 
Hz, 1H), 1.62 – 1.53 (m, 2H), 1.50 (dd, J = 13.0, 3.3 Hz, 1H), 1.43 – 1.35 (m, 2H), 1.29 (dd, J = 
12.5, 4.3 Hz, 1H), 1.26 – 1.19 (m, 1H), 1.01 (s, 3H), 1.09 – 0.90 (m, 2H). 
13C NMR (175 MHZ, CD3OD) δ 134.81, 111.63, 83.54, 67.46, 66.10, 55.75, 42.99, 42.68, 40.51, 
39.55, 37.31, 34.11, 29.75, 28.28, 27.22, 24.21, 21.66, 20.89, 18.61. 
[α]D20 = +23.26 (c 0.113 in MeOH) 
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IR = 3365, 2927, 2361, 2337, 1750, 1646, 1540 
(3S,5R,8R,9S,10R,13S,14S)-3-((tert-butyldimethylsilyl)oxy)-10-(((tert-
butyldimethylsilyl)oxy)methyl)-17-iodo-13-methyl-1,2,3,4,5,6,7,8,9,10,11,12,13,15-
tetradecahydro-14H-cyclopenta[a]phenanthren-14-ol (3.44) 
 
To a solution of vinyl iodide 3.34 (0.370 mmol, 160 mg, 1 equiv.) in dry DCM (37 mL) at -78 ˚C 
was added 2,6 lutidine (3.70 mmol, 430 µL, 10 equiv.) followed by dropwise addition of TBSOTf 
(1.850 mmol, 425 µL, 5 equiv.) and the resulting solution was warmed to -20 ˚C and stirred for 2 
h. The resulting colorless solution was quenched by addition of saturated aqueous NaHCO3 
solution and the aqueous phase was extracted with DCM (3 × 30mL). The combined organic layers 
were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
residue was purified by flash chromatography on silica gel (8:2 Hexanes: Ethyl acetate) to give 
3.44 (180 mg, 74%) as a white fluffy solid and unreacted starting material (40 mg, 98% brsm).  
Rf (Hexanes: EtOAc 9:1): 0.5 
1H NMR (500 MHZ, CDCl3) δ 6.11 (t, J = 2.3 Hz, 1H), 4.01 (s, 1H), 3.74 (d, J = 9.7 Hz, 1H), 
3.39 (d, J = 9.7 Hz, 1H), 2.57 (dd, J = 16.5, 1.9 Hz, 1H), 2.26 (d, J = 14.3 Hz, 1H), 2.21 (dd, J = 
16.5, 3.2 Hz, 1H), 1.92 (ddd, J = 13.8, 11.3, 6.9 Hz, 1H), 1.82 – 1.67 (m, 5H), 1.53 – 1.38 (m, 4H), 
1.33 – 1.14 (m, 5H), 1.07-1.01 (m, 1H), 1.04 (s, 3H), 0.89 (d, J = 7.6 Hz, 18H), 0.02 (dd, J = 9.2, 
1.2 Hz, 12H). 
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13C NMR (175 MHZ, CDCl3) δ 133.64, 111.56, 82.86, 67.20, 66.27, 54.96, 42.63, 41.48, 39.55, 
38.27, 36.20, 34.43, 28.83, 28.67, 26.27, 26.11, 26.03, 23.66, 20.93, 19.98, 18.43, 18.25, 18.17, -
4.70, -4.74, -5.36, -5.42. 
[α]D20 = +12.06 (c 0.0667 in CH2Cl2) 
HRMS (ESI-MS) calculated for C31H57IO3Si2 [M+Na]
+: m/z 683.2789, found: 683.2781 
IR = 2928, 2856, 2183, 1475, 1460, 1359, 1250, 1218  
4-((3S,5R,8R,9S,10R,13R,14S)-3-((tert-butyldimethylsilyl)oxy)-10-(((tert-
butyldimethylsilyl)oxy)methyl)-14-hydroxy-13-methyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-
tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one (3.45) 
 
To a flask with 3.44 (0.0696 mmol, 46 mg, 1 equiv.) was added Pd(PPh3)4 (0.00348 mmol, 4 mg, 
0.05 equiv.), LiCl (1.32 mmol, 56 mg, 20 equiv.) and CuCl (1.044 mmol, 103 mg, 15 equiv.) in a 
glovebox followed by addition of DMSO (7.5 mL) and stannane precursor 3.43 (0.2088 mmol, 78 
mg, 3 equiv.) and heated to 70 ˚C for 2 h. The resulting brown solution was cooled to rt and 
quenched with pH 7 phosphate buffer. It was then filtered through glass wool to remove solid 
residue and the aqueous phase was extracted with ethyl acetate (3 × 15 mL). The combined organic 
layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The residue was purified by flash chromatography on silica gel (6:4 Hexanes: Ethyl acetate) to 
give 3.45 (35 mg, 82%) as a white fluffy solid. 
Rf (Hexanes: Ethyl Acetate 6:4):  0.5 
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1H NMR (500 MHZ, CDCl3) δ 6.10 (s, 1H), 5.96 (s, 1H), 5.05 – 4.88 (m, 2H), 4.02 (s, 1H), 3.74 
(d, J = 9.7 Hz, 1H), 3.41 (d, J = 9.7 Hz, 1H), 2.72 (dd, J = 18.5, 2.2 Hz, 1H), 2.36 (dd, J = 18.4, 
3.1 Hz, 1H), 2.28 (d, J = 12.9 Hz, 1H), 2.04 – 1.96 (m, 1H), 1.91 (td, J = 13.3, 5.5 Hz, 1H), 1.82 
– 1.76 (m, 4H), 1.65 – 1.52 (m, 1H), 1.51 – 1.37 (m, 3H), 1.28- 1.18 (m, 4H), 1.25 (s, 3H) ,1.15 – 
1.00 (m, 2H), 0.89 (d, J = 7.6 Hz, 18H), 0.02 (dd, J = 9.2, 1.2 Hz, 12H). 
13C NMR (175 MHZ, CDCl3) δ 174.41, 158.34, 143.95, 132.09, 112.37, 85.81, 71.67, 66.94, 
66.27, 52.18, 41.00, 40.31, 39.33, 39.05, 35.97, 34.28, 28.77, 28.50, 26.14, 25.94, 25.85, 23.50, 
20.86, 19.93, 18.27, 18.08, 16.69, -4.87, -4.90, -5.52, -5.58. 
[α]D20 = +38.73 (c 0.225 in CH2Cl2) 
HRMS (ESI-MS) calculated for C35H60O5Si2 [M+H]
+: m/z 617.4058, found: 617.4046  
IR = 3420, 2927, 2120, 2010, 1750, 1730, 1620, 1210 
4-((3S,5R,8R,9S,10R,13R,14S)-3-((tert-butyldimethylsilyl)oxy)-10-(((tert-
butyldimethylsilyl)oxy)methyl)-13-methyl-14-((trimethylsilyl)oxy)-
2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-
2(5H)-one (3.46) 
 
To a solution of 3.45 (0.0486 mmol, 30 mg, 1 equiv.) in DMF (1 mL) at rt was added imidazole 
(0.486, 33 mg, 10 equiv.) and stirred for 5 minutes. TMSCl (0.243 mmol, 31 µL, 5 equiv.) was 
added dropwise to the reaction mixture and stirred overnight in a sealed vial. The resulting 
colorless solution was quenched by addition of saturated aqueous NaHCO3 solution dropwise and 
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the aqueous phase was extracted with DCM (3 × 15 mL). The combined organic layers were 
washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue 
was purified by flash chromatography on silica gel (8:2 Hexanes: Ethyl acetate) to give 3.46 (30 
mg, 90%) as a white fluffy solid. 
Rf (Hexanes: Ethyl Acetate 9:1): 0.6 
1H NMR (700 MHZ, CDCl3) δ 6.03 (s, 1H), 5.95 (s, 1H), 4.95 (ddd, J = 66.0, 16.4, 1.6 Hz, 2H), 
4.01 (d, J = 3.6 Hz, 1H), 3.73 (d, J = 9.7 Hz, 1H), 3.37 (d, J = 9.7 Hz, 1H), 2.62 (d, J = 19.5 Hz, 
1H), 2.41 (dd, J = 18.7, 3.4 Hz, 1H), 2.25 (d, J = 13.4 Hz, 2H), 1.95 (d, J = 13.5 Hz, 1H), 1.87 (d, 
J = 5.8 Hz, 1H), 1.82 – 1.74 (m, 3H), 1.70 (d, J = 12.7 Hz, 1H), 1.52 (m, 1H), 1.42 (d, J = 11.7 
Hz, 3H), 1.29 – 1.22 (m, 2H), 1.20 (s, 3H), 1.21- 1.18 (m, 1H), 1.09 (d, J = 13.3 Hz, 1H), 1.04 – 
0.94 (m, 1H), 0.90 (dd, J = 17.8, 1.1 Hz, 18H), 0.06 (t, J = 1.5 Hz, 6H), 0.01 (dd, J = 10.1, 1.1 Hz, 
15H). 
13C NMR (175 MHZ, CDCl3) δ 174.65, 158.67, 145.07, 132.16, 112.42, 90.35, 71.72, 67.19, 
66.80, 53.15, 42.13, 39.54, 39.45, 39.29, 36.16, 34.49, 29.31, 28.71, 26.53, 26.13, 26.03, 23.72, 
21.22, 20.11, 18.40, 18.26, 17.50, 2.84, -4.69, -4.74, -5.37, -5.38. 
[α]D20 = +10.86 (c 0.125 in CH2Cl2) 
HRMS (ESI-MS) calculated for C38H68O5Si3 [M+Na]
+: m/z 711.4267, found: 711.4276  
IR = 3745, 2928, 2856, 2359, 2338, 1783, 1751, 1456, 1250 
4-((3S,5R,8R,9S,10R,13R,14S,17R)-3-((tert-butyldimethylsilyl)oxy)-10-(((tert-
butyldimethylsilyl)oxy)methyl)-13-methyl-14-((trimethylsilyl)oxy)hexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one (SI-9) 
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To a solution of 3.46 (0.0436 mmol, 30 mg, 1 equiv.) in ethyl acetate (3 mL) was added 10% 
Palladium on activated carbon (0.0109 mmol, 1.3 mg, 0.25 equiv.) and purged with N2. The flask 
was then purged with H2 and stirred under H2 atmosphere at rt for 1 h. The completion of the 
reaction was confirmed by TLC. The resulting mixture was then filtered through celite and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel (9:1 
Hexanes: Ethyl acetate) to give SI-9 (25 mg, 83%) as a white solid. 
Rf (Hexanes: EtOAc 9:1): 0.5 
1H NMR (500 MHZ, CDCl3) δ 5.83 (s, 1H), 4.84 – 4.59 (m, 2H), 4.02 (t, J = 2.8 Hz, 1H), 3.67 
(d, J = 9.6 Hz, 1H), 3.43 (d, J = 9.6 Hz, 1H), 2.56 (t, J = 7.8 Hz, 1H), 2.24 (d, J = 13.4 Hz, 1H), 
2.10 – 2.01 (m, 1H), 1.98 – 1.87 (m, 3H), 1.82 – 1.76 (m, 1H), 1.76 – 1.66 (m, 4H), 1.63 – 1.52 
(m, 3H), 1.46 – 1.35 (m, 4H), 1.34 – 1.20 (m, 3H), 1.20 – 1.16 (m, 1H), 0.89 (d, J = 5.9 Hz, 18H), 
0.86 (s, 3H), 0.20 – -0.07 (m, 21H). 
13C NMR (126 MHZ, CDCl3) δ 174.49, 174.20, 117.15, 91.70, 74.06, 67.19, 66.34, 51.11, 50.84, 
42.33, 40.79, 40.02, 36.50, 34.61, 33.96, 28.84, 28.52, 27.42, 26.51, 26.11, 26.02, 23.76, 23.19, 
21.19, 18.46, 18.35, 18.25, 3.07, -4.69, -4.73, -5.39, -5.53. 
[α]D20 = +16.92 (c 0.20 in CH2Cl2) 
HRMS (ESI-MS) calculated for C38H70O5Si3 [M+NH4]
+: m/z 708.4869, found: 708.4867   
IR = 2937, 2928, 2857, 2155, 1781, 1752, 1471, 1250 
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4-((3S,5R,8R,9S,10R,13R,14S,17R)-3,14-dihydroxy-10-(hydroxymethyl)-13-
methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one (3.20) 
 
To a solution of SI-9 (0.065 mmol, 45 mg, 1 equiv.) in MeOH (3 mL) was added 3M HCl in 
MeOH (600 µL) and stirred at rt for 1 h. The resulting colorless solution was quenched by addition 
of saturated aqueous NaHCO3 solution dropwise and the aqueous phase was extracted with 2:1 
chloroform: ethanol (3 × 15mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(9:1 DCM: MeOH) to give 3.20 (25 mg, 92%) as a white solid. 
Rf (DCM: MeOH 9:1): 0.2 
1H NMR (500 MHZ, CD3OD) δ 5.90 (s, 1H), 5.09 – 4.90 (m, 2H), 4.04 (t, J = 2.9 Hz, 1H), 3.83 
(d, J = 11.2 Hz, 1H), 3.43 (d, J = 11.2 Hz, 1H), 2.83 (dd, J = 9.1, 5.9 Hz, 1H), 2.32 – 2.09 (m, 3H), 
1.99 – 1.91 (m, 1H), 1.87 (dt, J = 13.0, 6.9 Hz, 2H), 1.83 – 1.76 (m, 2H), 1.76 – 1.54 (m, 4H), 1.54 
– 1.41 (m, 3H), 1.37 (dq, J = 13.4, 3.2 Hz, 2H), 1.33 – 1.18 (m, 4H), 0.88 (s, 3H). 
13C NMR (175 MHZ, CD3OD) δ 178.41, 177.23, 117.79, 86.56, 75.35, 67.47, 66.04, 52.13, 51.05, 
42.53, 41.32, 40.54, 36.36, 34.12, 33.17, 29.81, 28.23, 28.03, 27.44, 24.20, 22.44, 22.17, 16.41. 
[α]D20 = +8.48 (c 0.15 in MeOH) 
HRMS (ESI-MS) calculated for C23H33DO5 [M+H]
+: m/z 392.2547, found: 392.2540 
IR = 3367, 2925, 2494, 1727, 1666, 1626, 1448, 1370 
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((3S,5R,8R,9S,10R,13R,14S,17R)-3,14-dihydroxy-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-
yl)hexadecahydro-10H-cyclopenta[a]phenanthren-10-yl)methyl 2-methoxyacetate (3.56) 
 
To a solution of cannogenol 3.20 (0.0589 mmol, 23 mg, 1 equiv.) in DCM (2.5 mL) at 0 ˚C was 
added DIPEA (0.141 mmol, 18 mg, 2.4 equiv.) and (MeOCH2CO)2O (0.07068 mmol, 11.5 mg, 
1.2 equiv.) and stirred overnight. The resulting colorless solution was quenched by addition of 
saturated aqueous NaHCO3 solution dropwise and the aqueous phase was extracted with DCM (3 
× 8mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(8:2 Ethyl acetate: Hexanes) to give 3.56 (27 mg, 99%) as a brown solid. 
Rf (DCM: MeOH 9:1): 0.5 
1H NMR (700 MHZ, CDCl3) δ 5.88 (d, J = 2.2 Hz, 1H), 4.97 (dd, J = 18.1, 1.8 Hz, 1H), 4.80 (dd, 
J = 18.1, 1.8 Hz, 1H), 4.44 (d, J = 11.2 Hz, 1H), 4.12 (s, 1H), 4.09-4.06 (m, 1H), 4.06 (s, 2H), 3.46 
(s, 3H), 2.78 (dd, J = 9.3, 5.5 Hz, 1H), 2.21 – 2.09 (m, 3H), 1.93 – 1.84 (m, 2H), 1.83 – 1.69 (m, 
5H), 1.63 – 1.51 (m, 5H), 1.50 – 1.41 (m, 2H), 1.40 – 1.35 (m, 1H), 1.32 – 1.19 (m, 3H), 0.88 (s, 
3H). 
13C NMR (175 MHZ, CDCl3) δ 174.30, 174.05, 170.55, 117.86, 85.51, 73.35, 69.84, 67.64, 66.11, 
59.43, 50.79, 49.49, 41.77, 40.13, 38.50, 35.02, 33.17, 32.92, 29.16, 27.46, 26.79, 25.99, 23.39, 
21.40, 20.80, 15.79. 
[α]D20 = +30.73 (c 0.10 in MeOH) 
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HRMS (ESI-MS) calculated for C26H38O7 [M+NH4]
+: m/z 480.2961, found: 480.2958   
IR = 3505, 2946, 1936, 1793, 1747, 1617, 1447, 1263 
(2R,3R,4R,5S,6S)-2-(((3S,5R,8R,9S,10R,13R,14S,17R)-14-hydroxy-10-((2-
methoxyacetoxy)methyl)-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-1H-
cyclopenta[a]phenanthren-3-yl)oxy)-6-methyltetrahydro-2H-pyran-3,4,5-triyl tribenzoate 
(3.57) 
 
To a solution of acetylated cannogenol 3.56 (0.019 mmol, 8.8 mg, 1.0 equiv.) in dry DCM (800 
µL) was added 4Å MS and cooled to 0 ˚C. The solution of donor 3.40 (0.0095 mmol, 6.6 mg, 0.5 
equiv.) in DCM (100 µL) was added to the flask followed by dropwise addition of the solution of 
TfOH (0.0057 mmol, 0.5 µM, 0.3 equiv.) and the resulting mixture was stirred at 0 ˚C for 1 h. 
Additional 0.5 equiv. of donor was added portion wise every hour for the next three hours. After 
the addition of 2 equiv. of total donor, the reaction mixture was warmed to rt and stirred for 1 h. 
The resulting colorless solution was quenched by addition of excess triethylamine dropwise and 
filtered through celite. This eluent was concentrated in vacuo and the residue was purified by flash 
chromatography on silica gel (6:4 Hexanes: Ethyl acetate) to give 3.57 (12.1 mg, 81%) as a 
colorless solid. 
Rf (EtOAc: Hexanes 6:4): 0.4 
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1H NMR (700 MHZ, CDCl3) δ δ 8.10 (d, J = 7.4 Hz, 2H), 7.98 (d, J = 7.5 Hz, 2H), 7.82 (d, J = 
7.6 Hz, 2H), 7.62 (t, J = 7.5 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.43 (t, J = 
7.4 Hz, 1H), 7.39 (t, J = 7.7 Hz, 2H), 7.26 (t, J = 7.7 Hz, 2H) 5.89 (s, 1H), 5.83 (dd, J = 10.2, 3.4 
Hz, 1H), 5.69 (t, J = 9.9 Hz, 1H), 5.61 (dd, J = 3.5, 1.8 Hz, 1H), 5.10 (d, J = 1.7 Hz, 1H), 4.99 (dd, 
J = 18.1, 1.8 Hz, 1H), 4.81 (dd, J = 18.1, 1.7 Hz, 1H), 4.50 (d, J = 11.1 Hz, 1H), 4.26 – 4.19 (m, 
3H), 4.09 (d, J = 11.2 Hz, 1H), 4.08 (s, 1H), 3.44 (s, 3H), 2.80 (dd, J = 9.3, 5.5 Hz, 1H), 2.27 – 
2.22 (m, 1H), 2.22 – 2.10 (m, 2H), 1.95 (td, J = 14.2, 3.9 Hz, 1H), 1.92 – 1.87 (m, 1H), 1.84 – 1.75 
(m, 5H), 1.74 – 1.71 (m, 1H), 1.66 – 1.61 (m, 3H), 1.60 – 1.53 (m, 3H), 1.43 – 1.38 (m, 2H), 1.35 
(d, J = 6.3 Hz, 3H), 1.31 (d, J = 3.4 Hz, 2H), 0.90 (s, 3H). 
13C NMR (175 MHZ, CDCl3) δ 174.45, 174.19, 171.05, 165.97, 165.89, 165.65, 133.67, 133.51, 
133.30, 130.04, 129.85, 129.77, 129.56, 129.44, 129.34, 128.76, 128.60, 128.47, 118.06, 96.00, 
85.66, 73.51, 72.94, 71.95, 71.62, 70.28, 69.88, 67.26, 67.07, 59.44, 50.98, 49.66, 42.01, 40.32, 
38.59, 35.48, 33.12, 29.86, 29.25, 26.97, 26.30, 26.21, 24.31, 21.58, 21.03, 17.87, 15.98. 
[α]D20 = +42.50 (c 0.133 in CH2Cl2) 
4-((3S,5R,8R,9S,10R,13R,14S,17R)-14-hydroxy-10-(hydroxymethyl)-13-methyl-3-
(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-
yl)oxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one (3.19) 
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To a solution of protected glycoside 3.57 (0.00543 mmol, 5.0 mg, 1.0 equiv.) was added half 
saturated solution of ammonia in methanol (600 µL) and let it stir at rt overnight in a sealed vial. 
The resulting solution was concentrated in vacuo with silica gel and purified by flash column 
chromatography on silica gel (9:1 → 8:2 DCM: MeOH) to give cannogenol-3-O-α-L-rhamnoside 
3.19 (2 mg, 69%) as an off-white solid.  
Rf (DCM:MeOH 9:1) : 0.2 
1H NMR (700 MHZ, C5D5N) δ 6.80 – 6.74 (m, 1H, C3-OH), 6.59 (s, 1H, C2-OH), 6.47 (s, 1H, 
C4-OH), 6.15 (t, J = 1.8 Hz, 1H, H-21), 5.88 (t, J = 5.6 Hz, 1H, C19-OH), 5.49 (s, 1H, H-1’), 5.39 
(s, 1H, C14-OH), 5.34 (dd, J = 18.1, 1.8 Hz, 1H, H-22), 5.06 (dd, J = 18.1, 1.8 Hz, 1H, H-22), 
4.66 – 4.56 (m, 2H, H-2’ and H-4’), 4.40 – 4.34 (m, 1H, H-5’), 4.32 (t, J = 9.1 Hz, 1H, H-3’), 4.27 
– 4.23 (m, 1H, H-3), 4.11 (dd, J = 10.9, 4.6 Hz, 1H, H-19), 3.78 (dd, J = 10.9, 5.2 Hz, 1H, H-19),  
2.83 (dd, J = 9.7, 5.5 Hz, 1H, H-17), 2.62 (d, J = 13.3 Hz, 1H, H-5), 2.43 (td, J = 14.4, 4.1 Hz, 1H, 
H-1), 2.23 – 2.10 (m, 3H, H-15, H-7, and H-16), 2.06 – 1.94 (m, 4H, H-6, H-8, H-16, and H-2), 
1.94 – 1.87 (m, 3H, H-4, H-9, and H-15), 1.76 (t, J = 14.0 Hz, 1H, H-2),  1.70 (d, J = 6.1 Hz, 3H, 
H-6’), 1.71 – 1.63 (m, 2H, H-4 and H-1), 1.57 – 1.52 (m, 1H, H-11), 1.50 – 1.37 (m, 4H, H-11, 
H12, H-7, and H-12), 1.25 (dt, J = 13.8, 2.8 Hz, 1H, H-6), 1.05 (s, 3H, H-18). 
13C NMR (175 MHZ, C5D5N) δ 176.43 (C23), 174.93 (C20), 118.02 (C21), 100.12 (C1’), 85.26 
(C14), 74.49 (C3’), 74.12 (C22), 73.35 (C2’), 73.33 (C4’), 72.38 (C3), 70.42 (C5’), 65.76 (C19), 
51.90 (C17), 50.58 (C13), 42.27 (C8), 40.77 (C12), 40.24 (C10), 36.16 (C9), 33.35 (C15), 30.54 
(C4), 30.36 (C5), 27.70 (C16), 27.52 (C6), 27.25 (C2), 25.19 (C1), 22.26 (C7), 22.14 (C11), 19.07 
(C6), 16.68 (C18). 
[α]D20 = -10.8 (c 0.147 in MeOH) reported -15.5 (c 0.55 in MeOH) 
HRMS (ESI-MS) calculated for C29H44O9 [M+Na]
+: m/z 559.2883, found: 559.2869  
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IR = 3375, 2927, 2905, 1731, 1626, 1450, 1380, 1313 
NOE correlations to confirm the stereocenter at C17 
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Table S1 Comparison of NMR Data between the Synthetic Cannogenol-3-O-α-L-rhamnoside and 
the Natural Product Reported by Schenk1 
 
C # Natural   Synthetic   Δδ 
1 25.3   25.2   0.1 
2 27.3   27.3   0 
3 74.3   74.5   -0.2 
4 30.6   30.6   0 
5 30.5   30.4   0.1 
6 27.5   27.5   0 
7 22.3   22.3   0 
8 42.2   42.3   -0.1 
9 36.1   36.2   -0.1 
10 40.2   40.2   0 
11 22.3   22.1   0.2 
12 40.8   40.8   0 
13 50.6   50.6   0 
14 85.2   85.3   -0.1 
15 33.4   33.4   0 
16 27.8   27.8   0 
17 51.8   51.9   -0.1 
18 16.7   16.7   0 
19 65.5   65.8   -0.3 
20 176.3   176.4   -0.1 
21 73.2   73.3   -0.1 
22 117.8   118   -0.2 
23 174.8   174.9   -0.1 
1' 99.9   100   -0.1 
2' 73.2   73.4   -0.2 
3' 72.4   72.4   0 
4' 74.1   74.1   0 
5' 70.3   70.4   -0.1 
6' 19.1   19.1   0 
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Appendix A 
 
X-ray Crystal Structure of Bis-benzoylated Vinyl Iodide 3.35a 
Structure Determination. 
 Colorless needles of 3.35a were grown from a dichloromethane/hexane solution of the compound 
at 22 deg. C.  A crystal of dimensions 0.11 x 0.08 x 0.08 mm was mounted on a Rigaku AFC10K Saturn 
944+ CCD-based X-ray diffractometer equipped with a low temperature device and Micromax-007HF Cu-
target micro-focus rotating anode ( = 1.54184 A) operated at 1.2 kW power (40 kV, 30 mA).  The X-ray 
intensities were measured at 85(1) K with the detector placed at a distance 42.00 mm from the crystal.  A 
total of 2028 images were collected with an oscillation width of 1.0 in   The exposure times were 1 sec. 
for the low angle images, 4 sec. for high angle.  Rigaku d*trek images were exported to CrysAlisPro for 
processing and corrected for absorption.  The integration of the data yielded a total of 43539 reflections to 
a maximum 2 value of 138.48 of which 5235 were independent and 5234 were greater than 2(I).  The 
final cell constants (Table 1) were based on the xyz centroids 38541 reflections above 10(I).  Analysis of 
the data showed negligible decay during data collection; the data were processed with CrystalClear 2.0 and 
corrected for absorption.  The structure was solved and refined with the Bruker SHELXTL (version 2014/6) 
software package, using the space group P2(1)2(1)2(1) with Z = 4 for the formula C33H37O5I.  All non-
hydrogen atoms were refined anisotropically with the hydrogen atoms placed in a combination of idealized 
and refined positions.  Full matrix least-squares refinement based on F2 converged at R1 = 0.0182 and wR2 
= 0.0477 [based on I > 2sigma(I)], R1 = 0.0182 and wR2 = 0.0477 for all data.  Additional details are 
presented in Table 1 and are given as Supporting Information in a CIF file.  Acknowledgement is made for 
funding from NSF grant CHE-0840456 for X-ray instrumentation. 
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USA 77381-5209, Rigaku Tokyo, 196-8666, Japan. 
 
CrysAlisPro 1.171.38.41 (Rigaku Oxford Diffraction, 2015). 
 
 
    
 
 
 
 Table A.1.  Crystal data and structure refinement for 3.35a.  
   
 Identification code                bb3136  
    
Empirical formula                C33 H37 I O5  
    
Formula weight                   640.52 
    
Temperature                       85(2) K  
    
Wavelength                        1.54184 A  
    
Crystal system, space group        Orthorhombic,  P2(1)2(1)2(1)  
    
Unit cell dimensions              
a = 7.86976(5) A   alpha = 90 deg.  
                                         
b = 10.63397(5) A    beta = 90 deg.  
                                      
c = 33.8380(2) A   gamma = 90 deg.  
    
Volume                         2831.80(3) A^3  
    
Z, Calculated density          4,  1.502 Mg/m^3  
    
Absorption coefficient             9.211 mm^-1  
    
F(000)                            1312 
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Crystal size                       0.110 x 0.080 x 0.080 mm  
    
Theta range for data collection    2.612 to 69.239 deg.  
    
Limiting indices                   -9<=h<=9, -12<=k<=12, -37<=l<=40  
    
Reflections collected / unique     43539 / 5235 [R(int) = 0.0405]  
    
Completeness to theta = 67.684     99.80% 
    
Absorption correction             Semi-empirical from equivalents  
    
Max. and min. transmission         1.00000 and 0.66548  
    
Refinement method                Full-matrix least-squares on F^2  
    
Data / restraints / parameters     5235 / 0 / 358  
    
Goodness-of-fit on F^2             1.002 
    
Final R indices [I>2sigma(I)]     R1 = 0.0182, wR2 = 0.0477  
    
R indices (all data)               R1 = 0.0182, wR2 = 0.0477  
    
Absolute structure parameter       -0.0113(16)  
    
Extinction coefficient             0.00050(7)  
    
Largest diff. peak and hole        0.551 and -0.499 e.A^-3 
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         Table A.2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for bb3136.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                                 x                y                     z             U(eq)  
         ________________________________________________________________  
   
           I(1)          5508(1)       6429(1)       3707(1)       17(1)  
          O(1)         5931(3)       3031(2)       4608(1)       16(1)  
          O(2)         9188(2)       4645(2)       6303(1)       14(1)  
          O(3)         9987(3)       2646(2)       6171(1)       18(1)  
          O(4)         4113(2)       5421(2)       6778(1)       14(1)  
          O(5)         2242(3)       6882(2)       6985(1)       16(1)  
          C(1)         4980(4)       5494(3)       4236(1)       15(1)  
          C(2)         3477(4)       5051(3)       4341(1)       17(1)  
          C(3)         3584(4)       4440(3)       4745(1)       16(1)  
          C(4)         5516(4)       4209(2)       4790(1)       13(1)  
          C(5)         6332(3)       5322(2)       4555(1)       12(1)  
          C(6)         8100(4)       5021(3)       4398(1)       18(1)  
          C(7)         6363(3)       6530(3)       4814(1)       14(1)  
          C(8)         7163(3)       6310(3)       5219(1)       14(1)  
          C(9)         6154(3)       5311(2)       5450(1)       11(1)  
          C(10)       6726(3)       5147(2)       5889(1)       12(1)  
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          C(11)       5712(3)       4065(2)       6087(1)       11(1)  
          C(12)       5829(3)       2838(2)       5853(1)       13(1)  
          C(13)       5201(3)       3008(2)       5428(1)       13(1)  
          C(14)       6175(3)       4060(2)       5216(1)       11(1)  
          C(15)       6438(3)       6359(3)       6133(1)       14(1)  
          C(16)       4569(4)       6707(2)       6189(1)       15(1)  
          C(17)       3558(4)       5632(3)       6371(1)       14(1)  
          C(18)       3837(3)       4405(3)       6153(1)       15(1)  
          C(19)       8643(4)       4861(3)       5899(1)       14(1)  
          C(20)       9809(3)       3511(3)       6402(1)       14(1)  
          C(21)     10266(3)       3434(2)       6826(1)       12(1)  
          C(22)     11273(4)       2429(3)       6948(1)       16(1)  
          C(23)     11740(4)       2327(3)       7342(1)       17(1)  
          C(24)     11180(4)       3203(3)       7615(1)       17(1)  
          C(25)     10158(4)       4198(3)       7496(1)       17(1)  
          C(26)       9713(3)       4329(2)       7102(1)       14(1)  
          C(27)       3314(3)       6104(2)       7058(1)       13(1)  
          C(28)        3893(3)       5780(2)       7463(1)       13(1)  
          C(29)        3160(4)       6444(3)       7778(1)       18(1)  
          C(30)        3618(4)       6156(3)       8162(1)       22(1)  
          C(31)        4814(4)       5225(3)       8236(1)       23(1)  
          C(32)        5546(4)       4564(3)       7925(1)       19(1)  
          C(33)        5077(4)       4836(3)       7538(1)       16(1)  
         ________________________________________________________________  
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           Table A.3.  Bond lengths [A] and angles [deg] for bb3136.  
           _____________________________________________________________  
   
             I(1) -C(1)                     2.090(3)  
            O(1)-C(4)                     1.436(3)  
            O(1)-H(1)                     0.72(4)  
            O(2)-C(20)                   1.343(3)  
            O(2)-C(19)                   1.452(3)  
            O(3)-C(20)                   1.213(4)  
            O(4)-C(27)                   1.349(3)  
            O(4)-C(17)                   1.462(3)  
            O(5)-C(27)                   1.207(3)  
            C(1)-C(2)                      1.322(4)  
            C(1)-C(5)                      1.526(4)  
            C(2)-C(3)                      1.516(4)  
            C(2)-H(2)                      0.9500  
            C(3)-C(4)                      1.547(4)  
            C(3)-H(3A)                   0.9900  
            C(3)-H(3B)                   0.9900  
            C(4)-C(14)                    1.539(4)  
            C(4)-C(5)                      1.565(4)  
            C(5)-C(6)                      1.523(4)  
            C(5)-C(7)                      1.554(4)  
            C(6)-H(6A)                   0.9800  
            C(6)-H(6B)                   0.9800  
            C(6)-H(6C)                   0.9800  
            C(7)-C(8)                      1.529(4)  
            C(7)-H(7A)                   0.9900  
            C(7)-H(7B)                   0.9900  
            C(8)-C(9)                      1.538(4)  
            C(8)-H(8A)                   0.9900  
            C(8)-H(8B)                   0.9900  
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            C(9)-C(14)                    1.548(3)  
            C(9)-C(10)                    1.562(4)  
            C(9)-H(9)                      1.0000  
            C(10)-C(19)                  1.539(4)  
            C(10)-C(11)                  1.553(3)  
            C(10)-C(15)                  1.548(4)  
            C(11)-C(12)                  1.529(3)  
            C(11)-C(18)                  1.535(4)  
            C(11)-H(11)                 1.0000  
            C(12)-C(13)                  1.530(4)  
            C(12)-H(12A)               0.9900  
            C(12)-H(12B)                0.9900  
            C(13)-C(14)                   1.534(4)  
            C(13)-H(13A)                0.9900  
            C(13)-H(13B)                0.9900  
            C(14)-H(14)                  1.0000  
            C(15)-C(16)                   1.529(4)  
            C(15)-H(15A)                 0.9900  
            C(15)-H(15B)                 0.9900  
            C(16)-C(17)                   1.524(4)  
            C(16)-H(16A)                0.9900  
            C(16)-H(16B)                0.9900  
            C(17)-C(18)                   1.516(4)  
            C(17)-H(17)                  1.0000  
            C(18)-H(18A)                0.9900  
            C(18)-H(18B)                0.9900  
            C(19)-H(19A)                0.9900  
            C(19)-H(19B)                0.9900  
            C(20)-C(21)                   1.483(4)  
            C(21)-C(22)                   1.393(4)  
            C(21)-C(26)                   1.402(4)  
            C(22)-C(23)                   1.388(4)  
133 
 
            C(22)-H(22)                   0.9500  
            C(23)-C(24)                   1.384(4)  
            C(23)-H(23)                   0.9500  
            C(24)-C(25)                   1.388(4)  
            C(24)-H(24)                   0.9500  
            C(25)-C(26)                   1.388(4)  
            C(25)-H(25)                   0.9500  
            C(26)-H(26)                   0.9500  
            C(27)-C(28)                   1.486(4)  
            C(28)-C(33)                   1.394(4)  
            C(28)-C(29)                   1.401(4)  
            C(29)-C(30)                   1.385(4)  
            C(29)-H(29)                   0.9500  
            C(30)-C(31)                   1.388(4)  
            C(30)-H(30)                   0.9500  
            C(31)-C(32)                   1.390(4)  
            C(31)-H(31)                   0.9500  
            C(32)-C(33)                   1.388(4)  
            C(32)-H(32)                   0.9500  
            C(33)-H(33)                   0.9500  
   
            C(4)-O(1)-H(1)              111(3)  
            C(20)-O(2)-C(19)          118.9(2)  
            C(27)-O(4)-C(17)            116.0(2)  
            C(2)-C(1)-C(5)                 113.0(2)  
            C(2)-C(1)-I(1)                  125.3(2)  
            C(5)-C(1)-I(1)                  121.61(19)  
            C(1)-C(2)-C(3)                 110.2(2)  
            C(1)-C(2)-H(2)                124.9  
            C(3)-C(2)-H(2)                124.9    
            C(2)-C(3)-C(4)                102.3(2)  
            C(2)-C(3)-H(3A)             111.3  
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            C(4)-C(3)-H(3A)             111.3  
            C(2)-C(3)-H(3B)             111.3  
            C(4)-C(3)-H(3B)             111.3  
            H(3A)-C(3)-H(3B)          109.2  
            O(1)-C(4)-C(14)             103.6(2)  
            O(1)-C(4)-C(3)               108.7(2)  
            C(14)-C(4)-C(3)             116.1(2)  
            O(1)-C(4)-C(5)               110.3(2)  
            C(14)-C(4)-C(5)             114.6(2)  
            C(3)-C(4)-C(5)               103.5(2)  
            C(6)-C(5)-C(1)               114.6(2)  
            C(6)-C(5)-C(7)               110.8(2)  
            C(1)-C(5)-C(7)               108.1(2)  
            C(6)-C(5)-C(4)               113.2(2)  
            C(1)-C(5)-C(4)                 99.5(2)  
            C(7)-C(5)-C(4)               110.1(2)  
            C(5)-C(6)-H(6A)            109.5  
            C(5)-C(6)-H(6B)            109.5  
            H(6A)-C(6)-H(6B)         109.5  
            C(5)-C(6)-H(6C)            109.5  
            H(6A)-C(6)-H(6C)         109.5  
            H(6B)-C(6)-H(6C)         109.5  
            C(8)-C(7)-C(5)               112.7(2)  
            C(8)-C(7)-H(7A)            109.0  
            C(5)-C(7)-H(7A)            109.0  
            C(8)-C(7)-H(7B)            109.0  
            C(5)-C(7)-H(7B)            109.0  
            H(7A)-C(7)-H(7B)         107.8  
            C(7)-C(8)-C(9)               110.4(2)  
            C(7)-C(8)-H(8A)            109.6  
            C(9)-C(8)-H(8A)            109.6  
            C(7)-C(8)-H(8B)            109.6  
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            C(9)-C(8)-H(8B)            109.6  
            H(8A)-C(8)-H(8B)         108.1  
            C(8)-C(9)-C(14)            109.2(2)  
            C(8)-C(9)-C(10)            114.2(2)  
            C(14)-C(9)-C(10)          112.7(2)  
            C(8)-C(9)-H(9)              106.7  
            C(14)-C(9)-H(9)            106.7  
            C(10)-C(9)-H(9)            106.7  
            C(19)-C(10)-C(11)        110.3(2)  
            C(19)-C(10)-C(15)        107.2(2)  
            C(11)-C(10)-C(15)        108.1(2)  
            C(19)-C(10)-C(9)          109.0(2)  
            C(11)-C(10)-C(9)          110.3(2)  
            C(15)-C(10)-C(9)          111.9(2)  
            C(12)-C(11)-C(18)        109.5(2)  
            C(12)-C(11)-C(10)        112.1(2)  
            C(18)-C(11)-C(10)        112.4(2)  
            C(12)-C(11)-H(11)        107.5  
            C(18)-C(11)-H(11)        107.5  
            C(10)-C(11)-H(11)        107.5  
            C(11)-C(12)-C(13)          111.5(2)  
            C(11)-C(12)-H(12A)       109.3  
            C(13)-C(12)-H(12A)       109.3  
            C(11)-C(12)-H(12B)       109.3  
            C(13)-C(12)-H(12B)       109.3  
            H(12A)-C(12)-H(12B)    108.0  
            C(12)-C(13)-C(14)          111.4(2)  
            C(12)-C(13)-H(13A)       109.4  
            C(14)-C(13)-H(13A)       109.4  
            C(12)-C(13)-H(13B)       109.4  
            C(14)-C(13)-H(13B)       109.4  
            H(13A)-C(13)-H(13B)    108.0  
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            C(13)-C(14)-C(4)            110.2(2)  
            C(13)-C(14)-C(9)            112.5(2)  
            C(4)-C(14)-C(9)              112.7(2)  
            C(13)-C(14)-H(14)         107.1  
            C(4)-C(14)-H(14)           107.1  
            C(9)-C(14)-H(14)           107.1  
            C(16)-C(15)-C(10)         114.1(2)  
            C(16)-C(15)-H(15A)      108.7  
            C(10)-C(15)-H(15A)      108.7  
            C(16)-C(15)-H(15B)      108.7  
            C(10)-C(15)-H(15B)      108.7  
            H(15A)-C(15)-H(15B)   107.6  
            C(17)-C(16)-C(15)         111.8(2)  
            C(17)-C(16)-H(16A)      109.3  
            C(15)-C(16)-H(16A)      109.3  
            C(17)-C(16)-H(16B)          109.3  
            C(15)-C(16)-H(16B)          109.3  
            H(16A)-C(16)-H(16B)       107.9  
            O(4)-C(17)-C(18)              106.5(2)  
            O(4)-C(17)-C(16)              109.9(2)  
            C(18)-C(17)-C(16)            111.8(2)  
            O(4)-C(17)-H(17)             109.5  
            C(18)-C(17)-H(17)           109.5  
            C(16)-C(17)-H(17)           109.5  
            C(17)-C(18)-C(11)           114.4(2)  
            C(17)-C(18)-H(18A)        108.7  
            C(11)-C(18)-H(18A)        108.7  
            C(17)-C(18)-H(18B)        108.7  
            C(11)-C(18)-H(18B)        108.7  
            H(18A)-C(18)-H(18B)     107.6  
            O(2)-C(19)-C(10)            110.0(2)  
            O(2)-C(19)-H(19A)         109.7  
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            C(10)-C(19)-H(19A)       109.7  
            O(2)-C(19)-H(19B)         109.7  
            C(10)-C(19)-H(19B)       109.7  
            H(19A)-C(19)-H(19B)    108.2  
            O(3)-C(20)-O(2)             124.3(2)  
            O(3)-C(20)-C(21)           123.5(3)  
            O(2)-C(20)-C(21)           112.2(2)  
            C(22)-C(21)-C(26)         120.0(2)  
            C(22)-C(21)-C(20)         117.9(2)  
            C(26)-C(21)-C(20)         122.1(2)  
            C(23)-C(22)-C(21)         119.7(3)  
            C(23)-C(22)-H(22)         120.1  
            C(21)-C(22)-H(22)         120.1  
            C(22)-C(23)-C(24)         120.2(3)  
            C(22)-C(23)-H(23)         119.9  
            C(24)-C(23)-H(23)         119.9  
            C(23)-C(24)-C(25)         120.3(3)  
            C(23)-C(24)-H(24)         119.8  
            C(25)-C(24)-H(24)         119.8  
            C(26)-C(25)-C(24)         120.1(3)  
            C(26)-C(25)-H(25)         120.0  
            C(24)-C(25)-H(25)         120.0  
            C(25)-C(26)-C(21)         119.6(3)  
            C(25)-C(26)-H(26)         120.2  
            C(21)-C(26)-H(26)         120.2  
            O(5)-C(27)-O(4)             123.5(2)  
            O(5)-C(27)-C(28)            124.2(2)  
            O(4)-C(27)-C(28)            112.3(2)  
            C(33)-C(28)-C(29)          120.0(3)  
            C(33)-C(28)-C(27)          122.7(3)  
            C(29)-C(28)-C(27)          117.2(2)  
            C(30)-C(29)-C(28)          119.6(3)  
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            C(30)-C(29)-H(29)          120.2  
            C(28)-C(29)-H(29)          120.2  
            C(29)-C(30)-C(31)          120.2(3)  
            C(29)-C(30)-H(30)          119.9  
            C(31)-C(30)-H(30)          119.9  
            C(32)-C(31)-C(30)          120.4(3)  
            C(32)-C(31)-H(31)          119.8  
            C(30)-C(31)-H(31)          119.8  
            C(31)-C(32)-C(33)          119.8(3)  
            C(31)-C(32)-H(32)          120.1  
            C(33)-C(32)-H(32)          120.1  
            C(32)-C(33)-C(28)          119.9(3)  
            C(32)-C(33)-H(33)          120.0  
            C(28)-C(33)-H(33)          120.0  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
             
 
139 
 
  
    Table A.4.  Anisotropic displacement parameters (A^2 x 10^3) for 3.35a.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
                U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
      I(1)     21(1)      20(1)       9(1)       4(1)       0(1)       4(1)  
    O(1)     28(1)      13(1)       8(1)      -3(1)      -3(1)       2(1)  
    O(2)     19(1)      14(1)       9(1)       0(1)      -4(1)       0(1)  
    O(3)     24(1)      19(1)      12(1)      -4(1)       0(1)       2(1)  
    O(4)     18(1)      17(1)       8(1)      -1(1)       1(1)       3(1)  
    O(5)     20(1)      15(1)      14(1)       1(1)       1(1)       3(1)  
    C(1)      22(1)      14(1)       9(1)       1(1)       0(1)       4(1)  
    C(2)      20(1)      18(1)      14(1)      -1(1)      -4(1)       2(1)  
    C(3)      19(1)      19(1)      12(1)       1(1)      -2(1)      -3(1)  
    C(4)      18(1)      11(1)       9(1)      -2(1)       0(1)      -1(1)  
    C(5)      17(1)      14(1)       7(1)       1(1)       0(1)       2(1)  
    C(6)      19(1)      20(1)      15(1)       4(1)       3(1)       6(1)  
    C(7)      18(1)      12(1)      14(1)       1(1)       1(1)      -2(1)  
    C(8)      20(1)      11(1)      11(1)       1(1)       0(1)      -3(1)  
    C(9)      15(1)       9(1)       9(1)       0(1)      -1(1)      -1(1)  
    C(10)    14(1)      12(1)       8(1)      -1(1)      -1(1)      -2(1)  
    C(11)    14(1)      11(1)       8(1)       1(1)       1(1)      -3(1)  
    C(12)    17(1)      11(1)      10(1)       1(1)       0(1)      -2(1)  
    C(13)    18(1)      11(1)      10(1)      -1(1)      -1(1)      -2(1)  
    C(14)    15(1)      11(1)       8(1)      -1(1)      -1(1)      -1(1)  
    C(15)    18(1)      15(1)       9(1)      -1(1)       0(1)      -5(1)  
    C(16)    22(1)      14(1)      10(1)      -2(1)       1(1)       1(1)  
    C(17)    18(1)      18(1)       7(1)       0(1)      -1(1)      -1(1)  
    C(18)    17(1)      16(1)      11(1)      -1(1)       2(1)      -3(1)  
    C(19)    17(1)      17(1)       6(1)       2(1)      -2(1)      -1(1)  
    C(20)    12(1)      16(1)      12(1)       0(1)       2(1)      -2(1)  
    C(21)    13(1)      14(1)       9(1)       0(1)       1(1)      -5(1)  
    C(22)    18(1)      16(1)      14(1)      -2(1)       3(1)      -3(1)  
    C(23)    18(1)      17(1)      17(1)       4(1)       0(1)       2(1)  
    C(24)    18(1)      22(1)      11(1)       2(1)      -1(1)      -5(1)  
    C(25)    21(1)      18(1)      11(1)      -4(1)       2(1)      -3(1)  
    C(26)    16(1)      13(1)      14(1)      -2(1)       1(1)      -1(1)  
    C(27)    15(1)      12(1)      13(1)      -1(1)       4(1)      -4(1)  
    C(28)    14(1)      11(1)      14(1)      -1(1)       1(1)      -2(1)  
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    C(29)    20(1)      16(1)      17(1)      -2(1)       0(1)       2(1)  
    C(30)    32(2)      22(2)      13(1)      -4(1)      -1(1)       3(1)  
    C(31)    32(2)      24(1)      12(1)       0(1)      -5(1)       0(1)  
    C(32)    21(1)      15(1)      22(2)       2(1)      -3(1)       1(1)  
    C(33)    17(1)      13(1)      16(1)      -2(1)       2(1)      -1(1)  
    _______________________________________________________________________  
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         Table A.5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for bb3136.  
   
         ________________________________________________________________  
   
                               x                  y               z               U(eq)  
         ________________________________________________________________  
   
          H(1)         5700(50)    3030(30)   4401(12)  19(10)  
          H(2)         2474          5108          4186          20  
          H(3A)        2941          3641          4753          20  
          H(3B)        3152          5008          4954          20  
          H(6A)        8033          4309          4215          27  
          H(6B)        8849          4804          4619          27  
          H(6C)        8556          5757          4260          27  
          H(7A)        7010          7192          4674          17  
          H(7B)        5185          6836          4849          17  
          H(8A)        7173          7108          5370          17  
          H(8B)        8353          6027          5186          17  
          H(9)         4947          5602          5456          13  
          H(11)        6230          3909          6353          13  
          H(12A)       5138          2184          5985          15  
          H(12B)       7024          2547          5849          15  
          H(13A)       3974          3214          5431          15  
          H(13B)       5348          2210          5281          15  
          H(14)        7388          3785          5197          14  
          H(15A)       6965          6248          6397          17  
          H(15B)       7025          7065          6001          17  
          H(16A)       4487          7456          6361          19  
          H(16B)       4070          6926          5929          19  
          H(17)        2321          5847          6369          17  
          H(18A)       3267          4458          5893          17  
          H(18B)       3288          3719          6304          17  
          H(19A)       8886          4107          5737          16  
          H(19B)       9281          5578          5786          16  
          H(22)       11640          1817          6762          19  
          H(23)       12447          1652          7425          21  
          H(24)       11496          3124          7885          21  
          H(25)        9763          4790          7686          20  
          H(26)        9039          5021          7019          17  
          H(29)        2353          7089          7727          21  
          H(30)        3112          6596          8376          27  
          H(31)        5135          5039          8500          27  
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          H(32)        6364          3929          7976          23  
          H(33)        5563          4377          7326          19  
         ________________________________________________________________  
 
143 
 
  
         Table A.6.  Torsion angles [deg] for bb3136.  
         ________________________________________________________________  
   
          C(5)-C(1)-C(2)-C(3)                                  -2.9(3)  
          I(1)-C(1)-C(2)-C(3)                                -179.66(19)  
          C(1)-C(2)-C(3)-C(4)                                 -18.6(3)  
          C(2)-C(3)-C(4)-O(1)                                 -85.7(2)  
          C(2)-C(3)-C(4)-C(14)                                158.0(2)  
          C(2)-C(3)-C(4)-C(5)                                  31.5(3)  
          C(2)-C(1)-C(5)-C(6)                                 143.6(3)  
          I(1)-C(1)-C(5)-C(6)                                 -39.5(3)  
          C(2)-C(1)-C(5)-C(7)                                 -92.3(3)  
          I(1)-C(1)-C(5)-C(7)                                  84.6(2)  
          C(2)-C(1)-C(5)-C(4)                                  22.6(3)  
          I(1)-C(1)-C(5)-C(4)                                -160.47(18)  
          O(1)-C(4)-C(5)-C(6)                                 -38.1(3)  
          C(14)-C(4)-C(5)-C(6)                                 78.4(3)  
          C(3)-C(4)-C(5)-C(6)                                -154.2(2)  
          O(1)-C(4)-C(5)-C(1)                                  83.9(2)  
          C(14)-C(4)-C(5)-C(1)                               -159.6(2)  
          C(3)-C(4)-C(5)-C(1)                                 -32.2(2)  
          O(1)-C(4)-C(5)-C(7)                                -162.7(2)  
          C(14)-C(4)-C(5)-C(7)                                -46.2(3)  
          C(3)-C(4)-C(5)-C(7)                                  81.2(3)  
          C(6)-C(5)-C(7)-C(8)                                 -74.3(3)  
          C(1)-C(5)-C(7)-C(8)                                 159.4(2)  
          C(4)-C(5)-C(7)-C(8)                                  51.7(3)  
          C(5)-C(7)-C(8)-C(9)                                 -60.4(3)  
          C(7)-C(8)-C(9)-C(14)                                 60.3(3)  
          C(7)-C(8)-C(9)-C(10)                               -172.3(2)  
          C(8)-C(9)-C(10)-C(19)                               -55.2(3)  
          C(14)-C(9)-C(10)-C(19)                               70.3(3)  
          C(8)-C(9)-C(10)-C(11)                              -176.5(2)  
          C(14)-C(9)-C(10)-C(11)                              -51.0(3)  
          C(8)-C(9)-C(10)-C(15)                                63.2(3)  
          C(14)-C(9)-C(10)-C(15)                             -171.3(2)  
          C(19)-C(10)-C(11)-C(12)                             -66.5(3)  
          C(15)-C(10)-C(11)-C(12)                             176.6(2)  
          C(9)-C(10)-C(11)-C(12)                               54.0(3)  
          C(19)-C(10)-C(11)-C(18)                             169.6(2)  
          C(15)-C(10)-C(11)-C(18)                              52.7(3)  
          C(9)-C(10)-C(11)-C(18)                              -69.9(3)  
          C(18)-C(11)-C(12)-C(13)                              68.2(3)  
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          C(10)-C(11)-C(12)-C(13)                             -57.3(3)  
          C(11)-C(12)-C(13)-C(14)                              56.2(3)  
          C(12)-C(13)-C(14)-C(4)                             -179.9(2)  
          C(12)-C(13)-C(14)-C(9)                              -53.4(3)  
          O(1)-C(4)-C(14)-C(13)                               -63.8(3)  
          C(3)-C(4)-C(14)-C(13)                                55.2(3)  
          C(5)-C(4)-C(14)-C(13)                               175.9(2)  
          O(1)-C(4)-C(14)-C(9)                                169.7(2)  
          C(3)-C(4)-C(14)-C(9)                                -71.3(3)  
          C(5)-C(4)-C(14)-C(9)                                 49.4(3)  
          C(8)-C(9)-C(14)-C(13)                               179.7(2)  
          C(10)-C(9)-C(14)-C(13)                               51.5(3)  
          C(8)-C(9)-C(14)-C(4)                                -55.1(3)  
          C(10)-C(9)-C(14)-C(4)                               176.8(2)  
          C(19)-C(10)-C(15)-C(16)                            -174.2(2)  
          C(11)-C(10)-C(15)-C(16)                             -55.2(3)  
          C(9)-C(10)-C(15)-C(16)                               66.3(3)  
          C(10)-C(15)-C(16)-C(17)                              55.3(3)  
          C(27)-O(4)-C(17)-C(18)                             -150.4(2)  
          C(27)-O(4)-C(17)-C(16)                               88.3(3)  
          C(15)-C(16)-C(17)-O(4)                               67.4(3)  
          C(15)-C(16)-C(17)-C(18)                             -50.7(3)  
          O(4)-C(17)-C(18)-C(11)                              -69.6(3)  
          C(16)-C(17)-C(18)-C(11)                              50.6(3)  
          C(12)-C(11)-C(18)-C(17)                            -178.1(2)  
          C(10)-C(11)-C(18)-C(17)                             -52.7(3)  
          C(20)-O(2)-C(19)-C(10)                              117.0(2)  
          C(11)-C(10)-C(19)-O(2)                              -56.0(3)  
          C(15)-C(10)-C(19)-O(2)                               61.4(3)  
          C(9)-C(10)-C(19)-O(2)                              -177.28(19)  
          C(19)-O(2)-C(20)-O(3)                                 1.7(4)  
          C(19)-O(2)-C(20)-C(21)                             -178.5(2)  
          O(3)-C(20)-C(21)-C(22)                               14.2(4)  
          O(2)-C(20)-C(21)-C(22)                             -165.5(2)  
          O(3)-C(20)-C(21)-C(26)                             -165.6(3)  
          O(2)-C(20)-C(21)-C(26)                               14.6(3)  
          C(26)-C(21)-C(22)-C(23)                              -0.6(4)  
          C(20)-C(21)-C(22)-C(23)                             179.5(2)  
          C(21)-C(22)-C(23)-C(24)                               1.3(4)  
          C(22)-C(23)-C(24)-C(25)                              -0.5(4)  
          C(23)-C(24)-C(25)-C(26)                              -1.0(4)  
          C(24)-C(25)-C(26)-C(21)                               1.6(4)  
          C(22)-C(21)-C(26)-C(25)                              -0.8(4)  
          C(20)-C(21)-C(26)-C(25)                             179.0(2)  
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          C(17)-O(4)-C(27)-O(5)                                -2.6(4)  
          C(17)-O(4)-C(27)-C(28)                              176.9(2)  
          O(5)-C(27)-C(28)-C(33)                              176.9(3)  
          O(4)-C(27)-C(28)-C(33)                               -2.6(4)  
          O(5)-C(27)-C(28)-C(29)                               -1.2(4)  
          O(4)-C(27)-C(28)-C(29)                              179.3(2)  
          C(33)-C(28)-C(29)-C(30)                               0.0(4)  
          C(27)-C(28)-C(29)-C(30)                             178.2(3)  
          C(28)-C(29)-C(30)-C(31)                               0.9(5)  
          C(29)-C(30)-C(31)-C(32)                              -0.8(5)  
          C(30)-C(31)-C(32)-C(33)                               0.0(5)  
          C(31)-C(32)-C(33)-C(28)                               0.9(4)  
          C(29)-C(28)-C(33)-C(32)                              -0.9(4)  
          C(27)-C(28)-C(33)-C(32)                            -178.9(3)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
           
   
 Table A.7.  Hydrogen bonds for bb3136 [A and deg.].  
 ____________________________________________________________________________  
   
 D-H...A                      d(D-H)      d(H...A)    d(D...A)    <(DHA)  
   
 O(1)-H(1)...O(3)#1           0.72(4)     2.14(4)     2.832(3)    160(4)  
 ____________________________________________________________________________  
   
 Symmetry transformations used to generate equivalent atoms:  
 #1 x-1/2,-y+1/2,-z+1      
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Chapter 4 
Synthesis and Structure-Activity Relationships of Cardiotonic Steroids and Their Analogs 
to Identify Nanomolar Inhibition Against Cancer Cell Lines 
(The manuscript for the work in this chapter is in preparation. All the biological data presented in 
this chapter is performed by Dr. Marcus John Curtis Long from our collaboration with Aye 
Research Group at Cornell University. Some of the analogs described in this chapter is synthesized 
by Dr. Hem Raj Khatri and Dr. Jia-Hui Tay and will be acknowledged where needed.)  
4.1. Introduction 
Cancer has been closely studied for a few decades and despite a major portion of the research 
and development funding being invested in studying the measures to counteract it, the desired 
progress in decreasing its effects or preventing it has been unsatisfactory. More recently, 
cardiotonic steroids (CS) have attracted attention as anticancer agents and interest in advancement 
of the applicability of these steroids for this purpose has raised progressively. Cardiotonic steroids 
had been known and used for their beneficial properties in traditional medicine around the world. 
Frogs1,2 and plants3,4 extract containing these steroids had been used as arrow poisons in parts of 
Africa, especially in Maasai plains of Kenya and East African Somalis.5 Foxglove plant, one of 
the natural source of these steroids, was used as juice for sprains and bruises by ancient Romans 
and Greeks.6 Foxglove juice was also found to release excess fluid by stimulating the kidneys and 
tea made from foxglove leaves were used to treat Dropsy. The publication “On the account of the 
foxglove” by Sir William Withering7 in 1785 opened a frontier of this plant to new medical 
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applications and physicians then started using it to treat chronic heart failure and irregular 
heartbeats, one of the more traditional use of cardiotonic steroids where they received their name 
from. In addition, the reports on the use of oleander, another natural plant source rich in CS, to 
treat cancer as well as AIDS patients have been documented in different geographical locations 
since the late Middle ages.8,9 
Several of these steroids are found as endogenous human hormones in mammalian body fluids 
and tissues. Cardenolides like digoxin have been detected in human urine10 and ouabain has been 
evidenced in human plasma, adrenal gland, and hypothalamus.11,12 In addition to this, 19-nor 
bufalin has been identified in human lenses and marinobufagenin,13 and proscillaridin-like 
bufadienolides observed in human urine and plasma.11,14  
4.2. Mode of Action of Cardiotonic Steroids 
4.2.1. Cardiovascular Effects 
Cardiotonic steroids have widely been used in biological research and lately their interaction 
with human body has been better understood. Traditionally, these steroids were used in the 
treatment of congestive heart failure by increasing a positive inotropic response. This response 
occurs when a cardiotonic steroid binds as a ligand to sodium pump or Na+/K+-ATPase, the ion 
transport protein that is inserted in the cell membrane. It contains two subunits: α-subunit, which 
is a trans-membrane protein that has binding sites for Na+, K+, cardiotonic steroids, and ATP and, 
β-subunit, which is a trans-membrane protein with site for glycosylation that is needed for enzyme 
complex activity.  
Na+/K+-ATPase is a receptor of cardiotonic steroids and that the steroids are specific inhibitors 
of sodium pump. The binding of these steroids in Na+/K+-ATPase enzyme increases the level of 
intracellular sodium ions and reduces the concentration of potassium ions in myocytes. This ion 
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exchange is facilitated by hydrolysis of the ATP. The concentration of Na+ ion controls the activity 
of Na+/Ca2+-exchanger that is involved in exchange of Na+ and Ca2+ in a cell (Figure 4.1). An 
increase in Na+ inside the cell exchanges for calcium results in the increase in intracellular 
concentration of Ca2+ ions, also called positive inotropic effect. An increase in the concentration 
of Ca2+ activates myocardial contractility due to the availability of more Ca2+ for contractile 
proteins. This way, the use of cardiac steroids like ouabain or digoxin during the congestive heart 
failure counteracts the condition and minimizes fatality. Regardless of the fact that cardiotonic 
steroids that are currently used as a drug have very narrow therapeutic doses, they are the best 
available treatment of congestive heart failure at the moment and about 1.7 million patients receive 
digoxin for atrial fibrillation or heart failure.15 
Figure 4.1. Mode of Action of Cardiotonic Steroids 
4.2.2. Anticancer Effects 
In addition to cardiovascular 
effects, the anticancer properties of 
steroids of this class have been 
studied and more recently, sodium 
pump has been a target in the 
anticancer therapy. There are several 
reports of cardiotonic glycosides and 
their derivatives, obtained from either direct isolation or semi-synthesis, showing promising results 
against cancer cells of various types.16,17 Although there have been several reports on these 
anticancer properties, the precise mechanism of action of these cardiac glycosides have not been 
sufficiently elucidated. There are several theories that describe independent pathways responsible 
151 
 
for these effects.18,19 Most of these studies make it clear that there lies a strong correlation of 
anticancer activities to inhibition of Na+/K+-ATPase. Different isoforms of α-subunits are found 
to overexpress in different types of cancer (α-1 in melanoma, glioma, renal carcinoma and α-3 in 
colon carcinoma).20–22 In addition to positive inotropic effects, the Na+/K+-ATPase can also 
activate intracellular signaling cascades.18,23  Although signaling cascades are very similar, if not 
the same, the final response of the tumor cells are abnormal and show difference in expression 
patterns than the normal cells.24 This difference in activity and expression of Na+/K+-ATPase of 
cancer cells (usually a significant increase in activity) in comparison to normal cells may be the 
reason for this difference in response. This difference in response is something that scientists 
believe could be explored in order to develop a unique anticancer drug of the future.  
Lopez-Lazaro et al. validated the anticancer activity of cardiotonic steroids by inhibiting the 
growth of a variety of cancer cells and presented a different but interesting hypothesis that the 
anticancer activity might be a result of inhibition of glycolysis that occurs with the inhibition of 
Na+/K+-ATPase.25 Growth of cancer cells required initiation of glycolysis and a higher rate of 
aerobic glycolysis is a known characteristic of cancer cells (Warburg effect).26,27 Difference in the 
activity of tumor cells in comparison to the normal cells and the ability of cardiotonic steroids to 
selectively kill them can be attributed to the long known ability of cardiotonic steroids to suppress 
aerobic glycolysis.28 Cardiotonic steroids are also reported to act as an immunogenic agents.14,29 
Inhibition of Na+/K+-ATPase alters the homeostatis of K+, Na+, and Ca2+ and homeostatis of Ca2+, 
in particular, induces immunogenic cell death.30 This theory is supported by both in vitro studies 
and an in vivo study in knockout mice.29  
4.3. Cardiotonic Steroids as Anticancer Agent 
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In 1967, the first antiproliferative activity of cardiotonic steroids against transformed cells was 
reported.31 Moreover, there are data that indicate that cancer patients who were exposed to digitalis 
therapy had lower mortality rates than those who were not exposed.32–34 Similarly, in 1980s, a 
study on cell-proliferation activity by Stenkvist et al. in breast cancer cells obtained from patients 
suffering from breast cancers showed that the proliferation capacity of the cells were lower in 
patients who underwent digitalis therapy. Moreover, a follow up study on this result showed that 
after 5 years, the recurrence rate of breast cancer of patients on digitalis therapy was 10 times lower 
than the patients who were not on digitalis therapy.34 After 20-years, it was disclosed that the 
mortality rate of patients on digitalis from breast carcinoma was 6% (2 of 32) in comparison to 
34% (48 of 143) of patients among patients not on digitalis.35  
Following the 1967 finding and Stenkvist’s reports, several scientists have investigated 
cardiotonic steroids against many other cancer cells lines including pancreatic,36 lung,16,37 breast,38 
melanoma,39 renal,38 leukemia,40,41 prostate,42 myeloma,43 and neuroblastoma44 and these studies 
(Table 4.1) show promising activity in vitro and in vivo.   
Table 4.1.  In Vitro Anticancer Studies of Cardiotonic Steroids in Cancer Cells  
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 Several in vitro studies have suggested an anti-proliferative action of cardiotonic steroids 
against cancer cell lines (Table 4.1). Some of the steroids have been shown to selectively kill 
cancer cells in the presence of normal cells. In fact, out of 9000 chemicals and known drugs tested 
in an in vitro study by Johnson et al. against human prostate cancer cell lines PC-3, digitoxin and 
ouabain were the most potent inhibitors.45 While many such reports on in vitro studies of these 
steroids for performance against cancer are known, only limited examples on the in vivo studies 
have been reported to date.46–48 These steroids demonstrate inhibition of tumor cell growth in in 
vivo studies but are either highly toxic (like ouabain) or lack practical anticancer activity (like 
digitoxin) at reasonable dose.47 From these aforementioned studies, it is quite evident that a 
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significant medicinal chemistry effort need to be employed to reduce the toxicity and increase the 
activity of these cardiotonic steroids in order for them to be developed as useful anticancer agents. 
One of a remarkable work on synthesis of numerous analogs of these steroids in an efficient 
fashion was done by Thorson and co-workers in 2005 on their glycorandomization studies.49 Their 
method allowed for a direct installation of sugars without the need for protection or for promoter 
during glycosylation. For this study, they used digitoxin as a model aglycone to test 
neoglycorandomization reaction. This method would allow for the generation of a library of 
analogs with a variety of sugar in a single aglycone. The reaction between secondary alkoxylamine 
of an aglycone with reducing sugars created a new glycosidic linkage to form neoglycosides. As 
shown in Scheme 4.1, 4.3β and 4.3α was synthesized in three steps from parent glycoside 
digitoxin. The reaction of 4.3β and 4.3α separately with the glucose in presence of 3:1 DMF/AcOH 
provided neoglycosides 4.4β and 4.4α in >70% yield. Using this method, β and α neoglycosides 
of 39 reducing sugars were synthesized to generate 78 derivatives of digitoxin. The authors were 
able to generate neoglycosides with a variety of reducing sugars like D-sugars, L-sugars, 
disaccharides, dideoxy sugars, and uronic acids and test these analogs against nine human cancer 
cells including ovary, lung, CNS, liver, breast, colon, and normal epithelial lines using high-
throughput assay. During their study, they were able to find neoglycosides with substantially 
enhanced potency and cancer specificity but with diminished Na+/K+-ATPase inhibition than the 
parent glycoside digitoxin. The SAR obtained from this study shows that all 38 β-neoglycosides 
performed better than the corresponding α neoglycosides, confirming the previous studies. L-
riboside and D-mannoside showed a better potency and good selectivity; D-taloside showed good 
selectivity but modest cytotoxicity; D-lyxoside and L-xyloside showed significant enhancement 
in cytotoxicity compared to digitoxin, however, lacked selectivity just like the parent glycoside. 
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One similarity among these five glycosides is the axial C2’ stereochemistry (S-configuration) and 
their epimer neoglycosides at C2’ shows relatively diminished potency. Unlike most of the 
proposed mechanism of cardiotonic steroids that shows strong correlation of anticancer activity 
with Na+/K+-ATPase inhibition,13,50 these results present a new class of glycosides specific to the 
tumor cells and cytotoxins without inhibiting Na+/K+-ATPase.49  
Scheme 4.1. Method for the Synthesis of Neoglycosides 
 
Easily accessible steroids like ouabain, digitoxigenin, digitoxin, digoxin, strophanthidin and 
their analogs, mostly obtained from their natural source, are subjects of most of these investigation 
on cardiotonic steroids, however, they present only a limited opportunity for modification and limit 
the scope of these studies.  
4.4. C19 Oxygenated Steroids and Their Scope in Anticancer Activities 
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There have been few recent studies on steroids with C19 hydroxyl group present, but only on 
highly oxygenated molecules. Despite the promising anticancer activity shown by molecules like 
digitoxigenin and strophanthidin against the variety of cancer cell lines,51,52 their C-19 
hydroxylated counterparts such as corotoxigenol, cannogenol and the respective glycosides 
(Figure 4.2) have not been well studied. This can be attributed to the global supply of these 
steroids, the complexity in their extraction from poisonous indigenous plants, their low 
concentration in these plant sources, and most importantly there being no robust method available 
to synthesize these steroids and their analogs.  
Figure 4.2. C10 Methyl and C19 Hydroxy Steroids with Promising Potency   
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4.5. Isolation of Cannogenol Based Steroids and their Anticancer Activity 
Cannogenol-based steroids have been isolated from plant sources for a long time. Cannogenol-
3-O-α-L-rhamnoside, itself, was first isolated in 1967 by Kislichenko et al. and since then, several 
other research groups have identified various other cannogenol (with hydroxyl at C19) and 
cannogenin (with aldehyde at C19) glycosides during the isolation of cardiac glycosides from 
different plant sources. Abe et al. reported the isolation of twenty-two glycosides from roots of 
Apocynum cannabinum including cannogenin, and cannogenol glycosides 4.20, 4.21.53 Compound 
4.19, another cannogenol glycoside was isolated from seeds of Corchorus olitorius along with 
eight other closely related cardiotonic glycosides by Nakamura et al.54 
There has not been as much report on the Na+/K+-ATPase activity of cannogenol based natural 
products as other members of this class. One report on the cardiotonic activity of cannogenin-3-
O-α-L-rhamnoside (Malayoside) showed similar safety index and potency to ouabain in the atria 
of guinea pigs.55   
In a study on antiproliferation of cardiac glycosides, Liu et al. isolated fifteen new and 
seventeen previously reported cardiac glycosides from the Latex of Antiaris toxicaria.56 Some of 
the relevant glycosides (Table 4.2, Compound 4.5-4.18) are listed for discussion. The toxicity of 
steroids (4.5-4.18) were investigated against human lung cancer cells NIH-H460 (Table 4.3). 
Compound 4.5, 4.9, 4.10, 4.12, and 4.16-4.18 significantly inhibited the viability of NIH-H460 at 
50 nM concentration. There is a clear SAR information that can be gathered from this table. 
Orientation of sugar is very important and steroids with alpha-orientation of the sugar at C3 did 
not inhibit growth of the cancer cells (4.6-4.8). Having sugar at C19 instead of C3 displayed weak 
activity (4.13). The inhibitory rate of rhamnose glycosides were better than other sugar moieties. 
The functionality at C19 played little role and only small change in inhibitory rate was observed 
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(4.14-4.18). In conclusion to this study, cannogenol-3-O-α-L-rhamnoside was one of the best 
candidates out of thirty-two steroids isolated.
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Table 4.2. Cardiotonic Steroids with C19 Oxygenation Isolated from Various Plants53,54,56,57
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Table 4.3. Inhibitory Rate of Cardiotonic Steroids Isolated by Liu et al.56 
 
In a separate study by Tian et al., anticancer activity of thirty-three cardiac glycosides, isolated 
from the seeds of Thevetia peruviana, against three cancer cell lines (human P15 lung cancer cells, 
human MGC-803 gastric cancer cell, and human SW1990 human pancreatic cancer cells) and a 
normal LO2 hepatocyte cell line was studied.57 Selected relevant steroids (Table 4.2, Compound 
4.22-4.31) and their performance in comparison to cannogenol and cannogenin glycosides are 
shown in Table 4.4. Across the board, thevetosides 4.22, 4.24, 4.25, 4.26, 4.28, and 4.31 showed 
promising inhibitory effects against P15, MGC-803, and SW1990 but did not show any 
cytotoxicity against the normal LO2 cells in up to 10 µM concentration. The study showed a 
general trend in the effect of the sugar on cytotoxicity and observed a reduced cytotoxicity with 
increase in number of sugar moieties (trisachharide 4.29<disachharide 4.28< monosachharide 
4.25). The carboxylic acid at C10 and 19-nor cardenolides showed significant reduction of toxicity 
in comparison to hydroxymethyl, formyl, or methyl group. Furthermore, 4.22, 4.24, 4.25, and 4.31 
were assessed for apoptosis-inducing abilities against MGC-803 cells and at half maximal 
inhibitory concentration (IC50) values of 0.53, 0.03, 0.03, 0.02 µM respectively, they showed 
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massive apoptosis. In summary, cannogenol-3-O-α-L-thevetose shows promising anticancer 
activities against P15, MGC-803, and SW1990 and did not have any effect in normal hepatocyte 
cell line LO2.  
Table 4.4. Cytotoxicity (IC50 values in µM) of the Steroids Isolated from Thevetia peruviana by 
Tian et al.57 
 
Shi et al. reported the isolation of cannogenol along with fifty-three other known and new 
cardiac glycosides and aglycones from trunk bark of Antiaris toxicaria and tested them against 
several human cancer cell lines (discussed in Chapter 2).58 In a separate isolation and anticancer 
study by Wang et al. in 2007, cannogenol-3-O-α-L-rhamnoside and nine other cardenolides were 
isolated from the whole dried plants of Saussurea stella and showed very impressive activity 
against human gastric cancer and human hepotama (Chapter 2).59 Similarly in 2008, in a study by 
Jiang et al., eleven cardenolides including cannogenol-3-O-α-L-rhamnoside were isolated from 
stem of Antiaris toxicaria and their ability to inhibit cancer cell growth was studied (discussed in 
chapter 2). All these three reports showed nanomolar half maximal inhibitory concentration (IC50) 
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of cannogenol-3-O-α-L-rhamnoside against several cancer cell lines that were studied and in all 
these cases, this molecule was one of the best candidates.59,60  
Although it exhibited an impressive activity against these cells, there have been no further 
reports on the elaboration of cannogenol based steroids towards medicinal chemistry studies and 
diversification of the mentioned natural products to generate other analogs for similar testing. As 
mentioned earlier, we believe this to be largely due to the difficulty in their extraction from natural 
sources compounded by a very low concentration of these compounds in their natural sources. 
This is a gap that an organic chemist could fill using their expertise in synthetic organic chemistry. 
4.6. Generation of Relevant Biological Analogs 
The continuous interest of our group towards cardiotonic steroids encouraged for us to design 
a concise synthetic pathway that would allow us an access to the natural products of this class. In 
addition, we wished to generate relevant analogues with minimum deviation from the synthetic 
pathway. The developed method would allow us to change functional group and stereochemistry 
at key position as well as installation of heterocycle and sugar moiety at late stage with minimum 
modifications.  
Figure 4.3 Sites of Modification in the Steroidal Core 
 
As discussed in the previous chapter, we were able to develop a strategy to synthesize cardiotonic 
steroids which could potentially be used to generate their analogs with modification of different 
functionality of the steroidal core (Figure 4.4) to obtain good structure-activity relationship 
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correlations. While there were a plentiful of studies on anticancer activity of cardiotonic steroids 
as described earlier, a comprehensive parallel study including natural and synthetic cardenolides 
and their derivatives along with some of the commercially available cardiotonic steroids was not 
performed before. Therefore, using our concise and divergent synthetic approach, we were able to 
generate a reasonable number of natural products, synthetic analogues, and their relevant synthetic 
intermediates and use them in such a parallel study.  
Compounds 4.44, 4.49, 4.51- 4.53 were obtained from commercial sources. Compounds 4.43 
and 4.45 were obtained by colleague Dr. Hem Raj Khatri and 4.46, 4.47, and 4.48 were synthesized 
by Dr. Jia Hui Tay and Valentin Dorokhov by semi-synthesis from commercially available 
cardiotonic steroids using the method developed in our lab and discussed in chapter three. 
Compounds 4.54-4.56 were synthesized by Dr. Hem Raj Khatri and Dr. Will Kaplan and the 
synthesis of 4.54 and 4.56 are discussed in chapter 2.61  
Figure 4.4. List of all the Cardiotonic Steroids and their Relevant Analogs Included in the Study 
and their EC50 Values against HEK393T 
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Initial biological activity of cannogenol along with other synthetic cardiotonic steroids were 
impressive, which encouraged us to construct several other natural products and biologically 
relevant analogs.  The goal of this study was to ultimately design more potent analogs by studying 
the structure-activity relationships (SARs) of these molecules for their anticancer properties in 
collaboration with Dr. Yimon Aye’s Research Group at the Cornell University. The initial 
biological activities on the four aglycone of cardiotonic steroids 4.36 and 4.54-4.56 (Figure 4.5) 
were obtained through NIH CANVAS high-throughput screen against a set of over 30 whole-cell 
assays designed to sample several areas (rare and neglected diseases, inflammation, cancer, and 
others). The NCGC ID for cannogenol is NCGC00488733-01, 19-hydroxy-sermentogenin is 
NCGC00488734-01, trewianogenin is NCGC00488732-01, and 17-epi trewianogenin is 
NCGC00488735-01 and full results of their assays can be obtained from NIH CANVAS website.   
High potency of cannogenol was observed during this screen against several assays which included 
against several cancer cell lines. This encouraged us to further investigate the molecules as 
described below. Cannogenol 4.36 showed an impressive activity (500 - 900 nM) against several 
cancer cell lines (HeLa, Cos-7, HEK, A2780cis, KB-3-1) and outperformed the other three, higher-
oxygenated steroids such as 19-hydroxy sarmentogenin 4.54, trewianogenin 4.55, and 17-epi-
trewianogenin 4.56, that were also synthesized by our group.  
Figure 4.5. Cardiotonic Steroids Aglycones Submitted for NIH CANVAS High-throughput 
Screening  
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During initial collaboration with Aye’s group, the following compounds (Figure 4.6) were 
tested against cancer cell lines to obtain a better idea on effects of different functional group, 
heterocycles, and stereocenters on their biological activity. The synthesis of 4.32-4.36, 4.39, and 
4.40 are described in the previous chapter (chapter 2).  
Figure 4.6. Steroids 4.32- 4.39 Included in Initial Assay 
 
To understand the importance of stereocenter at C17, compound 4.37 was synthesized 
(Scheme 4.2) by global deprotection of the silanes from compound 4.57 (an intermediate discussed 
in chapter 2). 
Scheme 4.2. Synthesis of 4.37 with no stereocenter at C17 
 
Reduced lactone 4.37 was synthesized (Scheme 4.3) as a variant to recognize the importance 
of lactone ring. Synthesis of 4.38 was carried out by exhaustive hydrogenation of 4.37 to get 
167 
 
compound 4.58 with ~1:1 dr at C20 followed by global deprotection of the silane groups to obtain 
the diastereomeric mixture of 4.38 in 79% yield over 2 steps. 
Scheme 4.3. Synthesis of 4.39 with reduced lactone 
 
4.7. Total Synthesis of Cannogenol-3-O-glucopyranoside and Analog 4.42 
The synthetic pathway towards the total synthesis of cannogenol-3-O-α-L-rhamnoside is 
robust and efficient. Late stage functionalization for generation of natural products or analogs with 
different sugar moiety or heterocycle was achieved using this method with minimum deviation. 
Described below is the synthesis of the natural product cannogenol-3-O-glycopyranoside and an 
analog with incorporated alkyne moiety at C3 of the sugar (Scheme 4.4). This was synthesized to 
identify the target protein of the cardiotonic steroids. Both molecules were synthesized using the 
same method developed for cannogenol-3-O-α-L-rhamnoside without any synthetic modification. 
The synthesis of cannogenol-3-O-glycopyranoside 4.41 commenced with glycosylation of 
methoxyacetate-protected cannogenol 4.59 (synthesized in chapter 2) catalyzed by TfOH to 
provide 4.65 in 85% yield. Compound 4.65 was subjected to ammonia (in methanol) to obtain the 
desired cannogenol-3-O-glycopyranoside (4.41) in 76% yield. Alkyne incorporated steroid 4.42 
was obtained using the same method. Methoxyacetate protected cannogenol 4.59 was subjected to 
TfOH-promoted glycosylation with 4.62 (obtained in 6 steps from L-rhamnose), which resulted in 
α-rhamnoside 4.63 in 59% yield (>20:1 dr) and the deprotection of esters in presence of ammonia 
resulted in analog 4.42 in 37% yield. The deprotection of C-4’ benzoyl group was very sluggish 
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and resulted into the serious concomitant side reactions at butenolide at prolonged reaction time 
which resulted in a lower yield. 
Scheme 4.4. Total Synthesis of Cannogenol-3-O-glucopyranoside and Analog 4.42 
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Commercially available, biologically active natural cardiotonic steroids 4.44, 4.49, and 4.51-
4.53 (Figure 4.7) were also included in our study to understand the anticancer properties. These 
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steroids are generally included in several Na+/K+-ATPase studies. But more recently, they have 
been included to anticancer studies as well and some of them have shown promising inhibitory 
activities in these studies.  
Figure 4.7. Commercially Available Cardiotonic Steroids Used During this Study 
 
The following steroids 4.43, 4.45-4.48, and 4.50 (Figure 4.8) were synthesized by semi-
synthetic methods by my co-workers Jia-Hui Tay and Dr. Hem Raj Khatri and the respective 
publication of detailed synthetic methods is underway. Ouabagenin was synthesized by 
deglycosylation of ouabain by stirring in conc. HCl for 2 days. Strophanthidiol was obtained by 
NaBH4 reduction of aldehyde of strophanthidin and the corresponding glycosides were obtained 
by TfOH-promoted glycosylation as discussed in Scheme 4.4 and chapter 3. Digitoxigenin-
rhamnoside and bufalin-rhamnoside were obtained from Digitoxigenin and bufalin respectively by 
the glycosylation method described in Scheme 4.4 as well.  
Figure 4.8. Cardiotonic Steroids Synthesized by Semi-Synthesis from Commercial Steroids 
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4.8. Structure Activity Relationships (SARs) Results from Figure 4.3. 
There has been clear literature reports indicating a correlation of the heterocycle and the sugar 
with the biological activities of these molecules including their anticancer activities.62 This study 
is no exception. From our collaboration with the Aye’s Research Group, the SAR we obtained by 
comparing the anticancer activities of the above listed molecules show a clear correlation of both 
the heterocycle and the sugar moiety confirming previously reported results on other cardiotonic 
steroids like strophanthidin, digitoxigenin, and bufalin.50,62 Substantial amount of SAR 
information were gathered on the importance of heterocycle, different sugar, C19, C11, C5, C1 
oxidations, stereochemistry at C17 and C5, among others.    
4.8.1. Importance of heterocycle and orientation at C17 
From the initial assay against HEK and Hela cell lines, cannogenol was found to have 
nanomolar half maximal inhibitory concentration (EC50) that encouraged us to further explore this 
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area. The lactone moiety is known to interact with the active site through electrostatic interaction 
with the two binding points (one to the carbonyl oxygen by hydrogen bond and second at the 
electron deficient C20 by electrostatic interaction).63 Hence, it led us to believe that changes in this 
part of the molecule would likely change the potency of the steroids. By comparing cytotoxic 
activities of the analogues from the same set of assays, the importance of heterocycle was 
elucidated (µM activity of 4.32-4.35 vs nm EC50 of cannogenol 4.36). Steroids 4.32-4.35 shows 
no activity in inhibition of cancer cell growth. The lactone ring plays an important role in the 
cytotoxicity of these steroids and hence the lack of stereocenter at C17 in compound 4.37 or 
reduced lactone ring in compound 4.38 shuts off the activity of these molecules (compare 4.37, 
4.38 and 4.36). From the initial NIH CANVAS screening, trewianogenin 4.55 was found to have 
15-25 mM toxicity against COV-362 (human ovarian epithelial carcinoma), A2780cis (human 
ovarian carcinoma), KB-3-1 (oral cancer), and PANC-1 (human pancreatic cancer cells) but the 
C17 epimer of trewianogenin 4.56 showed no activity against human cancer cell at all.  
4.8.2. Importance of rhamnose and effect of changing sugar 
To our excitement, synthetic cannogenol-3-O-α-L-rhamnoside 4.40 performed the best out of 
our set of compounds, with EC50 of 13 nM, which is consistent with reports on the increased 
activity because of the sugar moiety.50,62 The difference in activity can be visualized by comparing 
cannogenol 4.36 and cannogenol-3-O-α-L-rhamnoside 4.40 (600 nM vs 13 nM). The same trend 
was observed when comparing ouabagenin 4.50 to ouabain 4.49 (670 nM vs 68 nM), 
strophanthidol 4.46 to strophanthidol rhamnoside 4.47 (<1µM vs 18 nM) and, digitoxigenin 4.44 
to digitoxigenin-rhamnoside 4.43 (239 nM vs 23 nM). Rhamnoside was found to be crucial 
towards the biological activity of cardiotonic steroids and it has been uncovered that the activity 
can be tuned by changing the sugar fragment.50 Consistent with this result, introduction of glucose 
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instead of rhamnose in the cannogenol slightly decreased the EC50 value against HEK 293T 
although it remained highly potent (48 nM of 4.41 and 13 nM of 4.40). Similar trend was observed 
with strophanthidol as an aglycone. Glucose significantly reduced the activity (105 nM of 4.48 vs 
18 nM of 4.47). This is also consistent with isolation and anticancer study by Shi et al. where they 
reported significant reduction of the activity of aglycone and impressive anticancer activity of the 
rhamnose glycoside against several cancer cell lines.58  
4.8.3. Role of C19 functionality 
Protection of primary alcohol with esters significantly diminished the potency of cannogenol 
(µM of 4.39 and nm of 4.36). Hence, the free alcohol is an important functionality in dictating the 
biological activity for C19 hydroxy-cardiotonic steroids. Although both 4.37, and 4.45 are active 
against the cancer cell lines, having hydroxy group at C19 slightly enhances the potency (compare 
4.43, 4.45, and 4.40). Having an aldehyde at C19 as in strophanthidin 4.52 significantly diminishes 
the inhibition in comparison to strophanthidol.  
4.8.4. Other SAR 
The comparison of activity of six-membered lactone in bufalin rhamnoside 4.45 to five 
membered lactone in digitoxigenin-rhamnoside 4.43 showed that both steroids were potent 
anticancer agents with steroid containing five-membered lactone having slightly better activity. 
The C11 oxygenated natural products 19-hydroxysermentogenin showed no activity in preliminary 
assay performed by NIH CANVAS in comparison to cannogenol, which proved to be much better 
in inhibiting growth of cancer cells. Commercial steroids like digitoxin 4.53 and digoxin 4.51 with 
trisaccharide sugar, digitoxose showed promising activity as well.  
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4.8.5. Other Studies 
In order to identify the binding target of these class of steroids, a steroid with sufficient potency 
needed to be synthesized. Therefore, molecule 4.42, cannogenol-3-O-α-L-rhamnoside with an 
alkyne incorporated in the molecule, was constructed. To our excitement, compound 4.42 had EC50 
of 294 nm and study on target identification is currently underway.  
4.9. Cannogenol-3-O-α-L-rhamnoside as Anticancer Agent 
4.9.1. Potency of Cannogenol-3-O-α-L-rhamnoside Against Variety of Transformed Cell Lines 
Cannogenol-3-O-α-L-rhamnoside, after being proven superior out of all the compound tested 
in our series, was assayed against a variety of cancer cell lines. It showed remarkable inhibition 
(Figure 4.9) against transformed human embryonic kidney cells (HEK293T), blood cancer cell 
line (Raji), monkey kidney cell line transformed with simian virus (Cos-1), glioblastoma line 
(U87), and liver tumor line (HepG2). It also showed promising potency against triple-negative 
breast cancer cell line (MDA-MB), which is an aggressive form of breast cancer with limited 
treatment options.64  
Figure 4.9. Cannogenol-3-O-α-L-rhamnoside as Anticancer Agent 
 
4.9.2. Selectivity Studies Against Normal 3t3 and MEF Cell Lines  
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Cardiotonic steroids in our study showed promising inhibition against transformed cell lines. 
However, it is important for them to be selective to these transformed cell lines as well as show no 
cytotoxicity towards normal cell lines. To our delight, cannogenol-3-O-α-L-rhamnoside was very 
selective to the transformed cell lines and not too toxic to normal mouse fibroblast (3t3) and mouse 
embryonic fibroblast (MEF) at up to 1 µM concentration (Figure 4.10).   
Figure 4.10. Selectivity Studies Against Normal 3t3 and MEF Cell Lines 
 
 
 
 
 
 
 
4.9.3. Selectivity Study Against Zebra Fish Embryo 
Furthermore, to confirm the selectivity, zebra fish embryos were exposed to cannogenol-3-O-
α-L-rhamnoside for two days and the teratogenicity was studied. 4.40 was well tolerated at up to 
1000 nM. Out of twenty-one fish embryos used at 1000 nM of cannogenol, only two were 
deformed after two days (Figure 4.11a). The study also showed that cannogenol-3-O-α-L-
rhamnoside did not affect the heart beating in two-day old fish (Figure 4.11b).  
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Figure 4.11. Teratogenicity Studies of 4.40 Towards Zebra Fish Embryo 
  
4.10. 2nd Generation Analogs 
Amines are known to increase the solubility of organic compounds when compared to alcohol, 
while still maintaining the H-bonding ability, and in some instances increasing the potency of 
cardiotonic steroids.51 Hence, we desired to introduce the variant of cannogenol to incorporate 
amines into the molecule. Strophanthidin is commercially available and its C3 rhamnoside was 
found to be equally potent to cannogenol-3-O-α-L-rhamnoside, against Hela cells, hence initial 
optimization to convert the C19 alcohol to amines was performed in strophanthidin. The 
interconversion of C19 aldehyde to amine was performed by reductive amination of the aldehyde 
using methyl amine and NaBH4. Strophanthidin 4.52 formed an intermediate imine 4.66, the 
reduction of which produced amine analog 4.67.  The formation of imine wasn’t observed when t-
butyl carbamate was used in an attempt to synthesize primary amine. The reduction of intermediate 
4.66 wasn’t observed when sodium triacetoxyborohydride (STAB) was used and sodium 
cyanoborohydride led to a slower reaction.  
Scheme 4.5. Synthesis of Amine-incorporated Analog 4.67 
0
5
10
15
20
25
DMSO 100 nM 1000 nM
added live deformed
D
M
S
O
1
0
0
 n
M
1
0
0
0
 n
M
0
2 0
4 0
6 0
8 0
C m p d  5
h
e
a
r
t
 b
e
a
t
s
 p
e
r
 m
in
u
t
e
177 
 
 
4.11. Current and Future Directions: 
The current work is focused on designing more analogs of cannogenol-3-O-α-L-rhamnoside, and 
the analogs of strophanthidin, the molecules that have proven themselves in our medicinal 
chemistry studies. With the studies described above, we have been able to identify functionalities 
that can change the potency of these molecules through the SAR studies and in future, we will 
attempt to generate relevant analogs to tune the bioactivity. Amines are known to increase the 
bioactivity of these compounds towards anticancer as well as are better Na+/K+-ATPase inhibitor. 
To this direction, current work is based on replacing the C19 alcohol with amine to increase the 
solubility of strophanthidin based steroids and hence, potentially increase their bioactivity. 
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4.12. Experimental  
4-((3S,5R,8R,9S,10R,13R,14S)-3,14-dihydroxy-10-(hydroxymethyl)-13-methyl-
2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-
2(5H)-one 
 
To a solution of 4.57 (0.0090 mmol, 6.0 mg, 1 equiv.) in MeOH (1 mL) was added 3M HCl in 
MeOH (300 µL) and stirred at rt for 1 h. The resulting colorless solution was quenched by addition 
of saturated aqueous NaHCO3 solution dropwise and the aqueous phase was extracted with 2:1 
chloroform: ethanol (3 × 5mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(9:1 DCM: MeOH) to give 4.37 (3 mg, 91%) as a white solid. 
1H NMR (700 MHz, Methanol-d4) δ 6.25 (s, 1H), 5.99 (s, 1H), 5.14 (d, J = 16.7 Hz, 1H), 5.01 
(d, J = 16.7 Hz, 1H), 4.04 (s, 1H), 3.86 (d, J = 11.2 Hz, 1H), 3.44 (d, J = 11.2 Hz, 1H), 2.77 (d, J 
= 18.2 Hz, 1H), 2.32 (dd, J = 18.4, 3.1 Hz, 1H), 2.23 (d, J = 13.6 Hz, 1H), 2.09 – 2.05 (m, 1H), 
1.99 (t, J = 13.0 Hz, 1H), 1.90 (td, J = 13.9, 4.0 Hz, 2H), 1.86 – 1.78 (m, 2H), 1.72 (t, J = 10.0 
Hz, 1H), 1.66 – 1.54 (m, 2H), 1.49 (s, 1H), 1.40 (d, J = 14.4 Hz, 2H), 1.36 – 1.30 (m, 1H), 1.27 
(s, 3H), 1.24 (s, 1H), 1.15 (t, J = 8.6 Hz, 2H). 
13C NMR (700 MHz, Methanol-d4) δ 177.28, 161.95, 145.02, 134.72, 112.00, 86.82, 73.53, 
67.47, 66.13, 53.44, 42.02, 40.92, 40.51, 40.00, 37.09, 34.13, 29.75, 28.28, 27.26, 24.23, 21.83, 
21.02, 16.97. 
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HRMS (ESI-MS) calculated for C23H32O5 [M+H]
+: m/z 389.2328, found: 389.2321 
(2R,3R,4R,5S,6S)-2-(((3S,5R,8R,9S,10R,13R,14S,17R)-14-hydroxy-10-((2-
methoxyacetoxy)methyl)-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-1H-
cyclopenta[a]phenanthren-3-yl)oxy)-6-methyl-4-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-
3,5-diyl dibenzoate 
 
To a solution of compound 4.59 (5.0 mg, 0.011 mmol) in dry CH2Cl2 (800 µL) was added 4Å MS 
and cooled to 0 °C. The solution of donor 4.62 (3.0 mg, 0.0055 mmol) in CH2Cl2 (100 µL) was 
added to the flask followed by dropwise addition of the solution of TfOH (10 µL, 0.0033 mmol 
taken from the stock solution prepared by dissolving 3 µL TfOH in 100 µL CH2Cl2) and the 
resulting mixture was stirred at 0 ˚C for 1 h. Additional 0.5 equiv. of donor was added portion wise 
every hour for the next three hours. After the addition of 2 equiv. of total donor, the reaction 
mixture was warmed to room temperature and stirred for 1 additional hour. The resulting colorless 
solution was quenched by addition of excess triethylamine dropwise and filtered through celite. 
This filtrate was concentrated in vacuo and the residue was purified by flash chromatography (6:4 
Hexanes: Ethyl acetate) to give 59% (5.5 mg, 0.0064 mmol) of compound 4.63 as a colorless solid, 
Rf = 0.8 (10% MeOH in CH2Cl2). 
1H NMR (700 MHz, CDCl3): δ 8.10 (d, J = 7.8 Hz, 4H), 7.59 (td, J = 7.2, 4.1 Hz, 2H), 7.47 (dt, 
J = 11.5, 7.7 Hz, 4H), 5.89 (d, J = 1.8 Hz, 1H), 5.52 (dd, J = 3.3, 1.8 Hz, 1H), 5.40 (t, J = 9.8 Hz, 
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1H), 5.03 (d, J = 1.8 Hz, 1H), 4.98 (dd, J = 18.0, 1.7 Hz, 1H), 4.81 (dd, J = 17.9, 1.7 Hz, 1H), 4.48 
(d, J = 11.2 Hz, 1H), 4.34 (dd, J = 9.7, 3.3 Hz, 1H), 4.26 – 4.16 (m, 2H), 4.15 – 4.06 (m, 4H), 4.03 
(t, J = 2.9 Hz, 1H), 3.45 (s, 3H), 2.80 (dd, J = 9.3, 5.5 Hz, 1H), 2.38 (t, J = 2.4 Hz, 1H), 2.24 – 
2.06 (m, 3H), 1.89 (dtd, J = 17.5, 8.7, 8.0, 5.2 Hz, 1H), 1.85 – 1.69 (m, 7H), 1.69 – 1.50 (m, 6H), 
1.47 – 1.36 (m, 2H), 1.35 – 1.28 (m, 5H), 0.90 (s, 3H);  
13C NMR (176 MHz, CDCl3): δ 174.5, 174.2, 170.7, 166.2, 166.0, 133.5, 133.4, 130.1, 130.0, 
130.0, 129.7, 128.7, 128.5, 118.1, 96.2, 85.6, 79.6, 75.2, 74.4, 73.5, 73.1, 72.6, 70.2, 69.9, 67.8, 
67.3, 59.6, 57.0, 51.0, 49.6, 42.0, 40.3, 38.6, 35.5, 33.2, 30.0, 29.9, 27.0, 26.3, 26.2, 24.4, 21.6, 
21.0, 17.9, 16.0; 
 IR (thin film, cm-1): 711, 913, 1027, 1069, 1110, 1266, 1317, 1451, 1621, 1726, 2935, 3514 (br.); 
HRMS (ESI-MS) calculated for C49H58O13 [M+H]
+: 855.3956, found 855.3940;  
[α]D25 = +49.7 (c = 0.1, CHCl3).  
(2S,3S,4S,5R,6R)-5-hydroxy-6-(((3S,5R,8R,9S,10R,13R,14S,17R)-14-hydroxy-10-
(hydroxymethyl)-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-1H-
cyclopenta[a]phenanthren-3-yl)oxy)-2-methyl-4-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-
3-yl benzoate 
 
Compound 4.63 (5.5 mg, 0.0064 mmol) was dissolved in half saturated MeOH (1 mL) and stirred 
at room temperature for 24 hours. The reaction mixture was then concentrated in vacuo and 
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purified by flash column chromatography (5% to 10% MeOH in CH2Cl2) to afford 37% (1.6 mg, 
0.0024 mmol) compound 4.42 as a white film, Rf = 0.5 (10% MeOH in CH2Cl2). 
1H NMR (700 MHz, CD3OD): δ 8.05 (d, J = 7.7 Hz, 2H), 7.62 (t, J = 7.4 Hz, 1H), 7.49 (t, J = 7.7 
Hz, 2H), 5.90 (d, J = 2.0 Hz, 1H), 5.27 (t, J = 9.7 Hz, 1H), 5.04 (d, J = 17.6 Hz, 1H), 4.94-4.89 
(m, 2H), 4.25 – 4.18 (m, 2H), 4.14 (dd, J = 9.7, 3.1 Hz, 1H), 4.11 (t, J = 2.5 Hz, 1H), 4.08 – 4.02 
(m, 1H), 3.99 (t, J = 3.0 Hz, 1H), 3.88 (d, J = 11.2 Hz, 1H), 3.41 (d, J = 11.2 Hz, 1H), 2.84 (t, J = 
7.2 Hz, 1H), 2.26 – 2.15 (m, 3H), 2.03 (m, 1H), 1.96 (td, J = 13.8, 4.5 Hz, 1H), 1.90-1.81 (m, 4H), 
1.79 – 1.64 (m, 4H), 1.64 – 1.41 (m, 5H), 1.37 – 1.25 (m, 3H), 1.17 (d, J = 6.3 Hz, 3H), 0.89 (s, 
3H);  
13C NMR (176 MHz, CD3OD): δ 178.4, 177.3, 167.6, 134.4, 131.4, 130.7, 129.6, 117.8, 99.7, 
86.6, 80.6, 77.6, 76.2, 75.4, 74.6, 73.8, 69.8, 68.2, 65.6, 57.5, 52.1, 51.1, 42.6, 41.3, 40.5, 36.5, 
33.2, 30.7, 30.1, 28.0, 27.5, 27.2, 24.9, 22.4, 22.2, 17.9, 16.4; 
IR(thin film, cm-1): 637, 713, 1027, 1070, 1271, 1451, 1621, 1728, 2115, 2937, 3436(br.);  
HRMS (ESI-MS) calculated for C39H50O10 [M+H]
+: 679.3482, found 679.3491;  
[α]D25 = +1.7 (c = 0.08, CH3OH).  
(2R,3R,4S,5R,6R)-2-((benzoyloxy)methyl)-6-(((3S,5R,8R,9S,10R,13R,14S,17R)-14-hydroxy-
10-((2-methoxyacetoxy)methyl)-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-
yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl 
tribenzoate 
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To a solution of compound 4.59 (10.0 mg, 0.021 mmol) in dry CH2Cl2 (1.2 mL) was added 4Å 
MS and cooled to 0 °C. The solution of donor 4.64 (8.0 mg, 0.011 mmol) in CH2Cl2 (100 µL) was 
added to the flask followed by dropwise addition of the solution of TfOH (10 µL, 0.00648 mmol 
taken from the stock solution prepared by dissolving 5.7 µL TfOH in 100 µL CH2Cl2) and the 
resulting mixture was stirred at 0 ˚C for 1 h. Additional 0.5 equiv. of donor was added portion wise 
every hour for the next three hours. After the addition of 2 equiv. of total donor, the reaction 
mixture was warmed to room temperature and stirred for 1 additional hour. The resulting colorless 
solution was quenched by addition of excess triethylamine dropwise and filtered through celite. 
This filtrate was concentrated in vacuo and the residue was purified by flash chromatography (6:4 
Hexanes: Ethyl acetate) to give 85% (19.0 mg, 0.0183 mmol) of compound 4.65 as an off-white 
solid, Rf = 0.4 (60% EtOAc in hexanes). 
1H NMR (700 MHz, CDCl3) δ 7.99 (d, J = 7.8 Hz, 2H), 7.90 (dd, J = 14.4, 7.9 Hz, 4H), 7.84 (d, 
J = 7.8 Hz, 2H), 7.54 (t, J = 7.6 Hz, 2H), 7.50 (dt, J = 14.9, 7.6 Hz, 1H), 7.44 (t, J = 7.3 Hz, 1H), 
7.39 (q, J = 7.2 Hz, 4H), 7.34 (t, J = 7.7 Hz, 2H), 7.30 (t, J = 7.6 Hz, 2H), 5.90 (t, J = 9.7 Hz, 
1H), 5.85 (s, 1H), 5.67 (t, J = 9.7 Hz, 1H), 5.55 – 5.51 (m, 1H), 4.94 (d, J = 18.1 Hz, 1H), 4.85 
(d, J = 7.9 Hz, 1H), 4.77 (d, J = 18.1 Hz, 1H), 4.62 (dd, J = 12.0, 3.3 Hz, 1H), 4.51 (dd, J = 11.9, 
5.2 Hz, 1H), 4.04 – 3.92 (m, 5H), 3.46 (s, 3H), 2.74 (dd, J = 9.3, 5.6 Hz, 1H), 2.18 – 2.11 (m, 
1H), 2.03 (d, J = 3.7 Hz, 1H), 1.89 – 1.81 (m, 1H), 1.78 (d, J = 13.2 Hz, 1H), 1.65 (dd, J = 25.0, 
12.4 Hz, 5H), 1.56 (d, J = 10.6 Hz, 1H), 1.51 – 1.42 (m, 3H), 1.37 (d, J = 14.0 Hz, 1H), 1.33 – 
1.28 (m, 4H), 1.11 (q, J = 13.1 Hz, 2H), 0.81 (s, 3H). 
13CNMR (176 MHz, CDCl3) δ 174.45, 174.22, 170.79, 166.25, 165.98, 165.37, 164.98, 133.59, 
133.45, 133.41, 133.24, 129.95, 129.91, 129.86, 129.77, 129.72, 129.47, 128.97, 128.94, 128.62, 
128.56, 128.48, 128.46, 117.97, 100.57, 85.59, 75.34, 73.51, 73.06, 72.26, 72.04, 70.14, 69.65, 
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67.40, 63.48, 60.54, 59.50, 50.89, 49.61, 41.82, 40.23, 38.26, 35.28, 34.28, 32.97, 30.51, 29.85, 
29.79, 26.96, 26.24, 25.63, 23.94, 21.49, 20.88, 15.87, 14.35. 
4-((3S,5R,8R,9S,10R,13R,14S,17R)-14-hydroxy-10-(hydroxymethyl)-13-methyl-3-
(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one 
 
Compound 4.65 (9.0 mg, 0.0086 mmol) was dissolved in half saturated MeOH (1 mL) and stirred 
at room temperature for 24 h. The reaction mixture was then concentrated in vacuo and purified 
by flash column chromatography (5% to 15% MeOH in CH2Cl2) to afford 76% (3.6 mg, 0.0065 
mmol) compound 4.41 as a white film, Rf = 0.15 (10% MeOH in CH2Cl2). 
1H NMR (700 MHz, Pyridine-d5) δ 6.14 (s, 1H), 5.37 (s, 1H), 5.33 (d, J = 18.1 Hz, 1H), 5.07 
(d, J= 18.1, 1H), 4.60 (d, J = 10.6 Hz,1H), 4.45 (s, 1H), 4.41 (dd, J = 11.7, 5.4 Hz, 1H), 4.33 – 
4.19 (m, 1H), 4.11 (d, J = 10.9 Hz, 1H), 4.06 (t, J = 8.1 Hz, 1H), 4.02 – 3.98 (m, 1H), 3.79 (d, J 
= 10.7 Hz, 1H), 3.62 (s, 1H), 2.89 – 2.74 (m, 2H), 2.59 – 2.50 (m, 1H), 2.22 – 2.08 (m, 5H), 2.07 
– 1.95 (m, 2H), 1.95 – 1.83 (m, 4H), 1.80 – 1.73 (m, 1H), 1.67 (d, J = 14.0 Hz, 1H), 1.55 – 1.43 
(m, 4H), 1.41 – 1.36 (m, 1H), 1.28 (d, J = 13.4 Hz, 1H), 1.03 (s, 3H). 
13C NMR (176 MHz, pyridine) δ 176.45, 174.93, 117.98, 103.67, 85.28, 79.15, 78.86, 75.63, 
74.74, 74.11, 72.23, 65.98, 63.34, 51.88, 50.57, 42.27, 40.76, 40.19, 36.24, 33.33, 30.95, 30.36, 
27.69, 27.50, 27.42, 25.17, 22.26, 22.12, 16.67. 
IR (thin film, cm-1): 626, 1024, 1076, 1352, 1381, 1591, 1737, 2927, 3390 (br.); 
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HRMS (ESI-MS) calculated for C29H44O10 [M+H]
+: 575.2832, found 575.2826  
[α]D25 = +1.3 (c = 0.2, CH3OH). 
4-((3S,5S,8R,9S,10R,13R,14S,17R)-3,5,14-trihydroxy-13-methyl-10-
((methylamino)methyl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-
one65 
 
To a stirred solution of strophanthidin 4.57 (14 mg, 0.034 mmol, 1 equiv.) in CD3OD (0.5 mL) in 
an NMR tube at 0 oC, was added AcOH (2µL, 2 equiv.). MeNH2 in EtOH (30%) (18 µM, 0.136 
equiv.) was added to the reaction mixture slowly and stirred for 2 h at that temperature. The proton 
NMR showed complete conversion of aldehyde into imine by a characteristic peak at ~8.2 ppm. 
NaBH4 (4 mg, 3 equiv.) was added to the reaction mixture, and slowly warmed. Let it stir for 2.5 
h at room temperature. The crude NMR suggested the consumption of imine. The reaction was 
then quenched with aqueous saturated NaHCO3, and the aqueous layer was extracted with EtOAc 
(5 mL×3). The collective organic layer was dried with Na2SO4 and concentrated in vacuo followed 
by purification by flash column chromatography (5-15% MeOH in CH2Cl2) to afford (10 mg, 72%) 
of compound 4.67.  
1H NMR (700 MHz, CD3OD) δ 5.91(s, 1H), 5.03 (d, 1H), 4.92(d,1H), 4.11 (s, 1H), 3.85 (d, 1H), 
2.91 (d, 1H), 2.85 (dd, 1H), 2.56 (s, 3H), 2.19 (m, 4H), 1.98 (m, 1H), 1.88 (m, 2H), 1.75 (m, 4H), 
1.51 (m, 7H), 1.28 (m, 2H, 0.89 (s, 3H) 
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13C NMR (176 MHz, CD3OD) δ 178.09, 177.16, 118.00, 117.95, 86.09, 78.36, 75.30, 68.44, 
54.14, 51.83, 43.06, 41.07, 40.60, 39.79, 37.81, 36.81, 35.74, 33.21, 28.09, 27.80, 25.01, 22.21, 
20.57, 16.17 
HRMS(ESI): [M+H]+ calculated for C24H37NO5 420.2750, found 420.2760 
[α]D25 = +23.5 (c = 0.4, CH3OH). 
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